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of  Science is a republic, and all its citizens are brothers and equals, its princes of 
Monaco and its stonemasons of Cromarty meeting, barren of man-made gauds and 
meretricious decorations, upon the one majestic level!’ 
  -Mark Twain ‘Three Thousand Years Among the Microbes’ 
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ABSTRACT 
  Gain-of-function polymorphisms in the gene encoding human interferon 
regulatory factor-5 (IRF5) are associated with an increase in risk for the development of 
the autoimmune disease Systemic Lupus Erythematosus (SLE).  IRF5 is a transcription 
factor that participates in the activation of the immune system through its role in both 
innate and adaptive immune cells. To determine the role of IRF5 in lupus pathogenesis in 
vivo, we evaluated the effect of Irf5-deficiency in the MRL/lpr mouse lupus model.  We 
find that Irf5-deficient (Irf5-/-) MRL/lpr mice develop much less severe disease than their 
Irf5-sufficient (Irf5+/+) littermates, demonstrating an important role for IRF5 in disease 
pathogenesis in vivo.   
  Patients with SLE are at increased risk for the development of atherosclerosis due 
in large part to poorly-defined lupus-specific risk factors.  One such lupus-specific risk 
factor is thought to be chronic inflammation associated with the autoimmune process.   
As IRF5 is involved in pro-inflammatory responses we hypothesized that Irf5-deficiency 
would ameliorate atherosclerosis development in the context of autoimmunity.  We 
therefore examined the role of IRF5 in the gld.apoE-/- mouse model of lupus and lupus-
  xiii 
associated atherosclerosis. Irf5-deficiency led to a decrease in splenomegaly, 
lymphadenopathy, anti-nuclear autoantibody production and the severity of kidney 
disease.  Surprisingly, despite the reduction in systemic autoimmunity, Irf5-deficiency 
led to a marked increase in the severity of atherosclerosis and to metabolic dysregulation 
characterized by hyperlipidemia, increased adiposity and insulin-resistance.  Bone 
marrow chimera studies revealed that the pathogenic role of IRF5 in lupus was solely due 
to its expression in hematopoietic cells.  The atheroprotective effect of Irf5 and the 
suppression of adiposity were found to be due to Irf5 expression in both hematopoietic 
and non-hematopoietic cells, whereas protection from hyperlipidemia was solely due to 
the expression of Irf5 in non-hematopoietic cells. Together, our results reveal a role for 
IRF5 in metabolic homeostasis, as well as in protection against atherosclerosis even in 
the setting of reduced lupus severity. 
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CHAPTER ONE 
Introduction & Overview 
 Systemic Lupus Erythematosus 
 Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by 
chronic inflammation leading to damage of various organs including the kidneys, skin, 
joints, heart, brain and intestine.  Clinical features include malar rash, proteinuria and 
joint pain.   SLE is a heterogeneous disease, both in cause and disease features.  Severity 
of the clinical presentation waxes and wanes in the form of disease ‘flares.’   The cause of 
death in patients with SLE is bimodal with early death in patients associated with active 
lupus nephritis or infection and late death associated with inactive lupus but a high 
incidence of cardiovascular disease resulting from atherosclerosis (Urowitz et al. 1976).  
The diagnostic criteria of the American College of Rheumatology aid in the diagnosis of 
SLE.  Patients are considered to have SLE if they exhibit four or more of the established 
criteria.  Nearly all patients with SLE have elevated titers of anti-nuclear antibody (ANA) 
and many exhibit expression of genes regulated by type I interferon in peripheral blood 
leukocytes.  Immune complexes made up of autoantibodies bound to target antigens 
deposit in organs such as the kidney, skin and vascular system leading to an influx of 
immune cells and induction of type I interferon as well as other pro-inflammatory 
modulators. 
Epidemiology of SLE 
 An estimated 5 million people worldwide suffer from SLE, with an incidence of 1 
to 10 per 100,000 people per year (Pons-Estel et al. 2010).  Disease development is 
  
2 
associated with gender, age and race (Pons-Estel et al. 2010).  SLE is nine times more 
common in women than men.    It is also more common in certain ethnicities with a 
higher incidence in African American and Hispanic women of child-bearing age.  Indeed, 
there is a 2-4 times higher incidence in non-white ethnicities (i.e. African American, 
Asian, Hispanic and Native American).  
Etiology of SLE 
 SLE is a disease of complex etiology occurring as a result of both genetic and 
environmental factors.  Environmental factors may include exposure to tobacco smoke, 
chemicals and viral infection.  There is a strong heritable component as studies have 
shown 35% concordance in monozygotic twins and 2-5% concordance in dizygotic twins 
(Ramos et al. 2010).  In the past 10 years, a number of genome-wide association studies 
(GWAS) have been performed establishing several lupus susceptibility genes.  Most of 
these lupus-susceptibility genes fall in the category of immuno-modulatory in that their 
functioning protein product is involved in either the innate and/or adaptive branches of 
the immune system.  At risk polymorphisms have been identified in genes required for 
normal clearance of apoptotic cells, activation of B and T lymphocytes and innate 
immune receptor pathways (Liu and Davidson 2012).  SLE susceptibility genes include 
genes encoding human leukocyte antigen (HLA) complex, early components of the 
complement system and low-affinity inhibitory receptors for the Fc region of 
immunoglobulin G.   
 Of particular relevance to this dissertation, polymorphisms in the human gene 
encoding interferon regulatory factor-5 (Irf5) have been consistently identified as a 
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primary risk factor for the development of SLE as well as several other autoimmune 
diseases, such as rheumatoid arthritis, systemic sclerosis, inflammatory bowel disease 
and multiple sclerosis (Graham et al. 2006; Sigurdsson et al. 2005).  Gain-of-function 
polymorphisms in Irf5 are associated with autoimmune risk and are believed to 
exacerbate the innate and adaptive immune responses occurring in the setting of SLE 
(Graham et al. 2007). 
Pathogenesis of SLE 
 Chronic inflammation observed in lupus results from dysfunction of both the 
innate and adaptive arms of the immune system.  Loss of immune tolerance in 
autoreactive B and T lymphocytes leads to their survival, proliferation and the production 
of pro-inflammatory cytokines as well as autoantibodies specific to self-antigen (Cheung 
et al. 2009).  In addition, aberrant stimulation of innate immune receptors by endogenous 
self-ligands leads to an increase in self-antigen presentation to T cells, cytokine 
production and immune cell chemotaxis to affected organs (Liu and Davidson 2012).  
The family of Toll-like receptors (TLRs) are the major innate immune receptors 
implicated in the pathogenesis of SLE.  Specifically, TLRs 7 and 9 recognize endogenous 
nucleic acid-protein complexes and elicit inflammatory responses in dendritic cells, 
neutrophils and B lymphocytes (Garcia-Romo et al. 2011; Lau et al. 2005; Leadbetter et 
al. 2002; Yasuda et al. 2007).  Finally, self-antigen must be available at a threshold level 
sufficient for the stimulation of both arms of the immune system.  In the case of SLE, the 
self-antigen is thought to be nucleic acid (DNA and RNA) released from injured or dying 
cells that fail to be sufficiently cleared in a homeostatic manner (Shao and Cohen 2011).  
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Indeed, SLE patients have high levels of circulating apoptotic cells and nucleosomes in 
their serum (Rumore and Steinman 1990; Williams et al. 2001).  Thus, much research has 
been focused on the role of nucleic-acid-sensing TLRs in the pathogenesis of lupus. 
Toll-like receptors-discovery and normal function against pathogens 
 There are 13 TLRs responsible for the ability of the innate immune system to 
discriminate between self and non-self and mount an immune response against invading 
pathogens (Iwasaki and Medzhitov 2004).  All TLRs recognize conserved patterns 
expressed by either bacterial or viral pathogens termed pathogen-associated molecular 
patterns (PAMPs).  Cell membrane-localized TLRs recognize PAMPs located 
extracellularly.  For example, TLR1 forms heterodimers with either TLR2 or TLR6 and 
recognizes PAMPs present on gram-positive bacterial cell walls such as lipopeptides, 
peptidoglycan and lipoteichoic acid (O'Neill, Golenbock, and Bowie 2013).  TLR4 
recognizes and binds lipopolysaccharide (LPS) present on the walls of gram-negative 
bacteria.   Within the cell, nucleic acid-sensing TLRs recognize and bind PAMPs within 
the endosome or lysosomal compartments.  TLR3 recognizes viral double-stranded RNA.  
TLR7 recognizes viral single-stranded RNA and TLR9 recognizes bacterial 
hypomethylated CpG DNA (Diebold et al. 2004; Hemmi et al. 2000; O'Neill et al. 2013).   
 All TLRs, except for TLR3, signal through the common adaptor protein MyD88 
upon ligand binding.  Depending on the immune cell type, MyD88-dependent signaling 
induces the activation of several pathways including the MAP kinase, NFkB and IRF 
signaling pathways to elicit the expression of inflammatory cytokines and type I 
interferon (O'Neill et al. 2013).  TLR3 signaling is MyD88-independent and relies on the 
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adaptor protein TRIF (Yamamoto et al. 2003).  TLR4 can signal through both MyD88 
and TRIF-dependent pathways (Yamamoto et al. 2003). 
 The gene encoding Drosophila Toll was first described and named in 1985 by Dr. 
Christiane Nüsslein-Volhard (Anderson, Bokla, and Nusslein-Volhard 1985; Anderson, 
Jurgens, and Nusslein-Volhard 1985).  She observed that a mutated fly larva had a 
deformed appearance in that it lacked normal dorsoventrical structure.  She described this 
observation as ‘Toll!’ which means ‘great’ or ‘weird’ in German.  Ten years later, Dr. 
Jules Hoffman observed that Drosophila with the same mutation in the Toll gene were 
susceptible to fungal infection (Lemaitre et al. 1996).  The transmembrane receptor 
encoded by Toll activated the NFĸB signaling pathway, leading to immune defense 
against fungus. 
 Dr. Charles Janeway predicted that a mammalian homolog of the anti-fungal 
Drosophila Toll existed in humans that would control the ability of the immune system to 
distinguish self from non-self and initiate the first line of defense against invading 
pathogens (Janeway 1989).  In 1997, Medzhitov, Preston-Hulbert and Janeway published 
their seminal paper describing the mammalian homolog of the Drosophila Toll, which 
when constitutively activated led to activation of the NFkB pathway and expression of 
several pro-inflammatory cytokines (Medzhitov, Preston-Hurlburt, and Janeway 1997).  
A year later, Dr. Paul Godowski and colleagues determined that human LPS, in complex 
with LPS-binding protein (LBP), elicits NFkB signaling through activation of TLR2 
(Yang et al. 1998).  Very shortly after, Drs Bruce Beutler and Alexander Poltorak 
evaluated C3H/HeJ mice, which were unable to respond appropriately to LPS from 
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Gram-negative bacteria, and using a forward genetics approach discovered that these 
mice harbored a missense mutation in the murine gene encoding TLR4 (Poltorak et al. 
1998). 
 Although initially proposed as the major innate immune discriminators of self 
versus pathogenic non-self, it has since been described that in certain non-infectious 
circumstances TLRs are able to recognize self or endogenous ligands, signifying host cell 
stress or damage.  First described and named by Dr. Polly Matzinger, damage associated 
molecular patterns, or DAMPS, are endogenous ligands recognized by TLRs that elicit 
downstream signaling events and outcomes similar to those induced by PAMPs 
(Matzinger 1994, 2002). 
Toll-like receptors in SLE 
 For a long time it was known that SLE patients exhibited high titers of 
autoantibodies specific to nucleic acids and apoptotic debris in their sera, as well as an 
inflammatory ‘interferon-signature’ of gene expression in plasma blood leukocytes.  In 
1990, Dr. Lars Ronnblom observed that a cancer patient treated with interferon-α (IFNα) 
developed an SLE-like syndrome characterized by arthritis and high serum titers 
autoantibodies specific for nucleic acids (Ronnblom, Alm, and Oberg 1990).  Nucleic 
acid-containing-immune complexes were postulated to induce IFNα expression through 
engagement of Fcɣ receptors, but the receptor(s) critical for the induction of interferon 
was unknown (Batteux et al. 1999; Vallin et al. 1999). 
  Toll-like receptors (TLRs) are the critical innate immune receptors in SLE.  They 
are expressed in immune cells (i.e. macrophages, dendritic cells, neutrophils and B and T 
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lymphocytes) as well as in non-immune cells (e.g. endothelial cells).  In the case of SLE, 
TLRs 7, 8 and 9 are considered to be the most pathogenic of the innate immune receptors.  
Located within the endosome, these nucleic acid-sensing TLRs do not normally come 
into contact with self-DNA or self-RNA.  However, in SLE, self-DNA and self-RNA are 
delivered to TLR7 and TLR9 in the endosome after being internalized into the cell as an 
immune complex or bound to the anti-microbial peptide LL37 (Kahlenberg and Kaplan 
2013). 
 In 2002, Leadbetter et al published the seminal paper describing that when 
chromatin fragments are in complex with IgG, they are able to engage the B-cell receptor 
(BCR)  for delivery of nucleic acids to endosomal TLR9. (Leadbetter et al. 2002) At the 
time, the authors were working with a transgenic mouse model, termed AM14, which 
expressed a BCR specific for IgG2a a/j.  When these mice were crossed to an 
autoimmune background, the resulting generations produced high titers of antibody, 
specific for IgG2a a/j.  The anti-IgG antibodies are termed Rheumatoid Factor (RF) and 
are clones of or similar to those found at high levels in the sera of rheumatoid arthritis 
patients, in some SLE patients and in lupus-prone mice.  It was not fully understood why 
in wild type mice, AM14 B cells developed normally and remained naive and why it 
wasn’t until crossed to a lupus-prone background that they proliferated in abundance and 
secreted high amounts of RF.  Interestingly, in vitro, the AM14 B cells could be activated 
only by IgG2a isolated from sera of autoimmune mice or monoclonal IgG2a specific for 
nucleosomes but not from IgG2a isolated from sera of wild type mice or monoclonal 
IgG2a specific for bacterial proteins.  Importantly, AM14 activation by DNA-containing 
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immune complexes was MyD88-dependent and could also be blocked by a TLR9 
inhibitor.  Based on these results the authors concluded that ligation of the AM14 BCR 
by immune complex leads to its internalization into the endosomal compartment where 
the chromatin within the complex comes into contact with TLR9, promoting activation 
and proliferation of the B cell.   
 The concept of dual stimulation of the BCR and TLR9 by DNA-containing 
immune complexes was a breakthrough in the lupus field as it demonstrated the link 
between nucleic-acid-containing immune complexes and the activation of TLRs.  
Namely, that endogenous nucleic acids could come into contact with endosomally-
located TLRs through receptor engagement and internalization.  This led to a multitude of 
discoveries that demonstrated the pathogenic capacity of immune complexes and TLRs in 
SLE.  In addition to TLR9, the BCR was shown to facilitate the uptake of RNA-
containing immune complexes to activate endosomal TLR7 in B lymphocytes (Lau et al. 
2005).   Furthermore, dual stimulation extended to other immune cell types, such as 
dendritic cells.  Chromatin or nucleosome-containing immune complexes were shown to 
stimulate dendritic cells to produce TNFα in a manner dependent on the engagement of 
Fcɣ receptor III and TLR9 (Boule et al. 2004).  In a similar manner, 
ribonucleoprotein(RNP)-containing immune complexes from SLE patients were shown to 
induce IFNα production from human plasmacytoid dendritic cells (pDCs) by dual 
stimulation of  Fcɣ receptor II and TLR7 (Vollmer et al. 2005).   
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Interferon regulatory factor-5-discovery and normal function against pathogens 
 Interferon regulatory factors (IRFs) are a family of transcription factors that are 
critical in the development and function of immune cells.  All IRFs, except IRF1 and 2, 
contain a C-terminal interaction domain (IAD) and an N-terminal DNA binding domain 
in which five tryptophan repeats are located (Paun and Pitha 2007).  These tryptophan 
repeats recognize a GAAA sequence found in the Interferon Stimulatory Response 
Element (ISRE) present in the promoters of interferon (IFN)-stimulated response genes, 
promoters of IFNα and IFNβ as well as other inflammmatory genes. 
 In 1998, Dr. Paula Pitha, in the lab of Dr. Paul Moore, cloned the cDNA of 
murine Irf5 (Pitha et al. 1998).  In 2001, Dr. Betsy Barnes and Dr. Pitha functionally 
characterized IRF5 (Barnes, Moore, and Pitha 2001).  They showed that human Irf5 was 
mainly expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow and 
skeletal muscle. At the time, it was known that DNA and RNA viruses induced IFNα and 
IFNβ and that IRFs were involved in this pathway. The authors discovered that similar to 
IRF3 and IRF7, IRF5 was phosphorylated, translocated to the nucleus and induced the 
expression of IFNβ and IFNα subtype genes in response to Newcastle-Disease Viral 
(NDV)  infection.  However, TLRs had only just been discovered so that the innate 
immune receptors critical for IRF-dependent induction of type I interferon were not 
determined.   
 In  2005, Dr. Takaoka in the laboratory of Dr. Taniguchi, determined that IRF5 
was activated downstream from TLR-MyD88 pathways in hematopoietic cells and 
induced the expression of pro-inflammatory cytokines (Takaoka et al. 2005).  Irf5-/- 
  
10 
C57BL/6 mice were generated in the laboratory of Tak W. Mak and were made by 
replacing a 2.1kb fragment encoding part of exon 2 with a neomycin-resistance gene 
cassette leading to undetectable IRF5 transcript and protein.  Using wild type and Irf5-/- 
splenic conventional and plasmacytoid dendritic cells as well as splenic macrophages, the 
authors showed that IRF5 was required for the production of IL-16, IL-12 and TNFα, in 
response to stimulation with synthetic TLR3, 4, and 9 ligands.  In addition, they showed 
that IRF5 interacts with the adaptor protein MyD88 and TRAF6 and that these 
associations are required for the TLR9-stimulated transactivation of IRF5 to the  
interferon stimulatory response element (ISRE) in the IL-12p40 3’ UTR. 
 IRF5 has since been shown to regulate the production of TNFα in human 
dendritic cells in response to TLR4 stimulation and has been described as a  master 
regulator of macrophage polarization towards a pro-inflammatory (‘M1’) phenotype, 
although this was only evaluated in response to TLR4 stimulation (Krausgruber et al. 
2011; Krausgruber et al. 2010). 
 A role for IRF5 in TLR7 signaling was first demonstrated in HEK cell studies 
(Schoenemeyer et al. 2005).  Recent work from our laboratory has shown that IRF5 
functions downstream from 7 and 9, and that the specific genes regulated upon activation 
are cell type-dependent.  IRF5 controls IL-6 production in response to TLR7 and TLR9 
stimulation in murine B cells and pDCs (Yasuda et al. 2013).  IRF5 is also required for 
production of IFNα in pDCs in response to TLR9 stimulation (Yasuda et al. 2013).  
(Summary of IRF5 signaling downstream from TLRs in Illustration 1). 
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Illustration 1.  The cell-type and ligand-dependent role of IRF5 downstream from 
pattern recognition receptors. 
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Interferon regulatory factor-5 in SLE 
 In 2005, Sigurdsson et al published the first genetic association study revealing 
IRF5 as a lupus susceptibility gene in humans (Sigurdsson et al. 2005).  The authors 
analyzed single nucleotide polymorphisms (SNPs) in several genes known to be involved 
in the type I IFN pathway, including IRF5, in over 500 SLE patients, their unaffected 
family members and healthy controls.  They found several SNPs in the human Irf5 gene 
that strongly associated with SLE.   
 There are 14 human IRF5 isoforms or variants that result from alternative splicing 
of the IRF5 transcript.  Three major SNPs and one insertion-deletion mutation in the 
human gene encoding IRF5, together, make up the most at-risk haplotype (Graham et al. 
2007).  SLE patients with this haplotype have higher levels of Irf5 expression in 
monocytes (Feng et al. 2010b).    
 The role of IRF5 in SLE disease pathogenesis is due, in part, to its function 
downstream of TLR7 and 9 in dendritic cells, monocytes and B cells.  RNA-containing 
immune complexes can be internalized by dendritic cells through the ligation of Fcɣ 
receptors, leading to the activation of endosomal TLR7 (Vollmer et al. 2005).  IRF5 was 
shown to be required for TLR7-dependent induction of IFNα and IL-6 in pDCs in 
response to RNA-containing immune complexes (Yasuda et al. 2007).  Furthermore, 
IRF5 is upregulated in monocytes of SLE patients and nuclear localization of IRF5 in 
response to apoptotic and necrotic debris correlates with increased production of IFNα 
and TNFα (Stone et al. 2012).  Finally, IRF5 directly controls class-switch recombination 
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of IgG2a in B cells in response to TLR9 stimulation (Savitsky et al. 2010).  IgG2a is 
considered a dominant pathogenic isotype in SLE as an increased number of 
autoantibodies of IgG2a are present in the serum of lupus mice. 
 The discoveries above have led to a growing understanding of the pathogenicity 
of IRF5 in SLE.  However, the manipulation of Irf5 in mouse models of SLE has allowed 
for the elucidation of the function of IRF5 in an in vivo disease setting.  
TLRs and IRF5 in murine models of SLE 
 Murine models of SLE have proven to be invaluable tools in developing a more 
detailed understanding of the mechanisms of disease initiation and pathobiology of 
disease progression.  A number of mouse lines develop a lupus-like phenotype as a result 
of genetic modifications.  Several characteristics of human lupus are present in these 
models including production of autoantibodies specific to RNA and DNA autoantigens 
and the subsequent development of circulating immune complexes, splenomegaly and 
lymphadenopathy, and autoimmune end-organ damage including the development of 
dermatitis and proliferative glomerulonephritis.  These lupus-prone mice have been used 
to define the role of TLRs and their downstream signaling pathways during the initiation 
and effector phases of disease.   
The FcɣRIIB-deficient lupus model 
 
 Genetic studies in humans and mice have identified an orthologous region of 
chromosome 1, termed Sle1, that confers susceptibility to autoantibody production 
(Cheung et al. 2009).  Although multiple candidate genes are located in this genetic 
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interval, the gene encoding the inhibitory Fc gamma-receptor IIB or FcɣRIIB is thought 
to be an important disease modifier because FcɣRIIB restrains B cell and myeloid cell 
activation following B cell receptor or activating Fcɣ receptor engagement (Bolland and 
Ravetch 1999, 2000; Bolland et al. 2002; Boross et al. 2011).  FcɣRIIB-knockout 
(FcɣRIIB-/-) mice that lack this inhibitory Fc-receptor develop an autoimmune disease 
characterized by anti-RNA and anti-DNA autoantibodies, splenomegaly and 
lymphadenopathy, and severe, fatal proliferative glomerulonephritis (Bolland and 
Ravetch 2000; Richez et al. 2010).  This phenotype is in part attributable to the deletion 
of FcɣRIIB; however, it is important to recognize that more recent evidence suggests that 
the FcɣRIIB deletion alone is not sufficient to produce full-blown disease and that 
additional genetic modifiers (either linked to this locus or distant from this locus) are 
required for maximal disease expression (Bolland et al. 2002; Boross et al. 2011; 
Subramanian et al. 2006). 
Tlr7 or Irf5 deficiency ameliorates disease in FcɣRIIB-/- and   Yaa.FcɣRIIB-/- 
mice 
 
 The gene for TLR7 is located on the X-chromosome and, due to random X 
inactivation, only a single copy of TLR7 is thought to be expressed in a cell.  The Y-
chromosome-linked autoimmune accelerator (Yaa) is a 4Mb region of the mouse X-
chromosome that spontaneously translocated to the Y chromosome and was found to 
potentiate autoimmunity (Perry et al. 2011).  It was recently shown that TLR7 is the 
major, but not the only, gene within Yaa responsible for this enhancement of 
autoimmunity in FcɣRIIB-deficient mice (Bolland et al. 2002; Boross et al. 2011; 
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Pisitkun et al. 2006; Santiago-Raber et al. 2008; Subramanian et al. 2006).  Gain-of-
function IRF5 polymorphisms have been linked to lupus susceptibility in humans and our 
laboratory has recently shown that autoimmune disease in Yaa.FcɣRIIB-/- male and 
FcɣRIIB-/- female mice is dependent on the presence of two functional copies of the Irf5 
gene (Deng and Tsao 2010).  Irf5-deficiency markedly decreased autoantibody 
production, prevented end-organ disease and prolonged survival (Richez et al. 2010; 
Tada et al. 2011).   
The MRL/lpr lupus model 
 
 On the autoimmune-prone MRL background, mice with a mutation in the Fas 
gene develop lymphoproliferation (lpr) and a spontaneous lupus-like phenotype.  
Autoimmunity in MRL/lpr mice is due to a number of factors including an increased 
number of autoreactive B-and T-cells, impaired apoptosis, and an increased level of 
circulating, immunostimulatory RNA and DNA containing immune complexes (Kelley 
and Roths 1985; Perry et al. 2011).  MRL/lpr mice develop autoantibodies to chromatin, 
RNA and RNA-associated proteins that are detectable after 3-months of age.  
Subsequently, animals develop massive adenopathy and splenomegaly, dermatitis and 
glomerulonephritis.  Death, that is usually due to renal disease, occurs at about 5 months 
in females and about 8 months in males, although mice often have to be euthanized 
earlier due to severe dermatitis (Andrews et al. 1978; Ghoreishi and Dutz 2009; Kelley 
and Roths 1985). 
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Toll-like receptor signaling alters the phenotype in MRL/lpr mice 
 
 There is now considerable evidence to suggest that endogenous nucleic acids that 
are derived from injured or dying cells can be immuno-stimulatory via engagement of 
endosomal TLRs (Liu and Davidson 2012; Marshak-Rothstein and Rifkin 2007).  TLRs 
that can be activated by endogenous DNA or RNA are of particular interest in lupus 
given that immune complexes containing these autoantigens are a hallmark of the 
disease. MRL/lpr mice deficient in TLR9, a receptor for DNA, had reduced levels of anti-
DNA autoantibodies but, unexpectedly, were found to have an accelerated lupus 
phenotype (Christensen et al. 2006; Hemmi et al. 2000).  In contrast, MRL/lpr mice 
deficient in TLR7, a receptor for ssRNA, developed anti-DNA autoantibodies but not 
anti-RNA or anti-SmRNP antibodies and exhibited reduced disease severity (Christensen 
et al. 2006; Diebold et al. 2004) .  This highlights the important role of endogenous TLR7 
signaling during disease development. 
 In Chapter 3 of this dissertation, I show that Irf5-deficiency in MRL/lpr mice 
ameliorates disease.  Shortly after this work was completed, Tada et al published that 
IRF5 is required for disease development in MRL/lpr mice including results that are very 
similar to ours.  Irf5-deficient MRL/lpr survived longer, exhibited decreased titers of 
ANA and decreased splenomegaly, lymphadenopathy and kidney disease severity 
compared to Irf5-sufficient MRL/lpr mice (Tada et al. 2011). 
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Irf5-deficiency ameliorates disease in the pristane model of lupus 
 
 Intraperitoneal injection of pristane leads to the development of lupus-like disease 
in normal C57BL/6 mice.  Pristane injection induces apoptosis within the peritoneal 
cavity leading to immune cell activation and the production of anti-RNA and anti-DNA 
autoantibodies (Savitsky et al. 2010).  Pristane-injected mice develop immune complex-
mediated glomerulonephritis.  Irf5-deficiency was shown to ameliorate lupus-associated 
disease parameters as pristane-injected Irf5-deficient mice displayed a significant 
decrease in immune complex deposition within the kidney and a decrease in serum ANA 
titers (Savitsky et al. 2010).  Irf5-deficiency confers protection against pristane-induced 
lupus partially through a decrease in type I interferon production.  In addition Irf5-
deficient mice displayed skewing towards a Th2 immune response characterized by a 
prevalence of Th2-associated cytokines and Th2-dependent IgG class switching (Feng et 
al. 2012; Xu et al. 2012).  However, whether IRF5 is pathogenic in pristane-induced 
lupus due to its function downstream from TLR7 or TLR9 is not known. 
Presence of the DOCK2 mutation in the Irf5-/- C57BL/6 line; a major caveat 
in Irf5-/- lupus mouse studies 
 
 In 2010, a confounding gene mutation in the Irf5-/- mouse line was identified as a 
duplication of exons 28 and 29 in the gene encoding Dedicator of Cytokinesis 2 
(DOCK2) (Purtha et al. 2012).  The exon insertion mutation results in unstable mRNA 
and low DOCK2 expression.  DOCK2 is a guanine nucleotide exchange factor that 
interacts with Rac to control migration of plasmacytoid dendritic cells (pDCs), TLR-
induced type I interferon production by pDCs and the development of the normal B cell 
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compartments through its role in lymphocyte migration (Fukui et al. 2001; Gotoh et al. 
2010; Nishikimi et al. 2009).  DOCK2 mutant mice fail to develop normal B cells 
including the marginal zone B cell subset.  Through reasons that are still unclear, the 
DOCK2 mutation was not bred out of the Irf5-/-  mouse line until the ninth generation of 
backcrossing (Yasuda et al. 2013).   Due to the function of DOCK2 in immune cell 
function and trafficking, data from studies using lupus mice crossed to this Irf5-/- line may 
be a result of Irf5-deficiency, DOCK2-deficiency or a combination of the two mutations.   
 Dr. Kei Yasuda designed a PCR protocol able to recognize the 3’ insertion point 
of the exon 28-29 duplication in the mouse DOCK2 gene.  As a result, we were able to 
breed the DOCK2 mutation out of our Irf5-/- line and our Irf5-deficient lupus mouse lines.  
All data shown in my dissertation was generated using mice that did not have the 
DOCK2 mutation except where indicated in studies shown in Appendix I.  
Pathogenesis of atherosclerosis 
 Similar to SLE, atherosclerosis is also characterized by chronic inflammation, 
albeit at a localized area within the aorta and aortic sinus.  Turbulent blood flow as well 
as the deposition of excess lipids and cholesterol within the intima of the aorta lead to 
endothelial cell dysfuction and activation followed by the subsequent recruitment of 
innate immune cells.  Activated monocytes and macrophages infiltrate the intima and 
phagocytose excess lipids and cholesterol thereby becoming foam cells.  As the lesion 
progresses, inefficient clearance of apoptotic foam cells leads to the formation of a 
necrotic core.  In addition, dendritic cells, B and T lymphocytes are recruited to the 
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progressing atherosclerotic lesion forming tertiary lymph node-like structures(Grabner et 
al. 2009). 
SLE-associated atherosclerosis 
 The development of premature accelerated atherosclerosis is a major cause of 
morbidity and mortality in patients with lupus as it can lead to stroke and myocardial 
infarction (Urowitz et al. 1976).  Compared to the normal population, patients with SLE 
have 5-10 times the risk of coronary heart disease and related events.  Furthermore, 
premenopausal women with SLE are 50 times more likely to suffer from myocardial 
infarction than healthy women of the same age (Manzi et al. 1999).  Traditional 
Framingham risk factors for the development of atherosclerosis include hyperlipidemia, 
hypercholesterolemia, hypertension, diabetes, obesity, age and smoking.  As defined by 
the World Health Organization (WHO) criteria for metabolic syndrome, SLE patients 
have an increased prevalence of metabolic syndrome compared to healthy controls 
(discussed later on) (Chung et al. 2007).   However, patients with SLE are at increased 
risk for development of atherosclerosis due not only to the traditional Framingham risk 
factors but also due to lupus-specific risk factors such as systemic and chronic 
inflammation (Bruce, Gladman, and Urowitz 2000; McMahon et al. 2013; Skaggs, Hahn, 
and McMahon 2012).  After adjusting for the traditional Framingham risk factors for 
atherosclerosis, patients with SLE still have a 7-10 fold increase in risk (Wajed et al. 
2004).  One lupus-specific risk factor for atherosclerosis is high pro-inflammatory HDL 
(piHDL) (McMahon and Hahn 2007; McMahon et al. 2013).  Normally, HDL protects 
against atherosclerosis by promoting lipoprotein clearance from atherosclerotic lesions 
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and inhibiting oxidation of LDL.  But in the setting of chronic inflammation, such as that 
seen in SLE, HDL loses its anti-inflammatory capabilities (Van Lenten et al. 1995).  
Women with SLE have significantly higher serum piHDL and 85% percent of SLE 
patients with atherosclerosis show an increase in serum piHDL compared to controls 
(Skaggs et al. 2012). 
TLRs in atherosclerosis 
 The role of TLRs in atherosclerosis is complex with some TLRs promoting 
atherogenesis while others have been shown to be protective (Cole, Kassiteridi, and 
Monaco 2013; Falck-Hansen, Kassiteridi, and Monaco 2013).   TLR2 and TLR4 
recognize a variety of endogenous ligands including, but not limited to, saturated fatty 
acids and minimally oxidized LDL (mmLDL), respectively. TLR4 can also form a 
heterotrimer with TLR6 and CD36 and recognize oxLDL (Stewart et al. 2010).   Deletion 
of TLR2 or TLR4 in atherosclerosis-prone mice leads to a decrease in atherosclerotic 
lesion size (Bjorkbacka 2006; Mullick, Tobias, and Curtiss 2005).  Similarly, deletion of 
the TLR adaptor protein MyD88 also leads to a decrease in atherosclerotic lesion size in 
atherosclerosis-prone mice (Michelsen et al. 2004).  However, the effect of TLR2, TLR4 
and MyD88 in atherosclerosis may be cell-type specific.  TLR2 appears to promote 
atherogenesis mainly due to its expression on non-immune cells such as the endothelial 
cells lining the aorta in areas of disturbed blood flow which, when activated, can lead to 
endothelial dysfunction (Mullick et al. 2005).  Cell-specific deletion of MyD88 in 
CD11c+ dendritic cells actually led to more severe atherosclerosis in the LDLR-/- mouse 
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model of atherosclerosis as a result of decreased T regulatory cells within the lesion 
(Subramanian et al. 2013). 
 Interestingly, the nucleic acid sensing TLRs, TLR3, TLR7 and TLR9 may 
actually be protective against atherosclerosis.  When atherosclerosis-prone mice were 
treated with Poly I:C, a synthetic TLR3 ligand, mice deficient in Tlr3, which could not 
respond to Poly I:C, developed more severe atherosclerosis and at an earlier age (Cole et 
al. 2011).  In addition, Tlr3-/-.apoE-/- mice exhibited significantly more atherosclerosis 
than Tlr3+/+apoE-/- mice (Cole et al. 2011).  TLR7 deletion in atherosclerosis-prone mice 
leads to an increase in atherosclerotic lesion size as well as in plaque instability 
(Salagianni et al. 2012). The mechanism by which TLR7 is believed to protect against 
atherosclerosis is by limiting infiltration of inflammatory monocytes and macrophages 
into the lesion.  Finally, Tlr9-deficiency in apoE-/- mice led to an increase in 
atherosclerosis, in part, due to an influx of CD4+ T cells and an increase in IFNα within 
the lesion (Koulis et al. 2014).  Furthermore, when apoE-/- mice on a high fat diet were 
treated with CpG-B ODN, a synthetic TLR9 agonist, atherosclerotic lesion sizes were 
significantly reduced compared to vehicle-treated apoE-/- mice.  Nucleic acids released 
from apoptotic or necrotic cells within the atherosclerotic lesion are believed to serve as 
endogenous TLR ligands in the above models.  However, this has yet to be formally 
proven. 
 TLRs may also promote or protect against atherosclerosis indirectly.  For 
example, Tlr5-deficiency was shown to alter gut microbiota and thus promote insulin 
resistance, a risk factor for atherosclerosis (Vijay-Kumar et al. 2010).  Interestingly, 
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transplantation of the gut microbiota from a Tlr5-/- mouse to Tlr5+/+ recipients led to the 
development of metabolic syndrome in the recipient mice. Furthermore, pathogen-
derived TLR4 ligands can leak into the circulation and cause insulin resistance in a 
manner dependent on the specific bacterial populations colonizing the gut (Jin, Henao-
Mejia, and Flavell 2013).  (Refer to Illustration 2 for summary of TLRs in mouse models 
of atherosclerosis). 
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Illustration  2.  TLRs in mouse models of atherosclerosis and metabolic dysfunction.   
All comparisons are relative to Tlr+/+ or MyD88+/+ mice.  Abbreviations: Not determined 
(ND), high fat diet (HFD), western diet (WD), Low density lipoprotein receptor (LDLR),  
(-) is a decrease relative to +/+. References: 1-(Himes and Smith 2010; Kuo et al. 2011; 
Mullick et al. 2005). 2-(Cole et al. 2011). 3-(Michelsen et al. 2004),(Tsukumo et al. 
2007). 4-(Vijay-Kumar et al. 2010). 5-(Salagianni et al. 2012). 6-(Koulis et al. 2014). 7-
(Michelsen et al. 2004). 8-(Hosoi et al. 2010). 
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Murine models of lupus-associated atherosclerosis. 
The gld.apoE-/- mouse model of lupus-associated atherosclerosis 
 
 The first murine model of lupus-associated atherosclerosis was generated in 2004 
by Aprahamian et al.  A point mutation in the gene encoding murine Fas ligand (gld) 
leads to the spontaneous development of a mild form of autoimmune disease 
characterized by the production of low levels of pathogenic autoantibodies as well as the 
development of mild splenomegaly, lymphadenopathy and glomerulonephritis. apoE-/- 
mice lack the gene encoding apolipoprotein E (apoE) which is responsible for the 
transport of lipoproteins and cholesterol.  Without this important regulator of lipid 
catabolism, mice develop hypercholesterolemia and premature atherosclerosis initiated 
by the retention of these molecules in the subendothelium of the arterial wall, especially 
in areas of disturbed aortic blood flow.  As lipoproteins and cholesterol become oxidized, 
they trigger endothelial dysfunction and the production of chemokines necessary for the 
migration of monocyte-derived macrophages.  apoE-/- mice with beginning-stage 
atherosclerosis develop characteristic fatty streaks due to the phagocytosis of oxidized 
lipids and their accumulation within the cytoplasm of macrophages (foam cell formation).   
 When the gld and apoE-/- mutations are combined into the gld.apoE-/- murine 
model of SLE-associated atherosclerosis, mice develop a much more severe disease 
phenotype than mice homozygous for either mutation alone.  Aprahamian et al reported 
that gld.apoE-/- mice on western diet have, on average, three times as much 
atherosclerosis as their apoE-/- counterparts.  In addition, gld.apoE-/- mice displayed an 
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increase in the severity of lupus-associated disease manifestations compared to gld 
counterparts.  The authors proposed that the interrelationship between lupus and 
atherosclerosis seen in the gld.apoE-/- model is mediated by perturbations in the 
mechanisms that clear apoptotic cells.  The inefficient clearance of apoptotic cells is a 
major cause of aberrant inflammatory responses seen in both human and mouse SLE.  In 
addition, the progression of atherosclerotic lesions is caused, in part, by the inefficient 
clearance of apoptotic foam cells and the inflammatory response associated with 
apoptotic foam cells undergoing secondary necrosis.  The authors suggested that the 
results observed in the gld.apoE-/- model indicated a positive feedback interaction 
between SLE and atherosclerosis.  Therefore, one ‘lupus-specific’ risk factor for the 
development of premature atherosclerosis is chronic inflammation due in part to 
inefficient clearance of apoptotic cells. 
Other murine models of lupus-associated atherosclerosis 
 
 Other mouse models of lupus-associated atherosclerosis have been characterized.  
apoE-/- mice with a deletion in the gene encoding Fas (apoE-/-.Fas-/-) develop more severe 
lupus nephritis as well as more severe atherosclerosis attributed, in part, to increased 
antibodies against oxidized phospholipids (Feng et al. 2007).  Similar to the increase in 
apoptotic cells observed in gld.apoE-/- mice, the authors noted an increase in apoptotic 
cells in both the kidney and heart of apoE-/-.Fas-/- mice.  When LDL receptor-deficient 
mice are irradiated and transplanted with bone marrow from the lupus-prone B6.Sle 
strain, mice displayed an increase in atherosclerotic lesion size containing a greater 
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number of CD4+ T cells (Braun et al. 2008).  Interestingly, all three lupus-associated 
atherosclerosis models displayed a decrease in serum cholesterol yet an increase in 
atherosclerotic lesion burden.  Thus, in the context of murine lupus, autoimmunity 
exacerbates atherosclerosis independently of increased circulating lipids. 
Metabolic Syndrome 
 The World Health Organization’s criteria for metabolic syndrome are insulin 
resistance and impaired glucose tolerance in combination with at least two of the 
following clinical criteria:  hypertension, hypertriglyceridemia, low HDL cholesterol, 
obesity, or high levels of urinary albumin. 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1880831/    The primary complication of 
metabolic syndrome is cardiovascular disease.  Data from the Framingham Heart Study 
have shown that metabolic syndrome is a predictor of cardiovascular disease as metabolic 
syndrome increases the risk of the development of diabetes which, in itself, is a major 
risk factor for the development of cardiovascular disease.    
Obesity as a major risk factor for metabolic syndrome 
 Obesity is a major risk factor for metabolic dysfunction and correlates with an 
increased risk of the development of hypertension, hyperlipidemia, insulin resistance, 
hepatic steatosis (or nonalcoholic fatty liver disease) as well as cardiovascular disease 
(Berg and Scherer 2005; Hubert et al. 1983; Lusis, Attie, and Reue 2008).  In the past 
three decades the incidence of obesity has risen drastically with an estimated 11% of the 
world’s adult population being clinically obese in 2008. 
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http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1880831/  Chronic and low-grade 
inflammation associated with an increase in adiposity is believed to be a major driver of 
insulin resistance, increases in serum lipids and cholesterol, progression of 
atherosclerosis and increased lipid deposition in the liver characteristic of hepatic 
steatosis (Jin and Flavell 2013; Lusis et al. 2008).  Adipocyte hyperplasia or an expansion 
in the size of adipocytes due to an increase in stored triglycerides correlates with an 
increase in macrophage infiltrate within the adipose tissue (Sun, Kusminski, and Scherer 
2011).  These macrophages are pro-inflammatory in nature and secrete high amounts of 
inflammatory cytokines (Dalmas, Clement, and Guerre-Millo 2011).  Pro-inflammatory 
cytokines promote lipolysis in adipocytes leading to an increase in circulating fatty acids 
contributing to ectopic lipid deposition in the liver and muscle(Lumeng and Saltiel 2011).  
Ectopic lipid deposition promotes insulin resistance in liver and muscle and also leads to 
alterations in lipoprotein output by the liver (Angulo 2002).  Both insulin-resistance and 
an increase in lipid deposition in hepatocytes may directly lead to an increase in the 
release of VLDL from the liver (Browning and Horton 2004).  VLDL and LDL are the 
main lipoproteins implicated in the pathogenesis of atherosclerosis(Van Gaal, Mertens, 
and De Block 2006).  In addition, pro-inflammatory cytokines perturb normal insulin 
signaling in adipocytes rendering them insulin-resistant (Berg and Scherer 2005; Sun et 
al. 2011).  Therefore, the obesity-associated inflammation within adipose tissue is a 
major contributor to hyperlipidemia, hypercholesterolemia, adipocyte and peripheral 
insulin-resistance and ultimately, cardiovascular disease. 
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The apolipoprotein-E-deficient mouse model of metabolic dysfunction and 
atherosclerosis 
 The use of mouse models of metabolic dysfunction has generated a vast amount 
of data that has helped elucidate the mechanisms of genetic and diet-induced metabolic 
dysfunction in humans (Meir and Leitersdorf 2004).  Genetic manipulation as well as the 
use of high fat or fructose diets can lead to metabolic dysfunction in mice.  C57BL/6 
mice on normal chow (4% fat and <0.01% cholesterol by weight) exhibit plasma 
cholesterol levels of  ~80 mg/dL with the majority of the cholesterol carried in HDL 
particles (Pendse et al. 2009).  This is in stark contrast to humans, where the majority of 
cholesterol is carried in LDL particles. C57BL/6 mice placed on a high fat and fructose 
diet (diabetogenic diet) display diet induced obesity and diabetes (Plump and Breslow 
1995).   However, because of the ability of the C57BL/6 liver to rapidly clear LDL, mice 
maintain relatively low levels of plasma cholesterol, carried mainly in HDL particles and 
exhibit only mild atherosclerosis (Wu and Huan 2007).   
 In 1992, two separate laboratories developed apolipoprotein E (apoE)-deficient 
mouse lines using gene targeting in embryonic stem cells (Piedrahita et al. 1992; Plump 
et al. 1992).  Apolipoprotein E is a constituent of all lipoproteins except LDL and is 
critical in the transport and uptake of dietary and endogenous lipids and reverse 
cholesterol transport (Plump and Breslow 1995).  Apolipoprotein E acts as the ligand for 
the LDL receptor and VLDL receptor and is critical for uptake of chylomicron and 
VLDL remnants by peripheral tissues and the liver (Meir and Leitersdorf 2004).    apoE-/- 
mice on normal diet exhibit hypercholesterolemia with 400-500 mg/dL of plasma 
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cholesterol which is mainly carried in VLDL particles.  When apoE-/- mice are placed on 
a western diet (21% fat and 0.15% cholesterol by weight) plasma cholesterol levels 
display a 4-fold increase 1600-2000 mg/dL, with the majority of cholesterol carried in 
VLDL particles (Plump and Breslow 1995).  In addition, apoE-/- mice on western diet 
exhibit profound insulin-resistance and glucose-intolerance.   
 Unlike C57BL/6 mice, apoE-/- mice develop atherosclerosis at a young age even 
on normal diet.  At 5-6 weeks of age, apoE-/- mice develop endothelial dysfunction within 
the aorta and exhibit enhanced monocyte migration (Plump and Breslow 1995).  By 6-10 
weeks of age, the characteristic fatty-streak can be observed within the aorta of apoE-/- 
mice characterized by the presence of foam cells and migrating smooth muscle cells.  
When apoE-/- mice are placed on a western diet (21% fat and 0.15% cholesterol by 
weight) the rate at which the atherosclerotic lesion progresses increases substantially.  
The atherosclerotic lesions are 3-4 times larger in apoE-/- mice on western diet than that 
of apoE-/- mice on normal diet.  Rapidly progressing atherosclerotic lesions have 
characteristics similar to advanced human atheromas.  Progressive atherosclerotic lesions 
from apoE-/- mice contain large necrotic cores surrounded by migrating smooth muscle 
cells.  Foam cells and other immune cells are detected in high numbers surrounding the 
necrotic core.  Increased deposition of extracellular matrix leads to the formation of a 
fibrous cap surrounding the lesion which can protrude into the lumen of the aorta.  In 
summary, apoE-/- mice on normal diet and western diet are good models for human 
metabolic syndrome as they exhibit hypercholesterolemia with the majority of cholesterol 
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carried in non-HDL particles, insulin-resistance, glucose-intolerance and develop 
atherosclerosis.  
 However, one drawback of using the apoE-/- mouse as a model for human 
metabolic dysfunction is that apoE-/- mice are leaner compared to C57BL/6 mice, 
regardless of diet (Pendse et al. 2009).  This is believed to be a result of impaired delivery 
of VLDL to adipocytes as apolipoprotein E interacts with the VLDL receptor on 
adipocytes and facilitates the uptake and hydrolysis of triglycerides by lipoprotein lipase.  
Therefore, the size of adipose tissue depots are significantly decreased in apoE-/- mice 
compared to C57BL/6 mice. 
Metabolic Dysfunction in SLE 
 Although very few studies have focused on characterizing the metabolic state of 
patients with SLE, there is some evidence that supports a link between metabolic 
dysfunction and increased cardiovascular risk in patients with SLE.  As defined by the 
WHO criteria, SLE patients show an increased prevalence of metabolic syndrome (Chung 
et al. 2007).   Compared to healthy controls, 34-51% of SLE patients are 
hypercholesterolemic (Wajed et al. 2004).  However, a study by Chung et al showed that 
patients with SLE had significantly lower total and LDL cholesterol, but higher serum 
triglycerides than healthy controls (Chung et al. 2007).  Furthermore, many SLE patients 
are hypertensive which may be related to renal impairment due to lupus nephritis (Wajed 
et al. 2004).   
 As SLE is associated with systemic and chronic inflammation, it would be 
hypothesized that SLE patients might be at higher risk for the development of certain 
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aspects of metabolic dysfunction known to be promoted by inflammation.  For example, 
pro-inflammatory cytokines such as TNFα and IL-6 are found at high levels in the serum 
of SLE patients (Parker and Bruce 2013).  It is well documented that these cytokines can 
directly lead to insulin resistance by blocking the phosphorylation and activation of key 
signaling components downstream from the insulin receptor.  Therefore, patients with 
SLE might be at increased risk for the development of type 2 diabetes mellitus.  A small, 
but significant percentage of patients (5-7%) were shown to suffer from diabetes mellitus.  
Furthermore, fasting insulin levels were significantly higher in patients with SLE 
compared to healthy controls and SLE patients were more likely to be insulin-resistant 
(Chung et al. 2007; El Magadmi et al. 2006; Wajed et al. 2004).  Therefore, one major 
link between SLE and insulin resistance may be chronic inflammation. 
 An additional aspect of the relationship between chronic inflammation and 
metabolism in SLE involves the repetitive stimulation of autoreactive T cells.  A T-cell 
intrinsic switch in glucose metabolism occurs upon activation.  Normally, activated T 
cells undergo a switch from aerobic mitochondrial oxidation of glucose to anaerobic 
glycolysis (Michalek et al. 2011).  However, T lymphocytes from SLE patients and 
murine lupus models display an increase in oxidative glucose metabolism and 
dependence on mitochondrial metabolism (MacIver, Michalek, and Rathmell 2013).  
Furthermore, repetitive stimulation of autoreactive T cells leading to excessive 
mitochondrial dependence may lead to mitochondrial dysfunction.  Therefore, in a 
disease setting such as SLE, T-cell intrinsic changes in metabolism may lead to 
differences in energy usage and metabolic dysfunction.  Indeed, a metabolics scan of SLE 
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patients showed an imbalance in multiple metabolic processes, including glycolysis, 
oxidative phosphorylation, beta oxidation of fatty acids and increased production of 
reactive oxygen species (ROS) (Wu et al. 2012). 
Toll-like receptors in Metabolic Dysfunction 
 Chronic, low-grade inflammation is a characteristic of diet-induced obesity and 
has been linked to the development of several aspects of metabolic dysfunction.  TLRs 
may play a prominent role in the initiation of inflammation in response to high fat diet 
and an increase in adiposity.  In the context of diet-induced obesity, exogenous and 
endogenous ligands capable of stimulating TLRs may come from: 
 1) components of the specific diet and associated metabolites.  For example, palmitate, 
which is a saturated long-chain fatty acid and a major component of high fat or western 
diets, has been shown to directly activate TLR2 and TLR4. 
2) PAMPs from gut bacteria able to enter the blood stream in response to diet-induced 
changes in gut flora resulting in perturbations in gut endothelial cell homeostasis.  For 
example, LPS, a component of the cell walls of gram-negative commensal bacteria can 
leak into the blood stream in the setting of obesity or diabetes. 
 3)  DAMPs that may result from damage of tissues due to metabolic stress.  For 
example, HMGB1, heat shock proteins, and hyaluronan are all released by cells in 
response to stress or damage, have been shown to activate TLR4 and are upregulated in 
obesity. 
 Similar modes of stimulation could be true for endosomal TLRs that recognize 
nucleic acids and are important in the pathogenesis of SLE.  TLR9 may be activated in 
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the liver by hypomethylated CpG from commensal gram-negative bacteria present in the 
dysregulated gut.  It also seems likely that endogenous nucleic acids released by damaged 
or dying cells may directly stimulate TLR7 and/or TLR9 in immune cells present in 
tissues affected by metabolic dysfunction, such as adipose tissue, the pancreas or liver.   
 TLR activation has been implicated in obesity-associated inflammation, 
peripheral insulin-resistance and non-alcoholic fatty liver disease (NAFLD).  TLR2 and 
TLR4 are increased in the adipose tissue and muscle of obese and diabetic patients.  
TLRs are also upregulated in the adipose tissue of mice on high fat diet compared to mice 
on normal diet (Kim et al. 2012; Kwon et al. 2012). 
 In adipose tissue, activation of TLRs expressed by adipose tissue macrophages 
(ATMs), leads to insulin-resistance in the adipocyte (Orr et al. 2012). TLR4 activation 
leads to the activation of JNK and IKKβ, components of the MAPK and NFĸB signaling 
pathways.  JNK and IKKβ activation can directly lead to perturbations in insulin receptor 
signaling through inhibitory phosphorylation of IRS 1/2 (Jin et al. 2013).  Activation of 
TLR4 also leads to the induction of pro-inflammatory cytokines which, when bound to 
their receptors, can also elicit inactivation of key insulin receptor signaling components. 
Enhanced lipolysis in the insulin-resistant adipocyte leads to an increase in free fatty acid 
output to the periphery.  TLR2 activation within adipose tissue also induces insulin-
resistance.  TLR2 and TLR4-deficient mice show a decrease in inflammation and insulin-
resistance in response to high fat diet (Ehses et al. 2010; Himes and Smith 2010; Saberi et 
al. 2009; Tsukumo et al. 2007).   
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 Kupffer cells are macrophages located within the liver and have been shown to 
express TLR2, 4 and 9 (Jin et al. 2013).  TLR activation leads to insulin-resistance in the 
liver in a manner similar to that in adipose tissue.  Tlr2, Tlr4 and Tlr9-deficient mice are 
all protected from high fat diet-induced liver steatosis (Himes and Smith 2010; Miura et 
al. 2010; Saberi et al. 2009).   
 TLRs are critical mediators of the interaction between the gut microbiota and 
metabolism. Recently, it has been shown that Tlr2 and Tlr5-deficient mice are prone to 
obesity, insulin resistance and liver steatosis due to alterations in microbiota populations 
(Caricilli et al. 2011; Vijay-Kumar et al. 2010).  These results are intriguing as they show 
that TLRs may function either in a pathogenic or protective manner in metabolic 
dysfunction.  In support of a protective role for some TLRs in metabolic dysfunction, 
mice that lack the TLR adaptor protein MyD88 display hypercholesterolemia and a 
decrease in glucose tolerance compared to MyD88+/+ mice when fed a high fat diet 
(Hosoi et al. 2010).  Non-hematopoietic cells such as adipocytes, hepatocytes and 
endothelial cells have been shown to express TLRs (Batra et al. 2007; Curtiss and Tobias 
2009; Imaeda et al. 2009; Scott and Billiar 2008).  Therefore, specific TLRs may exert a 
pathogenic or protective effect upon diet-induced metabolic dysfunction through roles in 
immune or non-immune cell types.  Determining the cell-type specific roles of TLRs in 
metabolic regulation will require additional studies using conditional knockout mice. 
(Refer to Introduction Figure 2 for summary of TLRs in mouse models of metabolic 
dysfunction).  
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IRFs in metabolic dysfunction 
 Irf expression levels increase in the adipose tissue of mice fed a high fat diet 
compared to those fed normal chow (Kim et al. 2012; Kwon et al. 2012).  The increase in 
Irf expression may potentially be due to influx of Irf-expressing immune cells, an 
increase in the expression of Irfs in tissue-resident immune cells or to an increase in the 
expression of Irfs in adipocytes.  Thus, IRFs may affect metabolic dysfunction by 
promoting inflammation or by directly regulating genes within adipocytes. 
 IRFs are key transcription factors in the induction of inflammatory mediators in 
response to exogenous (PAMPs) and endogenous stimuli (DAMPs).  In the context of 
diet-induced obesity, endogenous stimuli released from damaged tissue may lead to the 
activation of IRFs in immune cells through stimulation of TLRs.  Because inflammation 
can directly lead to dysfunction of adipocytes, hepatocytes and other cells critical for 
maintaining metabolic homeostasis, it would be expected that blocking IRF-dependent 
inflammatory pathways would be protective.  Indeed, Irf7-deficient mice that were placed 
on a high fat diet for 24 weeks displayed a decrease in obesity, serum lipids and 
cholesterol as well as improved insulin-sensitivity compared to Irf7-sufficient mice 
(Wang et al. 2013b).  Serum from Irf7-deficient mice showed a reduction in pro-
inflammatory cytokines IL-1β, IL-4, IL-6, TNFα and MCP-1 compared to serum from 
Irf7-sufficient mice.  Consistent with the dramatic decrease in systemic inflammatory 
cytokines, liver-specific insulin-sensitivity was greatly improved as observed by an 
increase in the phosphorylation of key signaling molecules downstream from the insulin 
receptor.  Furthermore, Irf7-/- mice displayed a decrease in liver steatosis with 
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significantly decreased levels of triglyceride, cholesterol and non-esterified free fatty 
acids (NEFAs). 
 IRFs may directly regulate genes required for lipid homeostasis in an adipocyte-
specific manner and in response to high fat diet.  Recently, it was discovered that IRFs 
are key transcription factors in the regulation of adipogenesis (Eguchi et al. 2008).  
Eguchi et al performed high-throughput DNase I hypersensitivity analyses and 
determined that the regulatory regions of critical genes required for the differentiation of 
preadipocytes into mature adipocytes contained sequences known to be recognized by 
IRFs.  In a series of elegant experiments using ChIP and luciferase assays, the authors 
overexpressed and knocked down a panel of nine IRFs in differentiated 3T3L adipocytes 
and discovered that many IRFs acted as transcriptional repressors of adipogenesis by 
binding to IRF-response sequences located within the regulatory regions of genes 
required for adipocyte differentiation.  Irf7-deficient mice on high fat diet displayed 
changes in the expression level of genes required for lipolysis and lipogenesis in adipose 
tissue.  Therefore, IRF7 may directly regulate genes in adipocytes required for adipocyte 
function and differentiation (Wang et al. 2013b). 
 IRFs may directly control liver metabolic homeostasis.  Similar to that observed 
in adipose tissue, Irf7-deficiency led to changes in the expression levels of genes required 
for lipolysis as well as fatty acid and cholesterol synthesis in the liver of high fat diet fed 
mice (Wang et al. 2013b).  Therefore, the improvement in insulin-sensitivity and 
amelioration of liver steatosis observed in the Irf7-deficient mice might be a direct result 
of IRF7 transcriptional regulation of genes required for lipid and cholesterol homeostasis 
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within hepatocytes and not, as described above, as a result of the decrease in whole-body 
inflammation.  
  Irf3-deficient mice fed high fat diet develop more severe hepatic steatosis and are 
insulin-resistant compared to Irf3-sufficient mice (Wang et al. 2013a).  Adenoviral 
overexpression of Irf3 in the liver led to marked protection from diet-induced liver 
steatosis and showed that IRF3 improved liver function by inhibiting the NFĸB 
inflammatory pathway.  Furthermore, the IRF3-dependent inhibition of the NFĸB 
pathway was found to occur within hepatocytes.  Thus, IRFs can regulate metabolic gene 
expression by interfering with inflammatory pathways within non-hematopoietic cells, 
such as adipocytes.  However, whether the hepatocyte-specific role of IRF3 is the 
dominant protective mechanism in vivo remains to be determined.   
 Designating a direct role for IRFs in regulating metabolism has been difficult due 
to the prominent role of IRFs in inflammation and the relationship between inflammation 
and metabolic dysfunction.  However, in 2011, Eguchi et al crossed adipose-specific Cre 
mice to Irf4 floxed mice and placed the mice on high fat diet (Eguchi et al. 2011).  
Adipocyte-deletion of Irf4 led to a marked increase in adiposity and adipocyte 
hypertrophy.  Irf4-deficient adipocytes displayed a marked decrease in lipolysis in 
response to beta-adrenergic receptor ligation both in vivo and ex vivo.  Chromatin 
immunoprecipitation (ChIP) studies revealed that IRF4 directly bound to the promoter 
region of the gene econding adipose triglyceride lipase (ATGL) and increased the 
expression level of a ATGL-driven luciferase.  Furthermore, IRF4 activity was repressed 
by insulin signaling.  Whether IRF4 regulation in adipocytes requires TLR activation is 
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not known.  However, it is possible that IRFs modulate adipocyte metabolism in a TLR-
independent manner downstream from an as yet unidentified metabolic sensor. (Refer to 
Illustration 3 for summary of IRFs in mouse models of metabolic dysfunction). 
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Illustration 3.  IRFs in mouse models of atherosclerosis and metabolic syndrome.   
All comparisons are relative to Irf5+/+ mice.  Abbreviations: Not determined (ND), high 
fat diet (HFD), western diet (WD), (-) is a decrease relative to +/+.  References: 1-(Wang 
et al. 2013a), 2-(Eguchi et al. 2011), 3-(Wang et al. 2013b). 
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CHAPTER TWO 
The role of IRF5 in the gld.apoE-/- mouse model of lupus and atherosclerosis. 
Abstract 
 Patients with Systemic Lupus Erythematosus (SLE) are at increased risk for the 
development of atherosclerosis due in large part to poorly-defined lupus-specific risk 
factors.  One such lupus-specific risk factor is systemic and chronic inflammation 
associated with an over activation of the immune system.  Interferon regulatory factor-5 
(IRF5) is a transcription factor that participates in the activation of the immune system 
through its activity in both innate and adaptive immune cells.  Gain-of-function 
polymorphisms in the gene encoding human Irf5 are associated with an increase in risk 
for the development of SLE.  In addition, deletion of Irf5 in several lupus mouse models 
leads to amelioration of disease.  As little is known about the role of IRF5 in lupus-
associated atherosclerosis, we examined the role of IRF5 in the gld.apoE-/- mouse model 
of lupus and lupus-associated atherosclerosis. We observed that Irf5-deficiency led to a 
decrease in splenomegaly, lymphadenopathy, ANA production and the severity of kidney 
disease.  Surprisingly, despite the decrease in systemic immune activation, Irf5-
deficiency led to a marked increase in the severity of atherosclerosis and to metabolic 
dysregulation characterized by hyperlipidemia, increased adiposity and insulin-resistance.  
Bone marrow chimera studies revealed that the pathogenic role of IRF5 in lupus was 
solely due to its expression in hematopoietic cells.  The atheroprotective effect of IRF5 
and the suppression of adiposity was found to be due to Irf5 expression in both 
hematopoietic and non-hematopoietic cells, whereas protection from hyperlipidemia was 
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solely due to the expression of Irf5 in non-hematopoietic cells. Together, our results 
reveal a role for IRF5 in metabolic homeostasis and protection against atherosclerosis 
even in the context of reduced lupus severity. 
Introduction 
 Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by 
chronic inflammation leading to organ damage of the kidneys, skin, joints and heart.  It 
affects ~ 5 million people worldwide and about 1.5 million Americans, the majority 
being women.  The development of premature accelerated atherosclerosis is a major 
cause of morbidity and mortality in patients with lupus as it can lead to stroke and 
myocardial infarction (Urowitz et al. 1976).  Patients with SLE are at increased risk for 
development of atherosclerosis due not only to the traditional Framingham risk factors 
(such as hypertension, hypertriglyceridemia, hypercholesterolemia, and smoking) but 
also to lupus-specific risk factors such as systemic and chronic inflammation (Bruce et al. 
2000; Skaggs et al. 2012). 
 Human genetic studies have demonstrated that polymorphisms in the gene 
encoding interferon regulatory factor 5 (IRF5) are strongly associated with an increased 
risk of developing SLE (Graham et al. 2006; Graham et al. 2007; Sigurdsson et al. 2005).  
IRF5 is a member of the large interferon regulatory factor (IRF) family of transcription 
factors which are involved in hematopoietic cell differentiation and immune cell function.  
IRF5 functions downstream of Toll-like receptors (TLRs) as well as other innate pattern 
recognition receptors (PRRs) (Barnes et al. 2001; Pitha et al. 1998; Takaoka et al. 2005).  
Upon TLR ligation by pathogen associated molecular patterns (PAMPs), IRF5-dependent 
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and independent signaling cascades are initiated resulting in the expression of genes 
encoding pro-inflammatory cytokines as well as anti-viral genes such as type I interferon 
(IFN).  IRF5 has been shown to act downstream of TLR3, 4, 7 and 9 in immune cells. 
However, the requirement for IRF5 in pro-inflammatory cytokine and type I IFN 
production downstream from TLR activation is cell type and ligand-dependent (Cham, 
Ko, and Niewold 2012).   
 The role of IRF5 in SLE disease pathogenesis is thought to be due, in part, to its 
function downstream of TLR7 and TLR9 in dendritic cells, monocytes and B 
lymphocytes (Stone et al. 2012; Yasuda et al. 2013; Yasuda et al. 2007).  During a 
normal immune response, TLR7 and TLR9 recognize PAMPs such as viral single 
stranded RNA and bacterial double stranded DNA, respectively.  Normally, self-RNA 
and self-DNA do not associate with the endsomally-located TLR7 and TLR9.  However, 
in the context of an autoimmune disease such as SLE, self-RNA and self-DNA form 
immune complexes (ICs) with autoantibodies which enable the internalization of these 
self-ligands.  Self-RNA and self-DNA can also be shuttled to endosomal compartments 
containing TLR7 and TLR9 by binding positively charged anti-microbial peptides, such 
as LL-37 (Kahlenberg and Kaplan 2013).  Upon internalization, the RNA and DNA are 
able to associate with endosomally-located TLR7 and TLR9 and elicit the activation of 
downstream signaling events contributing to pathogenesis (Marshak-Rothstein and Rifkin 
2007; Walsh et al. 2012).   
 In murine models of lupus, TLR9 activation contributes to the development of 
anti-chromatin autoantibodies and TLR7 activation to the development of anti-
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ribonucleoprotein antibodies (Christensen et al. 2005; Lau et al. 2005).  These 
autoantibodies form immune complexes with their respective antigens and deposit in 
tissues such as the glomeruli of the kidneys as well as in joints leading to complement 
activation.  Although TLR7 deletion leads to amelioration of disease in several lupus 
mouse models, TLR9 deletion actually exacerbates disease (Christensen et al. 2006; 
Deane et al. 2007; Feng et al. 2012; Nickerson et al. 2010; Pisitkun et al. 2006; Richez et 
al. 2010; Tada et al. 2011; Xu et al. 2012; Yang et al. 2012).  The deletion of IRF5 
ameliorates disease in the FcɣRIIb-/-, Yaa.FcɣRIIB, MRL/lpr and pristane models of 
lupus (Feng et al. 2012; Richez et al. 2010; Savitsky et al. 2010; Tada et al. 2011; Xu et 
al. 2012).  However, as discussed in Chapter 3 and Appendix I of this dissertation, a 
mutation in the gene encoding DOCK2 in the Irf5-/- line may have confounded these 
studies (Purtha et al. 2012; Yasuda et al. 2013). 
 The role of TLRs in atherosclerosis is complex.  TLR2 and TLR4 recognize a 
variety of ligands including, but not limited to, unsaturated fatty acids and oxLDL, 
respectively.  Deletion of Tlr2 or Tlr4 in the apoE-/- atherosclerosis prone mouse model 
leads to a decrease in atherosclerotic lesion size (Falck-Hansen et al. 2013; Hansson and 
Edfeldt 2005).  Similarly, deletion of the TLR adaptor protein MyD88 also leads to a 
decrease in atherosclerotic lesion size in atherosclerosis-prone mice.  In contrast, the 
nucleic acid sensing TLRs, TLR3, TLR7 and TLR9 all seem to be protective against 
atherosclerosis.  The deletion of Tlr3, Tlr7 or Tlr9 in apoE-/- mice leads to an increase in 
atherosclerotic lesion size as well as a decrease in plaque stability.(Cole et al. 2011; 
Koulis et al. 2014)   
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 TLRs expressed by lesion-specific immune cells most likely influence 
atherosclerosis by recognizing endogenous ligands present within atherosclerotic lesions 
and regulating inflammation (Cole et al. 2013).  However, they may also influence 
atherosclerosis indirectly through their expression in the brain, adipose tissue, liver and 
gastrointestinal tract (Falck-Hansen et al. 2013).  Indeed, an increasing body of research 
suggests that TLRs influence atherosclerosis not only due to their role in atherosclerotic 
lesion-specific inflammation, but also to effects on adipose tissue homeostasis, gut 
microbe homeostasis and insulin sensitivity (Jin et al. 2013; McGettrick and O'Neill 
2013; Vijay-Kumar et al. 2010). 
 Although the precise etiology of SLE-associated atherosclerosis is unknown, the 
use of murine models of lupus and atherosclerosis allow for the identification of 
mechanisms underlying ‘lupus-specific’ risk factors for atherosclerosis.  For our studies 
we have used the gld.apoE-/- mouse model of lupus and atherosclerosis.  A point mutation 
in the gene encoding murine Fas ligand (gld) leads to the development of a mild form of 
spontaneous autoimmune disease characterized by the production of low levels of 
pathogenic autoantibodies as well as the development of mild splenomegaly, 
lymphadenopathy and glomerulonephritis (Bhandoola et al. 1994).  apoE-/- mice lack the 
gene encoding apolipoprotein E (apoE) which is responsible for the transport of 
lipoproteins and cholesterol (Meir and Leitersdorf 2004).  Without this important 
regulator of lipid metabolism, mice develop hypercholesterolemia and premature 
atherosclerosis (Wu and Huan 2007).  When the gld and apoE-/- mutations are combined 
into the gld.apoE-/- murine model of SLE-associated atherosclerosis, mice develop more 
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severe lupus and atherosclerosis, especially when fed a diet rich in fat (Aprahamian et al. 
2004).  
 In this study, our objective was to determine the role of IRF5 in lupus-associated 
atherosclerosis.  We found that IRF5 is required for the development of lupus-associated 
disease manifestations but, unexpectedly, IRF5 deletion led to increased atherosclerosis 
in the gld.apoE-/- mouse model.  Furthermore, bone marrow chimera studies show that 
Irf5 expression in hematopoietic cells is absolutely required for the development of lupus, 
whereas Irf5 expression in both hematopoietic and non-hematopoietic cells is required for 
protection against atherosclerosis.  Finally, we show that IRF5 may be important in 
maintaining metabolic homeostasis in that Irf5-deficiency leads to an increase in adipose 
tissue, hyperlipidemia and insulin-resistance.  Whereas IRF5 may contribute to adipose 
tissue regulation due to its expression in both hematopoietic and non-hematopoietic cells, 
hyperlipidemia is due exclusively to Irf5 expression in non-hematopoietic cells.  Our data 
highlights a dual role for IRF5 in the pathogenesis of lupus and the protection against 
atherosclerosis and metabolic dysfunction. 
Materials & Methods  
Mice 
 
Irf5-/- mice backcrossed eight generations to C57BL/6 were obtained from T. Taniguchi 
(University of Tokyo, Tokyo, Japan) and T. Mak (University of Toronto, Toronto, 
Ontario, Canada) (Takaoka et al. 2005).  Irf5-/- mice were backcrossed 8 generations to 
gld.apoE-/- mice (Aprahamian et al. 2004). The gld.apoE-/-.Irf5-/- line was screened for the 
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DOCK2 mutation and only DOCK2 wild type mice were used for breeding (see 
Appendix I).  gld.apoE-/-.Irf5-/- were crossed to newly generated gld.apoE-/- mice (derived 
from gld and apoE-/- crosses) to generate gld.apoE-/-.Irf5+/-.  Experimental mice were 
generated by breeding Irf5 heterozygous (Irf5+/-) gld.apoE-/- mice to obtain Irf5+/+, Irf5+/- 
and Irf5-/- gld.apoE-/- littermates.  Irf5-/- mice backcrossed 15 generations to C57BL/6 and 
wild type for DOCK2 were crossed to apoE-/- to generate apoE-/-.Irf5+/-.  Experimental 
mice were generated by breeding apoE-/-.Irf5+/- to generate Irf5+/+, Irf5+/- and Irf5-/-  
apoE-/- littermates.  Irf5-/- mice backcrossed 15 generations to C57BL/6 were used in 
comparison to age and sex-matched C57BL/6 mice.  Animal experiments were approved 
by the Institutional Animal Care and Use Committee at Boston University.   
All mice were littermates and gender differences were taken into account 
 
Differences in genetic background of mouse strains can influence the disease severity of 
lupus, atherosclerosis and metabolic syndrome (Maeda 2011).  The gld, apoE-/- and Irf5-/- 
mice used to generate the experimental mice were all backcrossed at least 12 generations 
to the C57BL/6 genetic background.  To further minimize the effect of background 
genetics, all mice used in this study were littermates.  In addition, a comparison between 
males and females was performed.  All of the IRF5-dependent effects in lupus, 
atherosclerosis and metabolism were observed in both males and females, although there 
were quantitative differences between males and females for some aspects of disease. 
 
  
47 
Littermate mice were housed in the same cage for the duration of the 
experiment limiting differences in gut microbiome 
 
The population of gut microbiota can influence obesity and other metabolic phenotypes 
in mice.  For example, Tlr5-/- mice display an increase in obesity compared to Tlr5+/+ 
mice as a result of Tlr5 expression within the gut and the critical function of TLR5 
activation in maintaining ‘healthy’ populations of gut microbiota (Vijay-Kumar et al. 
2010).  In addition, many recent studies have described that the transfer of microbiota 
from one mouse to another can lead to increased susceptibility of mice to inflammatory 
diseases such as inflammatory bowel disease and obesity (Elinav et al. 2011; Sommer 
and Backhed 2013).  Data shows that the specific populations of microbiota colonizing 
the adult mouse gut are dependent on the microbiota of the mother as well as the 
microbiota that colonize the gut between weaning and 8 weeks of age (Jiang, Bos, and 
Cebra 2001; Spor, Koren, and Ley 2011).  Therefore, Irf5+/+gld.apoE-/-, Irf5+/-gld.apoE-/- 
and Irf5-/- gld.apoE-/- littermates were housed together in the same cage from birth until 
the end of the 19 week experiment.  
Bone marrow chimera studies 
 
At 7 weeks of age male Irf5+/+ gld.apoE-/-  and Irf5-/- gld.apoE-/- bone marrow recipients 
were X-ray irradiated with 2 doses of 550 rads spaced three hours apart.  Bone marrow 
isolated from age-matched Irf5+/+ gld.apoE-/-  and Irf5-/- gld.apoE-/- donor mice was 
harvested and resuspended at a concentration of 5 x 10^6 cells/mL.  100-200 uL of bone 
marrow cells were transplanted into recipients via tail vein injection.  Bone marrow 
recipients were placed on antibiotics for three weeks.  At the end of three weeks, bone 
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marrow recipients were placed on western diet for 6-9 weeks and euthanized at 16-19 
weeks of age. 
Western Diet 
 
Western diet was purchased from Harlan Teklad (Cat. No. 88137).  Cholesterol (0.2% 
total cholesterol), total fat (21% by weight; 42% kcal from fat), saturated fatty acids 
(>60% of total fatty acids), high sucrose (34% by weight). 
PCR 
 
The PCRs used to detect gld, apoE-/- and Irf5-/- were described previously (Aprahamian et 
al. 2004; Richez et al. 2010).  gld F: 5’- TGA TCA ATT TTG AGG AAT CTA AGG CC 
-3’ and gld R: 5’-ATA GGT CTT AAG AAG ACT CTC ATT CAA G -3’.  DNA was 
then purified using phenol chloroform isoamylalcohol and ethanol purification for DNA 
sequencing of the gld locus.   
Serological assays 
 
Anti-nuclear autoantibody (ANA) titer was measured by immunofluorescence using 
slides coated with permeabilized human epithelial cells (HEp-2-coated-slides-Antibodies 
Incorporated, Davis, CA).  Serially diluted mouse serum was incubated on HEp2 slides, 
washed and incubated with a fluorophore-conjugated goat anti-mouse antibody (1:100).  
HEp2 slides were washed, mounted and photographed using an epifluorescent 
microscope.  The last positive dilution is plotted for each mouse serum sample.  Serum 
triglyceride, total cholesterol, phospholipids and non-esterified free fatty acids were 
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measured by the University of Cincinnati Mouse Metabolic Phenotyping Core (MMPC) 
core.  Serum leptin, glucose and insulin were measured by the University of 
Massachusetts Medical School Mouse Metabolic Phenotyping Center.  Serum cytokines 
were measured by Luminex at the University of Massachusetts Medical School Mouse 
Phenotyping-Analytical Core. 
Histology 
 
Kidney: Hematoxillin and eosin-stained kidney sections were evaluated in a blinded 
manner. Randomly selected areas of cortex were digitally photographed by a blinded 
investigator using an RT color spot camera (Diagnostic Instruments, Sterling Heights, 
MI), and Spot Advanced software version 4.0.9 (Diagnostic Instruments). Fifty glomeruli 
from each animal were examined to determine the percentage of glomeruli with severe 
lesions (i.e. glomerular crescents or areas of necrosis), mild lesions (i.e. mesangial 
expansion) or no lesions. In severe glomerular lesions, crescents were identified by the 
presence of >3 palisading layers of cells in the extra-capillary space, and fibrinoid 
necrosis was identified by its classic eosinophillic and acellular appearance. Mild 
glomerular lesions were defined as prominence of the mesangial matrix as compared to 
normal glomeruli that occurred in the absence of severe lesions.  
Liver: Liver was fixed in 4%  paraformaldehyde, parafin-embedded, cut into 8um 
sections and stained with hematoxylin and eosin.  Images were taken at 4x magnification 
using a light microscope. 
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Adipose tissue: Perigonadal fat pads from experimental mice were fixed in 4% formalin 
and stored in 1x phosphate buffered saline (PBS).  Samples were sent to the Dana-Farber 
Harvard Cancer Center Pathology Core for embedding, sectioning and H & E staining. 
Analysis of atherosclerosis 
 
Aortic root analysis: The apex of the heart was cut at a 45 degree angle, and the cut side 
of the heart was placed on the bottom of a plastic cartridge filled with OCT.  Correct 
placement of the cut heart was carried out so that the aortic root was parallel to the 
bottom of the plastic cartridge.  The aortic arch was cut at the point at which it joins the 
heart.  Hearts were snap-frozen in OCT in ice-cold methylbutane and dry ice. 8um serial 
aortic root sections were cut and slides were fixed in 4% paraformaldehyde.  In a blinded 
manner, 24-30 aortic root sections per mouse heart were stained with Oil Red O and 
hematoxylin, imaged at 4x magnification using a light microscope and the average area 
of aortic lesions was quantified using Adobe Photoshop CS3.   
Aortic arch analysis:  The aortic arch from each mouse was fixed in 4% 
paraformaldehyde, cut longitudinally, pinned and stained with Oil Red O to detect lipid 
deposition.  In a blinded manner, the area of the total aortic arch and area stained positive 
for Oil Red O was quantified using Adobe Photoshop CS3 color range tool.  The data is 
reported as average percentage of total aortic arch stained positive for Oil Red O in each 
experimental group. 
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Foam cell formation assay 
 
Sera were collected from gld.apoE-/- mice that had been on western diet for 12 weeks.  
Bone marrow was isolated from wild type and Irf5-deficient C57BL/6 mice and 
differentiated into macrophages for 6 days using L929 supernatant containing 
macrophage-colony stimulating factor, M-CSF.  On day 7 of differentiation, the 
macrophages were treated with media plus Irf5+/+ gld.apoE-/-   or Irf5-/- gld.apoE-/- sera to 
a final concentration of 10%.  24 hours later, the supernatant was removed and the cells 
were formalin fixed, stained with Oil Red O and imaged at 20x magnification.  Peritoneal 
lavage macrophages from Irf5+/+ gld.apoE-/-   and Irf5-/- gld.apoE-/- mice that had been on 
western diet for 12 weeks were plated and allowed to rest for 4-6 hours.  Peritoneal 
macrophages were then treated with media plus Irf5+/+ gld.apoE-/-  or Irf5-/- gld.apoE-/- 
sera to a final concentration of 10%.  24 hours later, the supernatant was removed and the 
cells were formalin fixed, stained with Oil Red O and imaged at 20x magnification.  The 
area of 20-25 macrophages in each experiment were measured and the percentage of area 
that was positive for Oil Red O was measured using Adobe Photoshop CS3 color range 
tool. Data is reported as the average of three separate experiments using serum from three 
different gld.apoE-/- littermate groups. 
Noninvasive magnetic resonance (NMR)  and Metabolic Phenotyping 
 
Assessment of body composition (fat mass and lean tissue mass) was performed by non-
invasive quantitative magnetic resonance (EchoMRI700) at the Boston University 
Metabolics Phenotyping Core.  Measurement of basal metabolic rate (including oxygen 
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consumption and thermogenesis) and physical activity was performed using the 
comprehensive laboratory animal monitoring system (CLAMS consisting of open circuit 
calorimeter & motion detectors) at the Boston University Metabolics Phenotyping Core. 
Adipocyte purification and quantification 
 
Adipocyte purification was performed using a protocol from the laboratory of Dr. Susan 
Fried at Boston University School of Medicine.  Briefly, perigonadal fat pads from 
experimental mice were minced in media containing Collagenase and adenosine (to 
inhibit lipolysis).  Mixtures were incubated in a 37 C water bath for 1-2 hours and 
agitated every 15 minutes.  PBS was added to a final volume of 10 mL and mixtures were 
run through two nylon screens.  Mixtures were incubated for 10-15 minutes at room 
temperature to allow adipocytes to float to the top.  A 16-gauge needle attached to a 
syringe and tubing was used to remove the fraction below the floating adipocytes.  This 
fraction contains stromal vascular cells.  The adipocyte fraction was then imaged using a 
light microscope or snap frozen in Qiazol for RNA analysis.  Images of purified 
adipocytes were taken at 4x magnification and the diameters of 50-60 adipocytes per fat 
pad were quantified and plotted by histogram. 
Body weight and food intake measurements 
 
 Irf5+/+ gld.apoE-/- , Irf5+/- gld.apoE-/-  and Irf5-/- gld.apoE-/- littermate mice were weighed 
weekly for 12 weeks after being placed on western diet at 7 weeks of age.  Littermate 
groups were separated into individual cages at the beginning of the 11th week on western 
diet. Daily food consumption was measured over a period of 2-7 days.   
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Glucose and insulin tolerance tests 
 
Irf5+/+ gld.apoE-/-, Irf5+/- gld.apoE-/-  and Irf5-/- gld.apoE-/- littermate mice on western diet 
for 6-8 weeks were fasted for 6 hours and baseline blood glucose was measured using a 
glucometer.  Mice were given either an intraperitoneal glucose or insulin injection 
normalized to body weight.  Subsequently, blood glucose was measured via tail bleed at 
15, 30, 45, 60, 90 and 120 minutes post-IP injection.   
In vitro primary immune cell cultures 
 
Macrophages-  Bone marrow from Irf5+/+ and Irf5-/- C57BL/6 mice was cultured in vitro 
for 6 days using L929 supernatant containing M-CSF or using recombinant GM-CSF to 
generate M-CSF and GM-CSF macrophages (Media-DMEM + 10% FBS + penicillin and 
streptomycin).  On Day 6, supernatant was removed, cells were washed with PBS, 
adherent cells were scraped and re-plated into flat-bottom 96 well plates.  On Day 7, 
macrophages were stimulated for 24 hours with the following TLR ligands: Pam3Cys 
(TLR2), Poly I:C (TLR3), LPS (TLR4), R837 (TLR7) and CpG-B 1826 (TLR9).  
Supernatant was collected and IL-10 protein levels were measured using a mouse IL-10 
ELISA kit from BD.   
Dendritic cells-  Bone marrow from Irf5+/+ and Irf5-/- C57BL/6 mice was cultured in vitro 
for 6 days using recombinant GM-CSF or for 7 days using Flt3 ligand to generate GM-
CSF and Flt3 dendritic cells.  (Media-RPMI+ 10% FBS+ penicillin and streptomycin).  
On Day 6 or 7, non-adherent cells were collected, spun down and re-plated in round-
bottom 96 well plates.  On Day 7, GM-CSF dendritic cells were cultured with following 
  
54 
TLR ligands for 24 hours: Pam3Cys (TLR2), Poly I:C (TLR3), LPS (TLR4), R837 
(TLR7), CpG-B 1826 (TLR9).  On Day 8, Flt3 dendritic cells were cultured with the 
following TLR ligands for 5 days: Pam3Cys (TLR2), Poly I:C (TLR3), LPS (TLR4), 
R848 (TLR7) and CpG-A 2336 (TLR9).  Supernatant was collected and IL-10 protein 
levels were measured by ELISA. 
B-cells:  Splenocytes were harvested from Irf5+/+ and Irf5-/- C57BL/6 mice.  B cells were 
positively selected using anti-B220 magnetic Miltenyi beads and plated in a round-
bottom 96 well plate (Media-RPMI +10% FBS + penicillin and streptomycin).check 
this!!! B cells were stimulated for 24 hours with the following TLR ligands: Pam3Cys 
(TLR2), LPS (TLR4), CLO97 (TLR7) and CpG-B 1826 (TLR9).  Supernatant was 
collected and IL-10 protein levels were measured by ELISA. 
RNA isolation 
 
Small pieces of perigonadal fat pad, liver and muscle were snap frozen and stored at -
80C.  Upon thawing, tissue was immediately resuspended in Qiazol and lysed using the 
TissueLyser.  RNA was then isolated using a Qiagen Kit and resuspended in RNAse-free 
water.  RNA yield was measured using Nanodrop. 
Real-time PCR 
 
RNA from perigonadal fat, liver and muscle was treated with DNase and reverse 
trancribed into cDNA using Thermoscript reverse transcriptase.  cDNA was diluted 1:100 
and PCR was performed using Taqman primers specific for murine Irf5.  Data was 
analyzed using the 2-∆ Ct (relative to housekeeping gene; termed ‘relative expression’) or  
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2-∆∆ Ct (relative to housekeeping gene and normalized to reference sample; termed ‘Fold 
Change’) calculations. 
Statistical analysis 
 
Groups were compared using the Unpaired T test, two-tailed.  The Mann-Whitney U was 
used for ANA titers as the data was not normally distributed.  Analysis of variance on 
ranks was used for atherosclerotic lesion area data.  All statistics were performed using 
GraphPad Instat or SigmaPlot 12.5 (Systat, San Jose, USA) with P < 0.05 considered as 
statistically significant.  
 
Results 
Irf5-deficiency protects against the development of lupus in the gld.apoE-/- 
mouse model 
 
As in other murine models, lupus-like disease is characterized by splenomegaly, 
lymphadenopathy, ANA production and kidney disease in the gld.apoE-/- mouse model 
(Aprahamian et al. 2004).  We generated Irf5+/+gld.apoE-/- (termed Irf5-sufficient), Irf5+/-
gld.apoE-/- and Irf5-/- gld.apoE-/- (Irf5+/- and Irf5-/- are termed Irf5-deficient) littermates 
and analyzed their lupus-associated disease parameters after 12 weeks on western diet. 
Littermate cohorts were used in order to minimize genetic differences and differences in 
gut micriobiota.  Irf5+/- gld.apoE-/- and Irf5-/- gld.apoE-/- displayed a significant decrease 
in spleen and lymph node size (Figure 1 A & B).  Furthermore, Irf5+/- gld.apoE-/- and 
Irf5-/- gld.apoE-/- mice displayed a significant reduction in serum titers of anti-nuclear 
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autoantibody.  (Figure 2A)  Irf5+/+ gld.apoE-/- mice show a homogenous staining pattern 
which points to the presence of anti-dsDNA antibodies within the serum.  This 
homogenous staining pattern was absent in assays using serum from Irf5-/-gld.apoE-/- 
mice (Figure 2B).    Notably, splenomegaly and lymphadenopathy were comparable 
between Irf5+/-gld.apoE-/- and Irf5-/-gld.apoE-/- mice whereas Irf5+/-gld.apoE-/- mice 
displayed an intermediate ANA titer. This shows that there is a threshold level of IRF5 
required for the development of specific outcomes of autoimmunity in gld.apoE-/- mice.  
Systemic inflammation and immune complex deposition contributes to kidney disease in 
mouse models of lupus (Richez et al. 2010).  Irf5-deficiency protected gld.apoE-/- mice 
from the development of kidney disease, as Irf5-deficient gld.apoE-/- mice showed a 
significant decrease in glomerular disease score as well as the percentage of glomeruli 
that were necrotic or crescentric (Figure 3A & B).  Finally, Irf5-deficient gld.apoE-/- mice 
displayed a significant decrease in levels of serum cytokines compared to Irf5-deficient 
gld.apoE-/- mice showing that Irf5-deficiency leads to a decrease in systemic 
inflammation (Figure 4A-E).  In summary, Irf5-deficiency prevents the development of 
lupus in the gld.apoE-/- model. 
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Figure 1 Splenomegaly and lymphadenopathy are reduced in Irf5+/- and Irf5-/- gld.apoE-/- mice. 
A)  Spleen and B) lymph node weights from male and female Irf5+/+gld.apoE-/- (n=27), 
Irf5+/-gld.apoE-/- (n=28), and Irf5-/-gld.apoE-/- (n=24) littermate mice were measured at 19 
weeks of age after being placed on western diet for 12 weeks.  Statistics: Unpaired T test. 
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Figure 2 Decreased ANA production in Irf5-/- gld.apoE-/- mice. 
A)  ANA titers in sera from Irf5+/+gld.apoE-/- (n=13), Irf5+/-gld.apoE-/- (n=11), and Irf5-/- 
gld.apoE-/-  (n=9) littermate mice were measured by immunofluorescence at 19 weeks of 
age after the mice has been on western diet for 12 weeks.  B)  Representative ANA 
immunofluorescence on Hep2 cells.  Upper image: serum from Irf5+/+gld.apoE-/- at a 
dilution of 1:100.  Lower image: serum from Irf5-/- gld.apoE-/- at a dilution of 1:100. 20x 
magnification.  Statistics: Mann-Whitney U test. 
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Figure 3 Scoring of kidney disease severity in gld.apoE-/- mice.   
Kidney sections from Irf5+/+ gld.apoE-/-  (n=15), Irf5+/ gld.apoE-/- - (n=9), and Irf5-/- 
gld.apoE-/-  (n=15) littermate mice fed high fat diet for 12 weeks were H & E stained and 
scored for kidney disease severity.  A)  Glomerular disease score.  B)  The average % of 
glomeruli per kidney that are necrotic or crescentic. Stained slides are scored by an 
investigator who is blinded to the groups.  Twenty-five to fifty glomeruli from one or two 
different kidney sections for each mouse were examined and the severity of injury in each 
glomerulus was graded using a scale of 0-4 where 0=Normal, 1=Mesangial Hypertrophy, 
2=Proliferative Glomerulonephritis and/or immune cell infiltration, 3=Glomerular 
Necrosis and 4=Crescentric Glomerulonephritis.  The mean glomerular score is then 
calculated for each mouse.  Statistics: Unpaired T test, 2-sided. 
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Figure 4 Serum cytokines in gld.apoE-/- mice.   
Sera from 19 week old Irf5+/+ (n=9) and Irf5-/- (n=9) gld.apoE-/- littermate mice fed 
western diet for 12 were analyzed for A) IL-10, B) IL-6, C) IL-12p70 D) IFNɣ and E) 
TNFα.  Statistics: Mann-Whitney U-test. 
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Irf5-deficient gld.apoE-/- mice develop more severe atherosclerosis than 
Irf5-sufficient gld.apoE-/- mice 
 
apoE-/- mice develop atherosclerotic lesions, which are made worse by a diet rich 
in cholesterol and fat (Pendse et al. 2009).  It has been reported that the severity of 
atherosclerosis increases when apoE-/- mice are crossed to mice on a lupus susceptible 
background (Aprahamian et al. 2004; Wade and Major 2011).  In addition, the severity of 
lupus-associated disease parameters, such as lupus nephritis, is exacerbated (Aprahamian 
et al. 2004).  As described in Figures 1-4, we knew that Irf5-deficiency protected 
gld.apoE-/- mice from developing lupus and, therefore, hypothesized that Irf5-deficiency 
would likewise protect against the development of atherosclerosis as inflammation is a 
major contributor to atherosclerosis.  Irf5-/- gld.apoE-/- mice were not protected against 
the development of atherosclerosis, but in fact they developed significantly larger 
atherosclerotic lesions as shown by Oil Red O staining of lesions present in the aortic 
roots of gld.apoE-/- mice (Figure 5A and B).  Here we compared the area of 
atherosclerotic lesion within the aortic root between each Irf5+/+ gld.apoE-/-, Irf5+/- 
gld.apoE-/-  and Irf5-/- gld.apoE-/-  littermate group and found that the Irf5-/- gld.apoE-/-  
mice had significantly increased atherosclerosis when directly compared to their Irf5+/+ 
gld.apoE-/-  littermate.  On average, Irf5-/- gld.apoE-/- mice showed a 46%  increase in 
atherosclerotic lesion size compared to their Irf5+/+ gld.apoE-/-  littermate, and Irf5+/-
gld.apoE-/- mice show a 31% increase in atherosclerotic lesion size compared to their 
Irf5+/+ gld.apoE-/-  littermate, although the comparison between Irf5+/+ gld.apoE-/-  and 
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Irf5+/- gld.apoE-/- mice did not reach statistical significance.  Representative images of 
Oil Red O stained aortic roots are shown in Figure 5B.  To further evaluate the role of 
IRF5 in atherosclerosis development we also measured the percentage of lesion within 
the aortic arches of gld.apoE-/- littermates.  Figure 5C shows that, similar to what was 
observed in the aortic root, Irf5-/-gld.apoE-/- mice showed a significant increase in the 
percentage of aortic arch with lesion compared to Irf5+/+gld.apoE-/- littermates.  On 
average Irf5-/-gld.apoE-/- displayed an 82% increase in aortic arch atherosclerosis 
compared to Irf5+/+ gld.apoE-/- littermates.  Thus, IRF5 inhibits the development of 
atherosclerosis in gld.apoE-/- mice.   
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Figure 5 Increased atherosclerosis in aortic root and aortic arch of Irf5-deficient gld.apoE-/- mice.   
A and D)  Serial aortic root sections from Irf5+/+ gld.apoE-/-  (n=12), Irf5+/- gld.apoE-/-  
(n=8), and Irf5-/- gld.apoE-/-  (n=14) littermate mice fed high fat diet for 12 weeks were 
stained with Oil Red O to detect lipid deposition.  24-30 aortic root sections per mouse 
heart were stained with Oil Red O and quantified using Adobe Photoshop CS3 after 
imaging at 4x.  The Y-axis represents the average fold change of aortic root lesion area in 
Irf5+/- gld.apoE-/-  and Irf5-/- gld.apoE-/- mice normalized to their Irf5+/+ gld.apoE-/-  
littermate. B)  Representative images of Oil Red O-stained aortic roots from Irf5+/+ 
gld.apoE-/-, Irf5+/- gld.apoE-/-  and Irf5-/- gld.apoE-/- mouse hearts.  C)  Aortic arches from 
Irf5+/ gld.apoE-/- + (n=6), Irf5+/ gld.apoE-/- - (n=6), and Irf5-/- gld.apoE-/- (n=7) littermate 
mice were formalin-fixed, pinned and stained with Oil Red O to detect lipid deposition 
within lesions.  In a blinded manner, the area of the total aortic arch and area stained 
positive for Oil Red O was quantified using Adobe Photoshop color range tool.  Y-axis 
represents average % of aortic arch stained positive for Oil Red O within each group.  
Statistics: A) Two-way ANOVA on fold change (not ranked).  B) Wilcoxon, ranked. 
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Irf5-deficient gld.apoE-/- mice are hyperlipidemic 
 
Atherosclerosis is a chronic inflammatory condition initiated by the oxidation of 
low density lipoprotein (LDL) (Libby 2012).  High serum LDL is a major risk factor for 
the development of atherosclerosis in humans (Van Gaal et al. 2006).  We observed that 
serum from Irf5-/- gld.apoE-/- mice appeared lactescent and more turbid than serum from 
Irf5+/+ gld.apoE-/- littermates, suggesting an alteration in serum lipids (Figure 6 A).   As 
hyperlipidemia can cause atherosclerosis, we speculated that Irf5-deficiency may be 
altering serum lipids and thereby contributing to the increased atherosclerosis seen in the 
Irf5-/-gld.apoE-/- mice. We therefore measured serum lipids and found that, indeed, Irf5-
deficient gld.apoE-/- mice showed a significant increase in serum levels of triglycerides, 
cholesterol, phospholipids, and non-esterified free fatty acids (NEFAs) compared to Irf5-
sufficient gld.apoE-/- mice (Figure 6 B-E).  Increased levels of very low and low density 
lipoprotein (VLDL and LDL) are thought to be the most pathogenic lipoproteins in the 
development of atherosclerosis.  We analyzed the lipoprotein profiles of Irf5+/+gld.apoE-/- 
and Irf5-/- gld.apoE-/- mice by fast-performance liquid chromatography (Figure 7).  
Strikingly, Irf5-/- gld.apoE-/- mice had much higher levels of serum VLDL than 
Irf5+/+gld.apoE-/- mice.  Although LDL levels were comparable between groups, Irf5-/-
gld.apoE-/- mice displayed a marked decrease in HDL compared to Irf5+/+gld.apoE-/- 
mice.  These results were intriguing as HDL has an atheroprotective role in that it 
participates in cholesterol efflux from macrophages within atherosclerotic lesions and has 
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anti-inflammatory properties (Navab et al. 2011).  Thus, IRF5 may protect against 
atherosclerosis by regulating serum lipids, specifically VLDL and HDL, in gld.apoE-/- 
mice. 
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Figure 6 Irf5-deficient gld.apoE-/- mice are  
A)  Images of representative sera from Irf5+/+ gld.apoE-/- (left) and Irf5-/- gld.apoE-/- 
(right) littermates after 12 weeks on western diet. B-E) Sera from 19 week old Irf5+/+ 
(n=18), Irf5+/- (n=15), and Irf5-/- (n=19) littermate mice fed western diet for 12 were 
analyzed for B) triglyceride, C) total cholesterol, D) phospholipid and E) non-esterified 
free fatty acid content.  Statistics: Unpaired T test, 2-sided. 
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Figure 7 Lipoprotein from Irf5+/+ and Irf5-/- gld.apoE-/- mice. 
Pooled sera from three Irf5+/+ gld.apoE-/-  (top panel) and three Irf5-/- gld.apoE-/- mice that 
had been on western diet for 12 weeks were pooled and lipoproteins were fractionated by 
fast-performance liquid chromatography.  The absorbance of each fraction was measured. 
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Figure 8 Correlation of total serum cholesterol and atherosclerosis in Irf5+/+, Irf5+/- and Irf5-/- gld.apoE-/- mice.  
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Sera from Irf5-deficient gld.apoE-/- mice is more atherogenic than sera 
from Irf5-sufficient gld.apoE-/- mice 
 
We have shown that Irf5-deficiency in gld.apoE-/- mice led to hyperlipidemia and 
an increase in atherosclerosis.  Hypertrigylceridemia and hypercholesterolemia are risk 
factors for atherosclerosis (Sherer and Shoenfeld 2006).  We found that cholesterol levels 
positively correlated with atherosclerotic lesion area in both male and female gld.apoE-/- 
mice (Figure 8).  To link the hypercholesterolemia observed in our model more directly 
with atherosclerosis development, we tested the ability of the sera from Irf5+/+ gld.apoE-/- 
and Irf5-/-gld.apoE-/- mice to induce macrophages to become foam cells.  Foam cells form 
after macrophage uptake of oxLDL in atherosclerotic lesions and are thought to play a 
central role in atherosclerosis pathogenesis (Moore and Tabas 2011).  As shown in Figure 
9, macrophages treated with sera from Irf5-/- gld.apoE-/- mice showed an increase in foam 
cell formation compared to the same macrophages treated with sera from Irf5+/+ 
gld.apoE-/- mice.  In summary, sera from Irf5-/- gld.apoE-/- mice, which exhibited 
significantly higher levels of cholesterol, was a better inducer of foam cell formation than 
serum from Irf5+/+ gld.apoE-/- mice.  Serum cholesterol levels positively correlated with 
atherosclerotic lesion size in gld.apoE-/- mice.  These data support the hypothesis that the 
hyperlipidemia (specifically hypercholesterolemia), in Irf5-deficient gld.apoE-/- mice 
contributes to the increased atherosclerosis. 
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Figure 9 Sera from Irf5-deficient gld.apoE-/- mice induces more foam cell formation than sera from Irf5-/- 
sufficient gld.apoE-/- mice. 
Sera were collected from Irf5+/+gld.apoE-/- and Irf5-/-gld.apoE-/- male mice after 12 weeks 
on western diet.  Bone marrow was isolated from wild type C57BL/6 mice and 
differentiated into macrophages for 6 days using L929 supernatant containing the 
macrophage growth factor, M-CSF.  On day 7 of differentiation, the macrophages were 
treated with media plus gld.apoE-/- sera (Irf5+/+ and Irf5-/-) to a final concentration of 10% 
serum.  24 hours later, the supernatant was removed and the cells were formalin fixed, 
stained with Oil Red O and imaged at 20x magnification.  A) Representative images from 
three experiments.  B)  The area of 20-25 macrophages in each experiment was measured 
and the percentage of area that was positive for Oil Red O was measured using Adobe 
Photoshop CS3 color range tool.  Data are the average of three separate experiments 
using serum from three different littermate groups. Statistics: Unpaired T test. p*<0.05.
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Irf5-deficiency leads to an increase in adiposity in gld.apoE-/- mice 
 
Hyperlipidemia can result from perturbations in normal adipose tissue 
homeostasis (Klop, Elte, and Cabezas 2013; Van Gaal et al. 2006).  Furthermore, adipose 
tissue dysfunction is directly linked to increased severity of atherosclerosis (Berg and 
Scherer 2005).  Interestingly, the interferon regulatory factor family of transcription 
factors have very recently been implicated in maintaining adipose tissue homeostasis and 
have been shown to be upregulated in the adipose tissue of mice fed a high fat diet 
(Eguchi et al. 2008).  Furthermore, Irf4-deficient mice on high fat diet exhibit marked 
obesity compared to wild type mice (Eguchi et al. 2011). Therefore, we hypothesized that 
IRF5 may regulate adipose tissue homeostasis in gld.apoE-/- mice.  To test this, we 
examined the size of major fat depots in gld.apoE-/- mice.  Perigonadal, subcutaneous and 
brown fat in Irf5+/-gld.apoE-/- and Irf5-/-gld.apoE-/- mice was significantly increased 
compared to Irf5+/+gld.apoE-/- mice (Figure 10 A-C).  To validate these findings in an 
independent assay, we performed NMR body composition analysis of Irf5+/+gld.apoE-/- 
and Irf5-/- gld.apoE-/- mice that had been on western diet for 12 weeks.  Irf5-/-gld.apoE-/- 
mice exhibited a 2-fold increase in percentage of total body mass that is fat compared to 
Irf5+/+gld.apoE-/- mice and a significant decrease in the percentage of total body mass that 
is lean (Figure 11).   
 To determine whether augmentation of the size of fat depots is a result of 
adipocyte hypertrophy, we performed H & E stains on perigonadal fat pads from Irf5+/+ 
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gld.apoE-/-, Irf5+/ gld.apoE-/- - and Irf5-/- gld.apoE-/- mice.  Adipocyte size in fat pads 
from Irf5+/- gld.apoE-/- and Irf5-/- gld.apoE-/- mice was increased compared to those of 
Irf5+/+gld.apoE-/- mice (Figure 12).  Strikingly, the adipocyte size of Irf5+/-gld.apoE-/- 
mice was comparable to that of Irf5-/-gld.apoE-/- mice.  When adipocytes were purified 
from the perigonadal fat pads and adipocyte diameters were quantified, we found 
adipocytes from Irf5+/+gld.apoE-/- mice were on average ~63 um in diameter, whereas 
adipocyes purified from Irf5+/- and Irf5-/- gld.apoE-/- fat pads were 72-94 um in diameter 
(Figure 13).  Therefore, we conclude that the enhancement in size of the fat pad depots in 
Irf5-deficient gld.apoE-/- mice compared to those of Irf5-sufficient gld.apoE-/- mice is 
due, at least in part, to adipocyte hypertrophy.  In addition, the loss of one Irf5 allele is 
sufficient to increase adiposity and promote adipocyte hypertrophy in gld.apoE-/- mice. 
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Figure 10 Irf5-deficient gld.apoE-/- mice display an increase in adipose tissue mass compared to Irf5-sufficient 
gld.apoE-/- mice.   
Perigondal fat (A), subcutaneous fat (B) and brown fat (C) were measured in 
Irf5+/+gld.apoE-/-  (n=25-26), Irf5+/-gld.apoE-/-  (n=27) and Irf5-/-gld.apoE-/-  (n=21-24) 
mice after 12 weeks on western diet.  Statistics:  Unpaired T test. 
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Figure 11 Irf5-deficient gld.apoE-/- mice have increased fat mass and decreased lean mass compared to Irf5-
sufficient gld.apoE-/- mice. 
 Nuclear magnetic imaging (NMR) studies performed on Irf5+/+ gld.apoE-/- (n=4) and 
Irf5-/-gld.apoE-/- (n=4) female mice after 12 weeks on western diet.  Statistics:  Unpaired 
T test, 2-sided. 
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Figure 12 Irf5-deficient gld.apoE-/- mice display adipocyte hypertrophy compared to Irf5-sufficient gld.apoE-/- 
mice. 
 H & E stained perigonadal fat was harvested from Irf5+/+gld.apoE-/-, Irf5+/-gld.apoE-/- , 
Irf5-/-gld.apoE-/- mice after 12 weeks on western diet.  4x magnification.
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Figure 13 Purified adipocytes from Irf5-deficient gld.apoE-/- fat pads are larger than those purified from Irf5-
sufficient gld.apoE-/- fat pads. 
 Adipocytes were isolated from the perigonadal fat pads.  Images of purified adipocytes 
were taken at 4x and the diameters of 50-60 adipocytes per fat pad were quantified and 
plotted by histogram.  Mean adipocyte diameter for representative Irf5+/+gld.apoE-/- (top 
panel) and Irf5-/-gld.apoE-/- mice are listed above the histograms. 
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Irf5-deficiency does not lead to changes in weight gain or food intake 
despite increases in leptin levels 
 
 SLE or other severe inflammatory conditions can lead to weight loss and 
suppression of appetite (Delano and Moldawer 2006).  To better understand whether the 
remarkable difference in metabolic phenotype observed between Irf5+/+gld.apoE-/-, Irf5+/-
gld.apoE-/-   and Irf5-/-gld.apoE-/-  mice was due to decreased nutrient intake or increased 
catabolism as a result of the severe lupus phenotype in Irf5+/+ gld.apoE-/- mice, male and 
female mice were weighed at the initiation of western diet and then weekly for 12 weeks.  
Both Irf5-sufficient and Irf5-deficient male and female gld.apoE-/- mice gained the same 
amount of weight and at the same rate after initiation of western diet (Figure 14).  
Furthermore, we found no difference in food intake between Irf5-sufficient and Irf5-
deficient gld.apoE-/- male or female mice measured during the last week of the 
experiment, when it would be expected that appetite suppression related to illness would 
be the most apparent (Table I).  Thus, Irf5-deficient and Irf5-sufficient gld.apoE-/- mice 
gain the same amount of weight and consume the same amount of food despite 
differences in lupus disease severity. 
  Leptin is an adipokine which induces satiety by binding to receptors within the 
hypothalamus of the brain (Kelesidis et al. 2010).  SLE patients have higher levels of 
leptin within their sera (McMahon et al. 2013).   We found that Irf5-deficient gld.apoE-/- 
mice showed a significant increase in serum leptin levels compared to levels observed in 
Irf5-sufficient gld.apoE-/- mice (Figure 15).  In summary, despite significant differences 
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in leptin levels and lupus disease severity, Irf5-sufficient and Irf5-deficient gld.apoE-/- 
mice consume the same amount of food and gain the same amount of weight over time.    
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Figure 14 No difference in body weight gain over 12 weeks on western diet between Irf5+/+, Irf5+/- and Irf5-/- 
male or female gld.apoE-/- mice. 
Mice were weighed weekly for 12 weeks after being placed on western diet at 7 weeks of 
age.  Data are +/- SEM for A) Irf5+/+gld.apoE-/- (n=11), Irf5+/-gld.apoE-/-  (n=15) and  Irf5-
/-gld.apoE-/- - (n=10) male mice and for B) Irf5+/+gld.apoE-/-  (n=10), Irf5+/- gld.apoE-/-  
(n=15) and Irf5-/-gld.apoE-/-  (n=10) female mice. 
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Table 1 Food consumption of Irf5+/+, Irf5+/- and Irf5-/- gld.apoE-/- mice. 
Littermate groups were separated into individual cages at the beginning of the 11th week 
on western diet.  Daily food consumption was measured over a period of 2-7 days.  Irf5+/+ 
gld.apoE-/- (n=9), Irf5+/-gld.apoE-/- (n=3) and Irf5-/- gld.apoE-/-  (n=7) male mice and 
Irf5+/+gld.apoE-/-  (n=9), Irf5+/-gld.apoE-/- (n=7) and Irf5-/-gld.apoE-/-  (n=13) female 
mice.  Statistics: No comparison significant. Unpaired Student T test. 
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Figure 15 Increased serum leptin levels in Irf5-deficient gld.apoE-/- mice. 
Serum from 19 week old Irf5+/+gld.apoE-/- (n=4), Irf5+/- gld.apoE-/- (n=3), and Irf5-/- 
gld.apoE-/- (n=7) littermate mice fed high fat diet for 12 weeks was assayed for leptin by 
Luminex. Statistics:  Unpaired T test. 
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Irf5-deficient gld.apoE-/- show an increase in activity, metabolic rate and 
thermogenesis compared to Irf5-sufficient gld.apoE-/- mice 
 
 Although Irf5-deficient gld.apoE-/- mice consumed the same amount of food as 
Irf5-sufficient gld.apoE-/- mice, we wondered if Irf5-sufficient gld.apoE-/- mice might 
have a higher rate of catabolism than Irf5-deficient gld.apoE-/- mice.  We hypothesized 
that increased metabolic consumption by autoreactive immune cells might drive 
decreased adipose tissue in Irf5-sufficient gld.apoE-/- mice.  Indeed, activated T cells and 
neoplastic myeloid cells undergo a shift in metabolism that can lead to adipose tissue loss 
(Delmastro-Greenwood and Piganelli 2013)  (Gautier et al. 2013; Michalek et al. 2011).  
We placed new cohorts of Irf5-sufficient gld.apoE-/- and Irf5-deficient gld.apoE-/- mice in 
metabolic chambers for 48 hours and measured oxygen consumption, thermogenesis and 
activity rate.  We found that Irf5-sufficient gld.apoE-/- mice had a lower metabolic rate 
and produced less heat than Irf5-deficient gld.apoE-/- mice (Figure 16 A & B).  However, 
although both genotypes were more active at night than during the day, Irf5-sufficient 
gld.apoE-/- mice were less active at night than Irf5-deficient gld.apoE-/- mice, potentially 
explaining the decrease in energy usage/expenditure and generation of body heat (Figure 
16 C).  Thus, the increase in adipose tissue observed in the Irf5-deficient gld.apoE-/- mice 
was not due to a decrease in catabolic rate, energy expenditure or an increase in nutrient 
intake.   
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Figure 16 Metabolic profiles of Irf5-sufficient and Irf5-deficient gld.apoE-/- mice. 
gld.apoE-/- female mice that had been on western diet for 12 weeks were placed in 
metabolic chambers for 48 hours during which their A) oxygen consumption (VO2) B) 
thermogenesis and C) activity were measured.  Irf5+/+gld.apoE-/- (n=4) Irf5-/-gld.apoE-/- 
(n=4). 
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Irf5-deficiency leads to hepatic steatosis in gld.apoE-/- mice 
 
One route by which adipose tissue dysregulation promotes atherosclerosis is 
through its impact on the liver.  Adipocyte hypertrophy promotes lipolysis and fatty acid 
secretion from adipose tissue, which can cause or enhance liver steatosis (Angulo 2002; 
Browning and Horton 2004).  Specifically, high levels of free fatty acids within the 
circulation lead to enhanced uptake and storage of fatty acids as well as de novo 
lipogenesis within the liver.  This increases the triglyceride pools stored in lipid droplets 
within hepatocytes, which can be observed in H & E stained steatotic livers.  
Hypertriglyceridemia and hypercholesterolemia are often associated with liver steatosis, 
as the liver secretes higher levels of lipoprotein to compensate for the increased 
triglyceride pools (Choi and Ginsberg 2011).  To determine whether the 
hypertriglyceridemia and hypercholesterolemia we observed in Irf5-deficient gld.apoE-/- 
mice was associated with liver steatosis, we performed H & E stains on liver sections 
from Irf5+/+gld.apoE-/-, Irf5+/-gld.apoE-/- and Irf5-/- gld.apoE-/- mice.  Indeed, while the 
livers from Irf5+/+gld.apoE-/- mice appeared mostly normal with little lipid droplet 
formation, the livers from Irf5+/- and Irf5-/- gld.apoE-/- showed extensive lipid droplet 
formation, signifying enhanced liver steatosis.  (Figure 17 and data not shown). 
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Figure 17 Irf5-deficient gld.apoE-/- mice show an increase in liver steatosis compared to Irf5+/+ gld.apoE-/- mice. 
 Hematoxylin and eosin stained liver sections from Irf5+/+gld.apoE-/- and Irf5-/- gld.apoE-/- 
mice on western diet for 12 weeks.  4x magnification. 
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Irf5-deficiency leads to glucose intolerance and insulin resistance in 
gld.apoE-/- mice 
 
Hepatic steatosis can be a direct result of obesity-induced insulin-resistance 
(Browning and Horton 2004).  Insulin-resistant adipocytes display an increase in lipolysis 
and free fatty acid secretion (Klop et al. 2013).  Because Irf5-deficient gld.apoE-/- mice 
had hepatic steatosis as well as an increase in adiposity, we assessed whether Irf5-
deficient gld.apoE-/- mice might also be diabetic.  We measured serum levels of glucose 
in unfasted Irf5+/+gld.apoE-/-, Irf5+/gld.apoE-/- - and Irf5-/- gld.apoE-/- mice and observed 
that Irf5-deficient gld.apoE-/- mice were hyperglycemic compared to their Irf5-sufficient 
gld.apoE-/- littermates (Figure 18 A).  We observed no significant difference in serum 
insulin levels between groups suggesting that the hyperglycemia was due to insulin-
resistance rather than insulin-deficiency (Figure 18 B).  We performed formal GTT and 
ITT on gld.apoE-/- littermate cohorts and observed that Irf5-deficient gld.apoE-/- mice 
were both glucose-intolerant and insulin-resistant compared to Irf5-sufficient gld.apoE-/- 
mice (Figure 18 C and D). Table II provides a summary of the effect of IRF5 in lupus, 
atherosclerosis and metabolic dysfunction in gld.apoE-/- mice. 
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Figure 18 Irf5-deficient gld.apoE-/- mice are hyperglycemic, glucose intolerant and insulin-resistant compared to 
Irf5-sufficient gld.apoE-/- mice.  
A)  Glucose levels in sera from Irf5+/+gld.apoE-/- (n=5), Irf5+/-gld.apoE-/- (n=4) and Irf5-/- 
gld.apoE-/- (n=7) mice were measured after 12 weeks on western diet.  B& C)  Irf5+/+ 
gld.apoE-/-  (n=7), Irf5+/-gld.apoE-/-  (n=8) and Irf5-/-gld.apoE-/- (n=5) littermate mice on 
western diet for 6-8 weeks were fasted for 6 hours, baseline blood glucose was measured 
using a glucometer, then mice were given either an intraperitoneal glucose (GTT, B) 
injection or insulin injection (ITT, C) with the amount being normalized to body weight.  
Subsequently, blood glucose was measured via tail bleed at 15, 30, 45, 60, 90 and 120 
minutes post-IP injection.  Data represents mean ± SEM of blood glucose at the indicated 
time points.  Irf5+/+gld.apoE-/- (n=7), Irf5+/-gld.apoE-/- (n=8), Irf5-/- gld.apoE-/- (n=5) 
mice.  Statistics: Unpaired T test. p**<0.001, p*<0.005. 
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Table 2 Summary of gld.apoE-/- lupus, atherosclerosis and metabolic phenotype.  
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Irf5-deficiency in hematopoietic cells ameliorates lupus 
 
 Irf5 is mainly expressed in hematopoietic cell lineages, such as B lymphocytes, 
monocytes, dendritic cells and macrophages (Barnes et al. 2001; Krausgruber et al. 2011; 
Krausgruber et al. 2010; Stone et al. 2012; Takaoka et al. 2005; Yasuda et al. 2013).  
However, Irf5 transcript is detected in muscle, which normally has low levels of immune 
infiltrate (Barnes et al. 2001; Takaoka et al. 2005).  Therefore, we speculated that Irf5 
expression in non-immune cells might also contribute to the differences in phenotype we 
observed between Irf5-sufficient and Irf5-deficient gld.apoE-/- mice.  In order to gain a 
better understanding of how IRF5 is pathogenic in lupus but protective against 
atherosclerosis and metabolic syndrome, we generated bone marrow chimeras in 
gld.apoE-/- mice (Figure 19-Schematic).  Seven week old Irf5+/+gld.apoE-/-  and Irf5-/- 
gld.apoE-/- recipient mice were irradiated and their bone marrow was reconstituted with 
bone marrow from either Irf5+/+gld.apoE-/-  or Irf5-/- gld.apoE-/- age-matched mice.  Three 
weeks later, mice were placed on western diet for 6-9 weeks, after which they were 
euthanized and disease parameters were measured.  Unless otherwise stated, when 
discussing bone marrow chimera studies, all donor and recipient mice were on a 
gld.apoE-/- background.  Only mice reconstituted with Irf5+/+ bone marrow developed 
significant splenomegaly and lymphadenopathy, whereas mice reconstituted with Irf5-/- 
bone marrow had spleen and lymph nodes of close to normal weight (Figure 20).  
Furthermore, Irf5 expression in hematopoietic cells was necessary and sufficient for the 
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development of ANAs (Figure 21).  In summary, Irf5 expression in hematopoietic cells 
was absolutely required for lupus disease development whereas its expression in non-
hematopoietic cells was not required.  
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Figure 19 Schematic of gld.apoE-/- bone marrow chimera experiments. 
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Figure 20 Splenomegaly and lymphadenopathy are reduced in gld.apoE-/- mice transplanted with Irf5-deficient 
bone marrow. 
 Irf5+/+gld.apoE-/-  and Irf5-/-gld.apoE-/-  recipients were lethally irradiated, then 
reconstituted with bone marrow from either Irf5+/+gld.apoE-/-  or Irf5-/- gld.apoE-/- donor 
mice.  Mice were placed on western diet and euthanized at 16-19 weeks of age and A) 
spleen and B) cervical lymph node were weighed.  +/+→+/+ (n=8), +/+→-/- (n=5-6), -/- → +/+ 
(n=9) and -/- → -/- (n=9).  Statistics: Unpaired T test. 
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Figure 21 Decreased ANA titer in gld.apoE-/- mice transplanted with Irf5-deficient bone marrow.
Irf5+/+gld.apoE-/-  and Irf5-/- gld.apoE-/- recipients were lethally irradiated, then 
reconstituted with bone marrow from either Irf5+/+gld.apoE-/-  or Irf5-/- gld.apoE-/- donor 
mice.  Mice were placed on western diet and euthanized at 16-19 weeks of age.  Serum 
was collected and ANA was measured by HEp2 immunofluorescence.   +/+ → +/+ (n=6), 
+/+→-/- (n=4), -/- → +/+ (n=6) and -/- → -/- (n=3).  Statistics: Mann-Whitney U Test. 
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Irf5 expression in both hematopoietic and non-hematopoietic cells 
protects against atherosclerosis 
 
IRF5 is a major transcription factor in immune cells in promoting inflammation 
(Krausgruber et al. 2011; Takaoka et al. 2005).  Inflammation is believed to be a main 
component of atherosclerosis.  However, Irf5-deficiency actually led to more severe 
atherosclerosis in gld.apoE-/- mice.  To determine whether IRF5 protects against 
atherosclerosis due to its expression in hematopoietic cells or non-hematopoietic cells we 
measured the average atherosclerotic lesion size in the aortic roots of the different bone 
marrow chimera groups.  We were able to recapitulate our original findings in the non-
bone marrow chimeras in that Irf5-/- (donor) → Irf5-/- (recipient) mice developed 
significantly more atherosclerosis than Irf5+/+ → Irf5+/+ mice (Figure 22).  When we 
compared Irf5+/+ recipients given Irf5+/+ or Irf5-/- bone marrow, we observed that mice 
given Irf5-/- bone marrow developed significantly larger atherosclerotic lesions.  
Therefore, we conclude that Irf5 expression in hematopoietic cells partially protects 
against the development of atherosclerosis in gld.apoE-/- mice.  We then compared the 
average atherosclerotic lesion size from Irf5+/+ recipients to that of Irf5-/- recipients given 
either Irf5+/+ or Irf5-/- bone marrow and observed that Irf5-/- recipients developed 
significantly larger atherosclerotic lesions.  Therefore, we conclude that Irf5 expression 
in non-hematopoietic cells protects against the development of atherosclerosis in 
gld.apoE-/- mice.  
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Figure 22 Irf5-deficiency in both the hematopoietic and non-hematopoietic compartments leads to more severe 
atherosclerosis in gld.apoE-/- mice. 
Serial aortic root sections from bone marrow chimera mice fed western diet for 6-9 weeks 
were stained with Oil Red O to detect lipid deposition.  In a blinded manner, 24-30 aortic 
root sections per mouse heart were quantified using Adobe Photoshop CS3 after imaging 
at 4x and the average lesion size per mouse was quantified.  The Y-axis represents the 
average aortic root lesion size for all mice in the experimental group.  +/+ → +/+ (n=3), 
+/+→-/- (n=4), -/- → +/+ (n=4) and -/- → -/- (n=4).  Statistics:  Unpaired T test. 
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Irf5 expression in both hematopoietic and non-hematopoietic cells 
protects against diet-induced obesity 
 
Diet-induced obesity is a well-known risk factor for atherosclerosis in humans 
(Hubert et al. 1983; Van Gaal et al. 2006).  We have shown above that Irf5-deficient 
gld.apoE-/- mice displayed an increase in adipose tissue depots and total fat mass 
compared to Irf5-sufficient gld.apoE-/- mice.  When we compared Irf5+/+ recipients given 
Irf5+/+ or Irf5-/- bone marrow, we observed that mice given Irf5-/- bone marrow displayed 
an increase in the size of both perigonadal and subcutaneous fat (Figure 23). Therefore, 
we conclude that Irf5 expression in hematopoietic cells partially suppresses adiposity in 
gld.apoE-/- mice.   We then compared the fat pads from Irf5+/+ recipients to that of Irf5-/- 
recipients given Irf5+/+ bone marrow and observed that Irf5-/- recipients displayed an 
increase in the size of both perigonadal and subcutaneous fat.  Therefore, we conclude 
that Irf5 expression in non-hematopoietic cells suppresses adiposity in gld.apoE-/- mice.   
Irf5-/- recipients given Irf5+/+ bone marrow and the reverse, Irf5+/+ recipients given Irf5-/- 
bone marrow displayed intermediate sized perigonadal and subcutaneous fat pads further 
supporting a role for IRF5 in both hematopoietic and non-hematopoietic cells in limiting 
adiposity.  In summary, we found that Irf5-deficiency in both the hematopoietic and non-
hematopoietic cell compartments contributed to increased adiposity in Irf5-deficient 
gld.apoE-/- mice fed western diet. 
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Figure 23 Irf5-deficiency in both hematopoietic and non-hematopoietic compartments leads to an increase in 
adiposity in gld.apoE-/- mice. 
Perigonadal fat pads (A) and subcutaneous fat pads (B) were measured in gld.apoE-/- 
bone marrow chimeras after 6-9 weeks on western diet.  +/+ → +/+ (n=8), +/+→-/- (n=6), -/- 
→ +/+ (n=9) and -/- → -/- (n=10).  Statistics:  Unpaired T test. 
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IRF5 is required for the production of IL-10 in immune cells in response to 
TLR7 and TLR9 stimulation 
 
 Having shown that Irf5-deficiency in hematopoietic cells led to more severe 
atherosclerosis and an increase in adiposity in gld.apoE-/- mice, we next wanted to 
consider possible mechanisms to explain these findings.  Inflammation is known to 
contribute to, or even be the main cause of atherosclerosis and low-grade, chronic 
inflammation is present in adipose tissue of obese mice and humans (Berg and Scherer 
2005).  Contributing to inflammation in both atherosclerotic lesions and obese adipose 
tissue is the presence of large amounts of apoptotic or necrotic cells (Alkhouri et al. 2010; 
Aprahamian et al. 2004; Van Vre et al. 2012).  Apoptotic and necrotic debris have been 
shown to contain endogenous TLR ligands (Cline and Radic 2004; Leadbetter et al. 2002; 
Marshak-Rothstein 2006; Rifkin et al. 2005).   Therefore, we wondered if IRF5 might 
protect against atherosclerosis through its role downstream from TLR stimulation in 
immune cells.   
 Interleukin-10 (IL-10) is a major anti-inflammatory cytokine which functions to 
suppress inflammation and promote tissue repair (Saraiva and O'Garra 2010).  There is a 
large body of literature supporting the protective role of IL-10 in atherosclerosis.  
Specifically, IL-10 suppresses inflammatory cytokine production and promotes 
cholesterol uptake and efflux from macrophages in atherosclerotic lesions (Han et al. 
2009; Han et al. 2010; Pisitkun et al. 2006).  Furthermore, Il-10-deficient apoE-/- mice 
develop more severe atherosclerosis (Caligiuri et al. 2003).  We detected significantly 
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reduced serum IL-10 levels in Irf5-deficient gld.apoE-/- mice compared to Irf5-sufficient 
gld.apoE-/- mice (Figure 4).  Therefore, we hypothesized that IRF5 may be protective 
against atherosclerosis as well as diet-induced obesity by regulating the production of IL-
10 in immune cells. We began by testing IL-10 production in macrophages as they are the 
prominent immune cell within atherosclerotic lesions (Moore and Tabas 2011).  They 
also infiltrate adipose tissue and can function to promote or suppress inflammation 
(Dalmas et al. 2011).  We stimulated Irf5+/+ and Irf5-/- bone marrow-derived macrophages 
from C57BL/6 mice with a panel of TLR ligands and measured IL-10 protein levels in 
the supernatant.  Both M-CSF and GM-CSF derived macrophages require IRF5 
downstream from TLR7 and TLR9 stimulation to produce high levels of IL-10 (Figure 24 
A & B).  Notably, IRF5 is not required for the production of IL-10 downstream from 
TLR2, 3, or 4.  Thus, the hypothesized role of IRF5 as a key transcription factor in 
polarization of macrophages towards an M1 phenotype may be dependent on the TLR 
stimulated (Krausgruber et al. 2011). 
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Figure 24 Irf5 is required for IL-10 production downstream from TLR7 and TLR9 in macrophages. 
Bone marrow from Irf5+/+ and Irf5-/- C57BL/6 mice was cultured in vitro for 6 days with 
either M-CSF or GM-CSF to generate A) M-CSF macrophages or B) GM-CSF 
macrophages.  On Day 7, macrophages were stimulated for 24 hours with the following 
TLR ligands: Pam3Cys (TLR2), Poly I:C (TLR3), LPS (TLR4), R837 (TLR7) and CpG-
B (TLR9).  M-CSF macrophages: Irf5+/+ (=3), Irf5-/- (n=3).  GM-CSF macrophages: 
Irf5+/+ (n=2), Irf5-/- (n=2).  Statistics:  Unpaired T test, 2-sided. 
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 Irf5 is highly expressed in dendritic cells and B lymphocytes, which have been 
shown to infiltrate to late-stage atherosclerotic lesions (Grabner et al. 2009).  Similar to 
its role in macrophages, IRF5 is critical for the production of IL-10 specifically 
downstream from TLR7 and TLR9 in dendritic cells and B lymphocytes (Figure 25 A & 
B and Figure 26).  These data support a role for IRF5 in immune cells in suppression of 
atherosclerosis by inducing IL-10 production downstream of TLR7 and TLR9.   
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Figure 25 Irf5 is required for IL-10 production downstream from TLR7 and TLR9 in dendritic cells. 
Bone marrow from Irf5+/+ and Irf5-/- C57BL/6 mice was cultured in vitro for 6 days with 
either GM-CSF or Flt3 ligand to generate A) GM-CSF dendritic cells or B) Flt3 dendritic 
cells.  On Day 7, cells were stimulated for 24 hours (for GM-CSF dendritic cells) or 5 
days (for Flt3 dendritic cells) with the following TLR ligands: Pam3Cys (TLR2), Poly 
I:C (TLR3), LPS (TLR4), R837 (TLR7-GM-CSF DCs) , R848 (TLR7-Flt3 DCs) ,CpG-B 
1826 (TLR9-GM-CSF DCs) and CpG-A 2336 (TLR9-Flt3 DCs) .  GM-CSF dendritic 
cells: Irf5+/+ (=2), Irf5-/- (n=2).  Flt3 dendritic cells: Irf5+/+ (n=4-5), Irf5-/- (n=3-5).  
Statistics:  Unpaired T test, 2-sided. 
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Figure 26 IRF5 is required for IL-10 production downstream from TLR7 and TLR9 in B cells. 
Irf5+/+ and Irf5-/- splenic B cells from C57BL/6 mice were positively selected using anti-
B220 magnetic Miltenyi beads then stimulated 24 hours with the following TLR ligands: 
Pam3Cys (TLR2), LPS (TLR4), CLO97 (TLR7) and CpG-B 2336 (TLR9).   Irf5+/+ 
(n=4), Irf5-/- (n=5).  Statistics:  Mann-Whitney U Test. 
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Irf5 expression in non-hematopoietic cells protects against dyslipidemia 
 
 We observed that Irf5-deficient gld.apoE-/- mice had higher serum levels of 
triglycerides, cholesterol, phospholipids and NEFAs than Irf5-sufficient gld.apoE-/- mice 
(Figure 6).  To determine whether IRF5 regulates lipids through expression in 
hematopoietic cells or non-hematopoietic cells, we measured lipids in the sera of the 
gld.apoE-/- bone marrow chimeras.  We were able to recapitulate our original findings in 
the non-bone marrow chimeras in that Irf5-/- → Irf5-/-  mice had significantly higher 
levels of serum cholesterol and phospholipids compared to Irf5+/+ → Irf5+/+ mice. (Figure 
27)   In addition, we observed a trend towards an increase in serum triglycerides when we 
compared Irf5-/- → Irf5-/- mice to Irf5+/+ → Irf5+/+ mice.  When we compared Irf5+/+ 
recipients given Irf5+/+ or Irf5-/- bone marrow, we observed no difference in serum lipid 
levels.  Therefore, we conclude that Irf5 expression in hematopoietic cells is not required 
for regulating serum lipids in gld.apoE-/- mice.  We then compared lipid levels from sera 
of Irf5+/+ recipients to that of Irf5-/- recipients and observed that Irf5-/- recipients had 
significantly higher levels of cholesterol compared to Irf5+/+ recipients regardless of 
whether they were reconstituted with Irf5+/+ or Irf5-/- bone marrow.  In addition, we 
observed a trend towards an increase in triglycerides from sera of Irf5-/- recipients 
compared to Irf5+/+ recipients regardless of whether they were reconstituted with Irf5+/+ 
or Irf5-/- bone marrow.  Irf5-/- recipients had significantly higher levels of phospholipids 
and NEFAs compared to Irf5+/+ recipients when mice were reconstituted with Irf5-/- bone 
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marrow.  Therefore, Irf5-deficiency in non-hematopoietic cells is necessary and sufficient 
for hypercholesterolemia, increased phospholipids and increased NEFAs in gld.apoE-/- 
mice on western diet.  In addition, Irf5-deficiency in non-hematopoietic cells most likely 
contributes to the increase in serum triglycerides observed in gld.apoE-/- mice.  Table III 
provides a summary of the effect of IRF5 in lupus, atherosclerosis and metabolic 
dysfunction in the bone marrow chimera mice.  
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Figure 27 Increased lipids in serum of gld.apoE-/- mice lacking Irf5 in the non-hematopoietic cell compartment. 
Sera from 22 week old bone marrow chimeras fed western diet for 6-9 weeks was 
analyzed for A) triglyceride, B) cholesterol, C) phospholipid and D) non-esterified free 
fatty acid content. +/+ → +/+ (n=8-10), +/+→-/- (n=7-10), -/-→ +/+ (n=6-9) and -/- → -/- (n=8-
9).  Statistics: Unpaired T test.
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Table 3 Summary of gld.apoE-/- bone marrow chimera phenotype. 
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Irf5 is expressed in metabolic tissues and is upregulated in response to 
western diet 
 
 We found that Irf5-deficiency in non-hematopoietic cells led to hyperlipidemia 
and an increase in adiposity.  Liver, muscle and adipose tissue all contribute to 
maintaining systemic metabolic homeostasis.  Irf5 expression has been detected in human 
muscle and in murine preadipocytes (Barnes et al. 2001; Eguchi et al. 2008; Takaoka et 
al. 2005).   Furthermore, IRF5 is upregulated in adipose tissue in response to high fat diet, 
although it was not determined whether this IRF5 upregulation was in adipocytes or in 
the macrophage-containing stromal vascular fraction (Eguchi et al. 2008).  To determine 
if Irf5 is expressed in metabolic tissue in gld.apoE-/- mice, we performed real-time PCR 
on RNA isolates from liver, muscle and adipose tissue after the mice has been on western 
diet for 12 weeks.  Irf5 is highly expressed in liver and adipose tissue and expressed, 
albeit at a lower level, in muscle tissue of gld.apoE-/- mice (Figure 28).  A future 
comparison of Irf5 expression in adipose tissue, liver and muscle of gld.apoE-/- mice on 
normal diet versus western diet will be useful in determining whether the expression of 
Irf5 is upregulated in response to western diet. 
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Figure 28 Irf5 expression in metabolic tissue. 
Real time PCR on cDNA reverse transcribed from RNA isolates from liver (L), muscle 
(M) and adipose tissue (AT) of gld.apoE-/- mice on western diet for 12 weeks.  Y-axis 
represents relative expression using ∆Ct method with expression levels of Irf5 normalized 
to expression level of the relevant housekeeping gene in each tissue.  Liver: n=3, Muscle: 
n=2, Adipose tissue: n=3. 
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 Muscle regulates metabolism by upregulating enzymes required for lipid uptake 
and by producing myokines during exercise, feeding and fasting (Pedersen and Febbraio 
2008).  The enzyme, lipoprotein lipase (LPL) is highly expressed by endothelial cells of 
blood vessels within muscle and regulates uptake and hydrolysis of lipids used for energy 
(Wang and Eckel 2009).  Mice lacking LPL within muscle develop obesity and insulin-
resistance, similar to that which we see in Irf5-deficient gld.apoE-/- mice (Wang and 
Eckel 2009).  We observed a reduction in Lpl transcript within the muscle of Irf5-
deficient C57BL/6 compared to Irf5-sufficient C57BL/6 mice and in Irf5-deficient 
gld.apoE-/- mice compared to Irf5-sufficient gld.apoE-/- mice (Figure 29 A and B). 
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Figure 29 Lipoprotein lipase gene expression in muscle. 
Real time PCR of cDNA reverse transcribed from RNA isolates from muscle of Irf5+/+ 
and Irf5-/- C57BL/6 mice on western diet for 16 weeks (A) or from muscle of 
Irf5+/+gld.apoE-/-, Irf5+/-gld.apoE-/-  and Irf5-/- gld.apoE-/- mice on western diet for 12 
weeks.  n=2 mice per group. 
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 IL-6 is a well-studied myokine produced in response to muscle contraction and 
low glycogen levels and acts in an endocrine fashion to stimulate metabolic changes in 
the liver and adipose tissue (Pedersen and Febbraio 2008).  IL-6-deficient mice develop 
late-onset obesity and insulin-resistance, similar to that which we see in Irf5-deficient 
gld.apoE-/- mice (Pedersen and Febbraio 2012).  We observed a reduction in IL-6 
transcript within the muscle of Irf5-deficient C57BL/6 compared to Irf5-sufficient 
C57BL/6 mice and in Irf5-deficient gld.apoE-/- mice compared to Irf5-sufficient 
gld.apoE-/- mice (Figure 30 A and B). 
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Figure 30 IL-6 gene expression in muscle. 
Real time PCR of cDNA reverse transcribed from RNA isolates from muscle of Irf5+/+ 
and Irf5-/- C57BL/6 mice on western diet for 16 weeks (A) or from muscle of Irf5+/+ 
gld.apoE-/-, Irf5+/-gld.apoE-/-  and Irf5-/- gld.apoE-/- mice on western diet for 12 weeks 
(B).  n=2 mice per group.
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 Tissue resident immune cells, mainly macrophages, populate metabolic tissue, 
and increase in number in response to high fat diet (Dalmas et al. 2011). As Irf5 is highly 
expressed in immune cells, we sought to determine whether Irf5 is expressed in non-
hematopoietic cells of metabolic tissue and whether its expression is altered in response 
to high fat diet.  C57BL/6 mice were placed on normal diet or high fat diet for 12 weeks.  
The stromal vascular fraction, containing immune cells, was separated from the adipocyte 
fraction and RNA isolates were used to detect Irf5 gene expression.  Irf5 was highly 
upregulated in purified adipocytes in response to high fat diet (Figure 31A).  In contrast, 
Irf5 expression in the SVF showed little change in response to high fat diet (Figure 31B).   
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Figure 31 Irf5 is upregulated in response to high fat diet in purified adipocytes. 
C57BL/6 mice were placed on normal or high fat diet for 12 weeks.  Perigonadal fat pads 
were fractionated into purified adipocytes and the stromal vascular fraction (SVF).  Real 
time PCR on cDNA reverse transcribed from RNA isolates from A) purified adipocytes 
and B) the SVF. Y-axis represents relative expression using ∆Ct method with expression 
levels of Irf5 normalized to expression level 18S in each fraction.  Each experiment 
represents one C57BL/6 male mouse on normal diet (ND) and one C57BL/6 male mouse 
on high fat diet (HFD). 
 
  
126 
 
The metabolic effect of Irf5-deficiency is not seen in C57BL/6 or apoE-/- 
mice on western diet 
 
 To further clarify the contribution of lupus-like disease to differences in metabolic 
phenotype between Irf5-sufficient gld.apoE-/-  and Irf5-deficient gld.apoE-/- mice, we 
performed experiments comparing normal C57BL/6 and apoE-/- mice with or without 
Irf5.  C57BL/6 mice were placed on western diet for 16-24 weeks. In contrast to 
gld.apoE-/- mice, the metabolic effects of Irf5-deficiency were not seen in C57BL/6 mice. 
Irf5-sufficient and Irf5-deficient C57BL/6 mice on western diet had comparable amounts 
of perigonadal fat, subcutaneous fat, serum triglycerides and serum total cholesterol.  
(Figure 32 A-D).   
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Figure 32 Irf5-deficient and Irf5-sufficient C57BL/6 mice on western diet show no difference in metabolic 
phenotype. 
 Age-matched Irf5-sufficient and Irf5-deficient male C57BL/6 mice were placed on 
western diet for 16-24 weeks.  Perigonadal fat (A) and subcutaneous fat (B) were 
measured in Irf5+/+ (n=8) and Irf5-/- (n=8) C57BL/6 mice.  C-D) Sera from 24 week old 
Irf5+/+ (n=2), and Irf5-/- (n=2) C57BL/6 mice fed western diet for 16 weeks were analyzed 
for C) triglyceride and D) total cholesterol.   
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  apoE-/- mice were placed on western diet for 12-16 weeks.   In contrast to 
gld.apoE-/- mice, the metabolic effects of Irf5-deficiency were not seen in apoE-/- mice. 
Irf5-sufficient apoE-/- and Irf5-deficient apoE-/- mice on western diet had comparable 
amounts of perigonadal fat, subcutaneous fat, serum triglycerides and total cholesterol.  
(Figure 33 A - D).   We provide a comparison of perigonadal, subcutaneous fat pads and 
serum lipids from Irf5-sufficient and Irf5-deficient apoE-/- and gld.apoE-/- mice.  (Figures 
34-36). Notably, only in mice that contain both the gld and apoE mutations and that had 
been on western diet for 12 weeks, did we observe a significant Irf5-dependent effect on 
fat pad size, serum triglycerides and total cholesterol. 
 
  
130 
 
 
 
 
 
 
 
  
131 
Figure 33 Irf5-deficient and Irf5-sufficient apoE-/- mice on western diet show no difference in metabolic 
phenotype. 
Irf5-sufficient and Irf5-deficient male and female apoE-/- mice were placed on western 
diet for 16 weeks.  Perigonadal fat (A) and subcutaneous fat (B) were measured in Irf5+/+ 
apoE-/- (n=17) and Irf5-/-apoE-/- (n=13) mice.  C-D) Sera from 23 week old Irf5+/+apoE-/- 
(n=12), and Irf5-/-apoE-/-  (n=11) mice fed western diet for 16 weeks were analyzed for C) 
triglyceride and D) total cholesterol.   
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Figure 34 Perigonadal fat size in Irf5-sufficient and Irf5-deficient apoE-/- and gld.apoE-/- mice. 
Perigonadal fat pads were measured in Irf5+/+  and Irf5-/- apoE-/- and gld.apoE-/- male (A) 
and female (B) mice.  Male apoE-/- and gld.apoE-/- mice were on western diet for 12-16 
weeks.  Female apoE-/- and gld.apoE-/- were on western diet for 12 weeks.   apoE-/- male: 
Irf5+/+ (n=9), Irf5-/- (n=6) and gld.apoE-/- male: Irf5+/+ (n=11), Irf5-/- (n=9).  apoE-/- 
female: Irf5+/+ (n=3), Irf5-/- (n=5) and gld.apoE-/- female: Irf5+/+ (n=14), Irf5-/- (n=12).  
Statistics:  Unpaired T test.  
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Figure 35 Subcutaneous fat size in Irf5-sufficient and Irf5-deficient apoE-/- and gld.apoE-/- mice. 
Subcutaneous fat pads were measured in Irf5+/+ and Irf5-/- apoE-/- and gld.apoE-/- male 
(A) and female (B) mice.  Male apoE-/- and gld.apoE-/- mice were on western diet for 12-
16 weeks.  Female apoE-/- and gld.apoE-/- were on western diet for 12 weeks.   apoE-/- 
male: Irf5+/+ (n=9), Irf5-/- (n=6) and gld.apoE-/- male: Irf5+/+ (n=11), Irf5-/- (n=9).  apoE-/- 
female: Irf5+/+ (n=3), Irf5-/- (n=5) and gld.apoE-/- female: Irf5+/+ (n=13), Irf5-/- (n=12).  
Statistics:  Unpaired T test.  
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Figure 36 Serum lipids in Irf5-sufficient and Irf5-deficient apoE-/- and gld.apoE-/- mice. 
Triglycerides (A) and total cholesterol (B) were measured from serum of Irf5+/+ and Irf5-/- 
apoE-/- and gld.apoE-/- male mice after 12-16 weeks on western diet.  Triglycerides: 
apoE-/-: Irf5+/+ (n=8), Irf5-/- (n=7) and gld.apoE-/-: Irf5+/+ (n=9), Irf5-/- (n=9).  Cholesterol 
apoE-/-: Irf5+/+ (n=8), Irf5-/- (n=7) and gld.apoE-/-: Irf5+/+ (n=9), Irf5-/- (n=9).   Statistics:  
Unpaired T test. 
  
138 
 
Irf5-deficiency leads to more severe atherosclerosis in apoE-/- mice 
 
 Irf5-deficiency led to an increase in atherosclerosis in apoE-/- mice on western 
diet (Figure 37).  Irf5-deficiency in apoE-/- mice led to a 60% increase in atherosclerosis 
within the aortic arch compared to Irf5-sufficient apoE-/- mice.  Notably, the atherogenic 
effect of Irf5-deficiency was even more pronounced in gld.apoE-/- mice (Figure 5).  We 
observed an increase of greater than 100% in atherosclerosis within the aortic arch when 
we compared Irf5-deficient gld.apoE-/- mice to Irf5-sufficient gld.apoE-/- mice.  Thus, 
IRF5 is atheroprotective in apoE-/- and gld.apoE-/- mice. 
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Figure 37 Increased atherosclerosis in Irf5-deficient apoE-/- mice. 
Aortic arches from Irf5+/+apoE-/- (n=7) and Irf5-/-apoE-/- (n=5)  mice fed western diet for 
16 weeks were formalin-fixed, pinned and stained with Oil Red O to detect lipid 
deposition within lesions.  In a blinded manner, the area of the total aortic arch and area 
stained positive for Oil Red O were quantified using Adobe Photoshop color range tool.  
Y-axis represents average % of aortic arch stained positive for Oil Red O within each 
group.  Statistics: Wilcoxon (Ranked). 
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Discussion 
 Atherosclerosis is a major cause of morbidity and mortality in patients with SLE.  
Gain-of-function polymorphisms in the human gene encoding Irf5 correlate with an 
increase in risk for the development of SLE.  We and others have shown that Irf5-
deficiency in murine models of lupus ameliorates disease due largely to a decrease in 
systemic inflammation (Feng et al. 2012; Richez et al. 2010; Savitsky et al. 2010; Tada et 
al. 2011; Xu et al. 2012).  However, up until this point, the effect of Irf5-deficiency on 
the development of atherosclerosis has not been reported.  Our overall goal of this study 
was to elucidate the role of IRF5 in lupus-associated atherosclerosis.   We hypothesized 
that Irf5-deficiency would ameliorate lupus, which would in turn improve atherosclerosis 
in the gld.apoE-/- mouse model of lupus-associated atherosclerosis.  Unexpectedly, we 
found that although Irf5-deficiency protected gld.apoE-/- mice from the development of 
lupus, it led to an increase in the severity of atherosclerosis.   This surprising phenotype 
led us to the discovery of a novel role for IRF5 as a regulator of metabolic homeostasis.  
Finally, bone marrow chimera studies revealed that IRF5 protects against atherosclerosis 
due to its expression in both hematopoietic and non-hematopoietic cells. 
 
Irf5-deficiency ameliorates lupus in gld.apoE-/- mice. 
 We found that Irf5-deficiency ameliorates lupus as Irf5-deficient gld.apoE-/- mice 
failed to develop splenomegaly, lymphadenopathy or anti-nuclear autoantibodies (ANA).  
In addition, the severity of kidney disease was significantly decreased in Irf5-deficient 
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gld.apoE-/- mice compared to Irf5-sufficient gld.apoE-/- littermates.  Interestingly, Irf5+/- 
gld.apoE-/- mice displayed spleen and lymph node size that were comparable to that 
observed in Irf5-/- gld.apoE-/- mice showing that a threshold level of IRF5 is required in 
order for the expansion of lymphoid organs.  Irf5+/- gld.apoE-/- displayed intermediate 
titers of ANA in their serum compared to Irf5+/+gld.apoE-/-  and Irf5-/- gld.apoE-/-  
littermates.  Antibodies specific for nucleic acid-protein complexes can form immune 
complexes and deposit in the kidneys leading to recruitment of innate immune cells and 
inflammatory cytokine production.  Inflammation resulting from immune complex 
deposition can lead to necrosis of glomeruli, mesangial expansion and impaired 
glomerular function characteristic of lupus nephritis (Kurts et al. 2013).  In support of this 
mechanism of disease, Irf5-/-gld.apoE-/- showed a significant decrease in kidney disease 
parameters and undetectable titers of ANA, while Irf5+/- gld.apoE-/- mice displayed an 
intermediate phenotype similar to that observed for ANA titers.  The extent of kidney 
disease may also be dependent on or be a cause of the amount of inflammatory cytokines 
in the blood (Kurts et al. 2013).  Serum levels of TNFα, IL-12p70 and IFNɣ were shown 
to be significantly higher in Irf5-sufficient gld.apoE-/- mice compared to Irf5-deficient 
gld.apoE-/- mice. 
 These data add to the growing number of lupus mouse models in which Irf5-
deletion has been shown to ameliorate disease.  Thus far, deletion of Irf5 in the FcɣRIIb-/-
.Yaa, FcɣRIIb-/-, MRL/lpr and pristane models of lupus has led to a decrease in disease 
severity (Feng et al. 2012; Richez et al. 2010; Savitsky et al. 2010; Tada et al. 2011; Xu 
et al. 2012).  Thus, IRF5 is pathogenic in murine lupus in a manner that is independent of 
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the genetic model used for experimentation.  A potential caveat of these studies, however, 
involves the recent discovery of a mutation in the gene encoding DOCK2 in the Irf5-/- 
C57BL/6 mouse line used to generate the experimental mice in the studies listed above.  
Using PCR primers designed by our laboratory that detect the mutated sequence of 
DOCK2, we screened all experimental mice used in this study and found them all to be 
wild type.  These data confirm the pathogenic role of IRF5 in murine lupus shown by our 
group as well as others and support the idea that most, if not all, of the protective effect 
observed upon crossing lupus mouse models with the Irf5-/- line is due to ablation of Irf5 
and not the presence of the DOCK2 mutation.  
 
Potential mechanisms by which IRF5 is pathogenic in lupus due to its expression in 
hematopoietic cells. 
 The pathogenic effect of IRF5 in murine lupus is usually attributed to its 
expression in immune cells such as B lymphocytes, dendritic cells and monocytes. (Feng 
et al. 2012; Yang et al. 2012; Yasuda et al. 2013).  However, IRF5 can be detected in 
non-immune cells, such as endothelial cells, and in tissues that do not normally contain 
high infiltrates of immune cells, such as muscle (Barnes et al. 2001; Takaoka et al. 2005).  
Bone marrow-chimera studies revealed that only gld.apoE-/- mice transplanted with 
Irf5+/+ bone marrow exhibited lupus disease manifestations.  Our results show that Irf5 
expression in hematopoietic cells is necessary and sufficient for the development of lupus 
in mice.   
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 IRF5 functions as a transcription factor downstream from TLR3, 4, 7 and 9 in 
immune cells and induces the expression of several pro-inflammatory cytokines, 
chemokines and type I IFN (Takaoka et al. 2005; Yasuda et al. 2013).  However, the 
induction of specific proteins is cell-type and ligand-specific.  Nucleic-acid sensing 
TLRs, such as TLR7, TLR8 and TLR9, are considered to be critical for lupus 
pathogenesis.  IRF5 controls IL-6 production and class-switching to IgG2a in TLR-
activated B cells downstream of TLR9 (Savitsky et al. 2010; Yasuda et al. 2013).  We 
have previously shown that IRF5 is required for the production of IL-6 and Type I IFN in 
dendritic cells in response to RNA-immune complexes (Yasuda et al. 2007). Gain-of-
function polymorphisms in the human gene encoding Irf5 are associated with an 
overproduction and increased activity of IRF5 (Feng et al. 2010b).  Increased levels and 
activity of IRF5 may lead to enhanced TLR signaling.  Therefore, it is likely that IRF5 is 
pathogenic in lupus in the gld.apoE-/- model due to its function in immune cells 
downstream from TLR7 and/or TLR9 activation.  Indeed, we observed that IRF5 is 
required for the production of IL-10 in macrophages, dendritic cells and B cells 
downstream from TLR7 and TLR9 stimulation, but not downstream from other TLRs.  
Thus, these data strongly support the role of IRF5-dependent TLR signaling in immune 
cells as a mediator of lupus pathogenesis.   
 Studies using MRL/lpr mice, which, similar to gld mice, also lack a functioning 
Fas-FasL pathway and develop spontaneous lupus, have shown that whereas TLR7 is 
pathogenic, TLR9 is protective (Christensen et al. 2005; Christensen et al. 2006; 
Nickerson et al. 2013).  A future comparison of Tlr7-deficient, Tlr9-deficient and Irf5-
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deficient gld.apoE-/- mice will be useful in determining for certain whether IRF5 is 
pathogenic in lupus in this model due to its function downstream of TLR7, TLR9 or both.  
If we observe a protective effect of Tlr7-deficiency and a pathogenic effect of Tlr9-
deficiency in gld.apoE-/- mice, this will show that IRF5 is most likely pathogenic in lupus 
due to its function downstream of TLR7, and not TLR9, in gld.apoE-/- mice. 
 Finally, we cannot exclude the possibility that IRF5 is pathogenic in lupus in 
gld.apoE-/- mice independently of its function downstream of TLR7 and TLR9.  For 
example, IRF5 may contribute to lupus in this model through its activity downstream 
from other pattern recognition receptors, such as NOD or RIG-I, although there is little 
evidence for these proteins in lupus pathogenesis (Cham et al. 2012; Pandey et al. 2009).  
Furthermore, IRF5 functions in several apoptotic pathways in response to DNA damage 
or death receptor ligation (Couzinet et al. 2008; Hu and Barnes 2009).  Therefore, it is 
possible that IRF5 drives lupus through enhanced apoptosis leading to an increase in 
stimulatory nucleic acids in the periphery.    
 
The effect of Irf5-deficiency in atherosclerosis and metabolic dysfunction is not due to 
genetic background, gender, gut microbiome or lupus-disease severity.   
 We observed that Irf5-deficient gld.apoE-/- mice displayed marked metabolic 
changes and an increase in the severity of atherosclerosis.  A role for IRF5 in maintaining 
metabolic homeostasis has not previously been described.  It has been reported that 
genetic background , gender, the gut microbiome, diet and lupus disease severity can 
influence atherosclerosis and metabolism in mice (Caligiuri et al. 1999) (Braun et al. 
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2008; Loscalzo 2013; Maeda 2011).  We provide the following evidence in points 1-6 
below to demonstrate that the protective effect of IRF5 in atherosclerosis and metabolic 
dysfunction is not due to these factors:  
1.  All mice were littermates and gender differences were taken into 
account.  (See Materials and Methods). 
2.  Littermate mice were housed in the same cage for the duration of the 
experiment limiting differences in gut microbiome. (See Materials and 
Methods). 
3.  Irf5-sufficient and Irf5-deficient mice gained the same amount of 
weight over time and showed no difference in food intake despite 
differences in lupus disease severity.  (See Figure 14 and Table I). 
4.  Irf5-sufficient gld.apoE-/- mice displayed a lower metabolic rate and 
decreased activity compared to Irf5-deficient gld.apoE-/- mice (See Figure 
16). 
 
 Severe inflammatory conditions can lead to increases in catabolic rate and loss of 
adipose tissue mass (Delano and Moldawer 2006; Gautier et al. 2013; MacIver et al. 
2013). Irf5-sufficient gld.apoE-/- had decreased adipose tissue mass compared to Irf5-
deficient gld.apoE-/- mice.  In extreme cases of systemic inflammation, catabolic rate may 
increase due to the energy requirement of activated immune cells or to effects of 
inflammatory cytokines on metabolic enzymes.  Indeed, there has long been a recognized 
relationship between the immune system and regulation of metabolism.  The pro-
inflammatory cytokine TNFα was originally described as a regulator of lipoprotein 
lipase, an enzyme required for the hydrolysis of triglycerides into fatty acids (Beutler et 
al. 1985).  We found that Irf5-sufficient gld.apoE-/- mice do not display an increased 
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catabolic rate compared to Irf5-deficient gld.apoE-/- mice.  Therefore, a difference in 
catabolic rate due to a difference in lupus-disease severity does not explain the decreased 
adipose tissue mass we observed in Irf5-sufficient gld.apoE-/- mice compared to Irf5-
deficient gld.apoE-/- mice.    
5.  IRF5 regulates metabolism and protects against atherosclerosis in non-
hematopoietic cells in mice without lupus (See Table III). 
 The most convincing data that the metabolic effect of IRF5 was independent of 
lupus disease severity was achieved in the bone marrow chimera studies in which we 
compared Irf5+/+ and Irf5-/- gld.apoE-/- recipients given Irf5-/- bone marrow.  Neither 
Irf5+/+ gld.apoE-/- or Irf5-/- gld.apoE-/- recipients given Irf5-/- bone marrow developed 
lupus.  However, Irf5-deficient gld.apoE-/- recipients displayed an increase in serum 
cholesterol, phospholipids and NEFAs compared to Irf5-sufficient gld.apoE-/- recipients 
(both groups given Irf5-/- bone marrow).  Furthermore, Irf5-deficient gld.apoE-/- 
recipients displayed a strong trend towards an increase in atherosclerosis compared to 
Irf5-sufficient gld.apoE-/- recipients (both groups given Irf5-/- bone marrow), although 
this did not achieve statistical significance most likely because only four mice were 
analyzed per group.  Thus, IRF5 regulates metabolism and protects against 
atherosclerosis through its expression in non-hematopoietic cells independently of its 
pathogenic effect in lupus. 
6.  IRF5 protects against atherosclerosis in apoE-/- mice. 
 Although Irf5-deficient apoE-/- and Irf5-sufficient apoE-/- mice showed no 
difference in metabolic features after 16 weeks on western diet, we did see a significant 
  
147 
increase in atherosclerosis in Irf5-deficient apoE-/- mice.  Thus, even in mice that display 
a similar metabolic phenotype, IRF5 is protective against atherosclerosis.  An 
atheroprotective effect of IRF5 in hematopoietic cells was observed in Irf5+/+  
gld.apoE-/- recipients given Irf5+/+ bone marrow compared to those given Irf5-/- bone 
marrow.  Therefore, IRF5 most likely protects against atherosclerosis through its 
expression in hematopoietic cells, and not in non-hematopoietic cells, in apoE-/- mice as 
there was no difference in metabolic characteristics between the groups. 
 
Irf5-deficiency leads to an increase in atherosclerosis despite a lack of systemic 
inflammation. 
 Over the past decade, great emphasis has been placed on the role of the innate and 
adaptive immune systems in the initiation and progression of atherosclerosis (Libby 
2012).  In the early atherosclerotic lesion, monocytes infiltrate the activated endothelium, 
phagocytose oxidized LDL and become foam cells which secrete large amounts of pro-
inflammatory cytokine and produce reactive oxygen species (ROS).   Chemokines are 
secreted by the activated endothelium and macrophages and signal for the influx of more 
monocytes as well as effector T cells.  IRF5 has been shown to be a major transcription 
factor in promoting the polarization of macrophages towards an M1 or ‘pro-
inflammatory’ phenotype in response to TLR4 stimulation (Krausgruber et al. 2011).  As 
oxLDL has been shown to be one of multiple endogenous TLR4 ligands present within 
an atherosclerotic lesion, one would predict that Irf5-deficiency in atherosclerotic lesion-
specific macrophages might lead to a decrease in inflammatory cytokine production, thus 
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suppressing lesion development.  Furthermore, antibodies specific to oxLDL may 
contribute to atherosclerosis pathogenesis by forming immune complexes within the 
intima and inhibiting the clearance of oxLDL by macrophages.  We observed a 
significant decrease in IgG in the serum of Irf5-deficient gld.apoE-/- mice, although this 
data needs to be confirmed using sera from gld.apoE-/- littermates. (Appendix 1-Figure 
7).  Finally, inflammation elsewhere in the body, characteristic of lupus, likely 
contributes to the initiation and progression of atherosclerosis and markers of systemic 
inflammation predict cardiovascular risk in SLE patients (Bruce et al. 2000).    
 In our study, we observed evidence that systemic inflammation was ameliorated 
in Irf5-deficient gld.apoE-/- mice. (See Table II).  Namely, Irf5-deficient gld.apoE-/- mice 
displayed a decrease in kidney disease severity.  In addition, pro-inflammatory cytokines 
within the serum were significantly lower compared to Irf5-sufficient gld.apoE-/- mice.  
Many of the same cytokines that contribute to lupus nephritis are also important in 
atherosclerotic lesion progression (Kurts et al. 2013).  As IL-6, TNFα, IFNɣ and IL-12 
were much lower in the serum of Irf5-deficient gld.apoE-/- mice, we predicted that Irf5-
deficiency would protect against the development and progression of atherosclerosis.  
Surprisingly, not only were Irf5-deficient gld.apoE-/- mice not protected, but they actually 
developed significantly larger atherosclerotic lesions in both the aortic root and aortic 
arch.    When atherosclerosis was compared in Irf5+/+ gld.apoE-/- recipients given either 
Irf5+/+ or Irf5-/- donor bone marrow, we found that mice given Irf5-/- bone marrow 
developed significantly larger atherosclerotic lesions.  Therefore, we conclude that Irf5-
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deficiency leads to atherosclerosis, in part, due to its deficiency in bone marrow-derived 
cells. 
 
Potential mechanisms by Irf5-deficiency in immune cells results in increased 
atherosclerosis. 
 In the past several years, surprising findings using apoE-/- mice, have shown that 
endosomally-located and nucleic-acid sensing TLRs are protective against atherosclerosis 
(Cole et al. 2013).  This is in contrast to cell-surface TLRs, such as TLR2 and 4, which 
promote atherosclerosis in mouse models of disease (Curtiss and Tobias 2009; Falck-
Hansen et al. 2013).  Tlr3-deficiency led to larger atherosclerotic lesions in apoE-/- mice, 
possibly through its expression in lesion-specific smooth muscle cells (Cole et al. 2011).  
Tlr7-/-.apoE-/- mice also developed more severe atherosclerosis (Salagianni et al. 2012).  
TLR7 was shown to be critical for constraining inflammatory monocyte populations and 
inhibiting the skewing of macrophages towards an M1 phenotype perhaps by suppressing 
TLR2 and/or TLR4 signaling within the atherosclerotic lesions of apoE-/- mice.  Finally, 
TLR9 is also atheroprotective in the apoE-/- mouse model by limiting the number of 
infiltrating CD4+ effector T cells (Koulis et al. 2014).  In addition to the increased 
atherosclerosis observed in the Irf5-deficient gld.apoE-/- mice, we also observed a 
significant increase in atherosclerosis in Irf5-deficient apoE-/- mice compared to Irf5-
sufficient apoE-/- mice.  Based on the above studies, it is tempting to speculate that IRF5 
is atheroprotective, in part, due to its role in TLR3, 7, or 9 signaling in atherosclerotic 
lesion-specific immune cells.  TLR7 and TLR9 can respond to RNA and DNA, 
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respectively, that is released from apoptotic or necrotic cells.  In the setting of an 
atherosclerotic lesion, it is possible that endogenous RNA and DNA released from dying 
cells within the necrotic core stimulate TLR7 and TLR9 leading to IRF5 activation.  
Furthermore, the atheroprotective effect of TLR7 and TLR9 might be enhanced in the 
gld.apoE-/- model as gld.apoE-/- mice were shown to have impaired clearance of apoptotic 
cells.  This may lead to an increase in endogenous TLR7 and TLR9 ligands within the 
lesion.  Indeed, we observed a greater atheroprotective effect of IRF5 in gld.apoE-/- mice 
compared to mice with apoE-/- alone.  However, this may be related to the effect of IRF5 
in metabolism in gld.apoE-/- mice (discussed later on).   
 IRF5 may be exerting an atheroprotective effect in immune cells in several ways.  
Firstly, my in vitro studies showed that IRF5 is required for IL-10 production in response 
to TLR7 and TLR9 stimulation in macrophages, dendritic cells and B cells. All of these 
cell types can be identified in specific stages of a progressing atherosclerotic lesion and 
IL-10 is a critical suppressor of inflammatory cytokines and chemokines (Grabner et al. 
2009; Ouyang et al. 2011).  The atheroprotective function of IL-10 has been shown in 
overexpression and knockout studies using several mouse models of atherosclerosis 
(Caligiuri et al. 2003; Han et al. 2010; Pinderski et al. 2002).  In particular, apoE-/- mice 
deficient in IL-10 develop larger atherosclerotic lesions as do IL-10-deficient C57BL/6 
mice fed an atherogenic diet (Caligiuri et al. 2003; Mallat et al. 1999).  In addition, IL-10 
is critical for promoting cholesterol efflux from foam cells by upregulating the 
cholesterol transporter, ABCA1 (Han et al. 2009).  Therefore, Irf5-deficiency in immune 
cells may lead to a decrease of IL-10 within the lesion, contributing to progression of 
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atherosclerosis.  Future studies will involve measuring IL-10 gene expression in lesion-
containing aortic arches of Irf5-deficient and Irf5-sufficient apoE-/- and gld.apoE-/- mice. 
 IRF5 may be required in B cells for the production of atheroprotective natural 
IgM.  IgM specific for phosphorylcholine present in oxLDL and apoptotic cells promotes 
their clearance from the atherosclerotic lesion (Binder et al. 2008).  Natural IgM is 
produced mainly by B-1 cells of the peritoneum, in a manner that is partially dependent 
on TLR9 stimulation (Stoehr et al. 2011).  We found that Irf5+/- gld.apoE-/- mice 
displayed a significant decrease in T15 idiotype IgM levels, the prototypical natural IgM 
shown to be atheroprotective (Appendix I-Figure 7).  As will be described in Appendix I, 
initial studies of IRF5 in gld.apoE-/- mice were confounded as most of the experimental 
mice expressed mutant DOCK2.  However, there were a number of Irf5+/- gld.apoE-/- 
mice that were wild type for DOCK2 and these displayed a significant decrease in T15 
IgM compared to Irf5+/+ gld.apoE-/- mice expressing wild type DOCK2.  To confirm this 
data in a greater number of mice, measurement of natural T15 IgM from serum of the 
Irf5+/+gld.apoE-/-, Irf5+/-gld.apoE-/-  and Irf5-/- gld.apoE-/- littermate mice described here 
will be performed in the near future.  In addition, whether or not IRF5 regulates natural 
IgM production in a B cell-intrinsic manner downstream from TLR9, or in a B cell-
extrinsic manner is an interesting question for future study.  (See Figure 39 for summary 
of potential atheroprotective mechanisms of IRF5 in immune cells). 
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Figure 38 Potential mechanisms by which IRF5 protects against atherosclerosis. 
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Irf5-deficiency leads to hyperlipidemia and hypercholesterolemia potentially 
contributing to atherosclerosis. 
 The role of IRF5 in maintaining metabolic homeostasis in gld.apoE-/- mice is a 
novel finding in our study and likely a major mechanism by which IRF5 is protective 
against atherosclerosis in this model.  A proportion of SLE patients have serum lipid 
imbalances and metabolic signatures suggestive of an overall reduction in energy-
generating pathways (Wu et al. 2012).  Furthermore, SLE patients show an increased 
incidence of metabolic syndrome characterized by elevated fasting insulin levels and 
elevated serum triglycerides compared to healthy controls (Chung et al. 2007). However, 
increased risk for atherosclerosis in SLE patients is believed mainly to be an effect of 
increased inflammation driven by the autoimmune process.  Chronic inflammation, like 
that observed in the setting of SLE, leads to an increase in pro-inflammatory HDL 
(piHDL) (McMahon et al. 2013; Skaggs et al. 2012).  piHDL is characterized by an 
inability to clear lipids from atherosclerotic lesions as well as an inability to suppress 
oxidation of LDL (Hahn et al. 2010; McMahon and Hahn 2007; Van Lenten et al. 1995).   
We observed a decrease in HDL levels within the serum of Irf5-/- gld.apoE-/- mice 
compared to Irf5+/+.gld.apoE-/- mice.  Although we cannot exclude the possibility that 
Irf5-/-gld.apoE-/- mice have increased piHDL compared to Irf5+/+ gld.apoE-/- mice, it 
seems more likely that HDL serves an atheroprotective role in gld.apoE-/- mice.  Because 
we observe a decrease in markers of systemic inflammation (i.e decreased serum pro-
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inflammatory cytokines and decreased kidney disease severity) in Irf5-deficient  
gld.apoE-/- mice compared to Irf5-sufficient gld.apoE-/- mice, we would expect that Irf5-
deficient gld.apoE-/- mice would have lower levels of piHDL. 
 Although the risk of SLE associated with Irf5 polymorphisms has been described, 
little is known regarding the metabolic phenotype or susceptibility to atherosclerosis in 
SLE patients with Irf5 polymorphisms.  The stark difference in the color and opacity of 
serum from Irf5-sufficient gld.apoE-/- mice compared to Irf5-deficient gld.apoE-/- mice 
indicated a difference in serum lipid levels.  Indeed, Irf5-deficient gld.apoE-/- mice were 
hypertriglyceridemic and hypercholesterolemic compared to Irf5-sufficient gld.apoE-/- 
littermates.  In addition, Irf5-deficient gld.apoE-/- mice had an increase in phospholipids 
and non-esterified free fatty acids compared to Irf5-sufficient gld.apoE-/- mice.  Although 
largely known for its function in immune cells, IRF5 has been detected in metabolic 
organs such as adipose tissue, muscle and fetal liver (Barnes et al. 2001; Kim et al. 2012; 
Takaoka et al. 2005).  Bone marrow chimera studies revealed that gld.apoE-/- mice that 
lacked Irf5 in the non-hematopoietic cell compartment displayed significantly higher 
levels of triglycerides, cholesterol and phospholipids compared to those that expressed 
Irf5 in the non-hematopoietic cell compartment.  To our knowledge, this is the first report 
of IRF5 functioning as a critical regulator of lipid homeostasis.  Furthermore, the 
expression of Irf5 in non-hematopoietic cells is necessary and sufficient for regulation of 
lipid homeostasis in gld.apoE-/- mice.   
 Hypertriglyceridemia and hypercholesterolemia are classical risk factors for the 
development of atherosclerosis, in part, by promoting an increase in oxLDL load within 
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the atherosclerotic lesion (Van Gaal et al. 2006).  To confirm this in our model, we tested 
the atherogenecity of serum from Irf5-deficient and Irf5-sufficient gld.apoE-/- mice using 
a foam cell assay.  Serum from Irf5-deficient gld.apoE-/- mice, containing high levels of 
triglycerides and cholesterol, promoted increased foam cell formation compared to serum 
from Irf5-sufficient gld.apoE-/- mice.  In addition, there was a positive correlation 
between cholesterol and atherosclerosis in gld.apoE-/- mice.  Therefore, we conclude that 
one mechanism by which Irf5-deficiency in non-hematopoietic cells contributes to 
atherosclerosis is through the regulation of serum lipids. 
 
Which Irf5-expressing metabolic tissue is critical for regulating metabolism? 
 Irf5 mRNA has been detected in human and mouse skeletal muscle (Barnes et al. 
2001; Takaoka et al. 2005).  IRF5 has been implicated in apoptosis in the liver (Couzinet 
et al. 2008).  Finally, multiple IRFs, including IRF5, have been shown to be upregulated 
in adipose tissue of mice fed high fat diet (Kim et al. 2012; Kwon et al. 2012).  In order 
to determine the specific metabolic tissue in which IRF5 regulates metabolism, we first 
measured transcript levels of Irf5-sufficient gld.apoE-/- mice that had been on western 
diet for 12 weeks.  We detected Irf5 expression in adipose tissue, liver and muscle and 
discuss in points 1-3 below potential tissue-specific roles of IRF5 in metabolism. 
1.  IRF5 in adipose tissue 
 Recently, it has been established that the family of IRF transcription factors are 
important regulators of adipose tissue metabolism (Eguchi et al. 2008).  Mice lacking 
IRF4 specifically in adipocytes displayed an increase in overall adiposity with marked 
  
156 
adipocyte hypertrophy (Eguchi et al. 2011).  In the absence of insulin, which exerts an 
inhibitory effect on IRF4 in adipocytes, IRF4 was shown to induce genes required for 
lipolysis and suppress genes required for lipogenesis.  IRF5 has been shown to be 
upregulated in adipose tissue of mice on high fat diet compared to those on normal diet 
(Kim et al. 2012; Kwon et al. 2012).  However, it was not known whether this 
upregulation of IRF5 was a result of an increase in Irf5 expression in adipocytes or an 
increase in the number of Irf5-expressing immune cells in the stromal vascular fraction.  
In this study, we found that Irf5 is indeed upregulated in the stromal vascular fraction of 
adipose tissue in C57BL/6 mice in response to high fat diet.  Interestingly, Irf5 was more 
strongly upregulated in the purified adipocyte fraction.  In gld.apoE-/- mice on western 
diet, we found that Irf5-deficiency led to a significant increase in adipocyte size and 
adipose tissue weight, both in the perigonadal and subcutaneous fat depots.  Bone 
marrow chimera studies revealed that Irf5-deficiency in the non-hematopoietic cell 
compartment was sufficient for the increase in adiposity observed in gld.apoE-/- mice.  lt 
is possible that, similar to IRF4, adipocyte-intrinsic IRF5 acts as a transcriptional 
regulator to promote lipolysis and inhibit lipogenesis.  If this is true, IRF5 may also be 
inhibited by insulin signaling.  This idea is intriguing as we observed that Irf5-deficient 
gld.apoE-/- mice are insulin-resistant.  Whether or not IRF5 contributes to insulin-
dependent regulation of adipocyte lipid handling requires further study.   
2.  IRF5 in the liver 
Although a specific role for IRF5 in adipocytes in regulation of metabolism is 
compelling, we cannot overlook a potential role for IRF5 in other metabolic tissues.  We 
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observed that Irf5-deficient gld.apoE-/- mice developed marked liver steatosis compared 
to Irf5-sufficient gld.apoE-/- mice.  This could be a result of liver-intrinsic or extrinsic 
functions.  Irf5 was found to be expressed in the livers of gld.apoE-/- mice after 12 weeks 
on western diet.  Furthermore, IRF5 mediates Fas-induced apoptosis in livers of C57BL/6 
mice (Couzinet et al. 2008).  However, whether Irf5-deficiency protected C57BL/6 mice 
against Fas-induced liver disease due to its expression in hepatocytes is unclear (Couzinet 
et al. 2008).   
 Although IRF5 may potentially protect from the development of liver steatosis 
through its expression in the liver, the liver steatosis we observe in the Irf5-deficient 
gld.apoE-/- mice is likely a secondary effect of insulin-resistance.  Irf5-deficient  
gld.apoE-/- were insulin-resistant compared to Irf5-sufficient gld.apoE-/- mice.  Hepatic 
steatosis occurs in 90-100% of obese individuals with type 2 diabetes and is considered a 
secondary effect of diet-induced insulin-resistance (Angulo 2002).  Upon eating, insulin 
is released from beta cells of the pancreas and binds to its receptor on adipocytes to 
induce glucose uptake, suppress lipolysis and promote lipogenesis.  In the insulin-
resistant adipocyte, lipolysis continues unabated leading to an increase in free fatty acid 
efflux (Alkhouri et al. 2010; Van Gaal et al. 2006).   Free fatty acids are then transported 
in complex with albumin to the liver where they are either catabolized through beta 
oxidation, stored as triglycerides, or secreted in VLDL particles (Browning and Horton 
2004; Klop et al. 2013).  The insulin-resistant liver has enhanced de novo lipogenesis and 
decreased fatty acid oxidation.  The liver attempts to compensate for the increased levels 
of free fatty acid and triglycerides by secreting higher levels of VLDL (Choi and 
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Ginsberg 2011).  Indeed, Irf5-deficient gld.apoE-/- mice displayed a significant increase 
in serum triglycerides and cholesterol transported in VLDL particles compared to Irf5-
sufficient gld.apoE-/- mice.  In addition, gld.apoE-/- mice lack functioning apolipoprotein 
E.  As a result, triglycerides stored in VLDL may not be properly hydrolyzed by adipose-
specific lipoprotein lipase, further increasing serum levels of VLDL (Pendse et al. 2009).  
VLDL is converted to LDL, a portion of which is taken to the periphery where it can 
become deposited within the endothelium of blood vessels, initiating atherosclerosis 
(Choi and Ginsberg 2011; Van Gaal et al. 2006).  Therefore, the higher serum VLDL 
levels we observed in Irf5-deficient gld.apoE-/- mice compared to Irf5-sufficient 
gld.apoE-/- mice may partially explain the enhanced atherosclerosis observed. 
3.  IRF5 in muscle 
 Irf5 is expressed in muscle of C57BL/6 mice and we detected Irf5 transcript in the 
muscle of Irf5-sufficient gld.apoE-/- mice on western diet (Takaoka et al. 2005).  The 
effect of muscle physiology on the regulation of lipid and glucose metabolism in the 
setting of obesity and insulin-resistance is gaining substantial interest.  Exogenous-
derived triglycerides packaged in the form of chylomicrons and endogenous triglycerides 
packaged in the form of VLDL, are hydrolyzed by the muscle and catabolized for energy 
(Corcoran, Lamon-Fava, and Fielding 2007).  Thus, the high levels of triglycerides and 
VLDL we observe in Irf5-deficient gld.apoE-/- mice may be a result of a failure of Irf5-
deficient muscle to metabolize triglycerides.  The enzyme, lipoprotein lipase (LPL) is 
highly expressed by endothelial cells of blood vessels within adipose tissue and muscle 
(Wang and Eckel 2009).  LPL binds to apolipoprotein C2 on chylomicrons and VLDL 
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and facilitates the hydrolysis of triglycerides from these particles.  Mice lacking LPL 
within muscle develop obesity and insulin-resistance, similar to that which we see in Irf5-
deficient gld.apoE-/- mice (Wang and Eckel 2009).  Indeed, preliminary results indicate a 
significant reduction in LPL transcript within the muscle of Irf5-deficient C57BL/6 
compared to Irf5-sufficient C57BL/6 mice and in Irf5-deficient gld.apoE-/- mice 
compared to Irf5-sufficient gld.apoE-/- mice.  (Figure 29 A and B). 
 IRF5 may also regulate the production of endocrine proteins within the muscle 
which are required for the maintenance of full body metabolic homeostasis.  During 
physical activity, muscle contraction leads to the secretion of muscle-specific cytokines, 
or myokines.  Originally believed to be produced by immune cells in response to muscle 
tissue damage, myokines are now known to be largely produced by the myocytes 
themselves.  IL-6 is a well-studied myokine produced in response to muscle contraction 
and low glycogen levels and its production in muscle can increase 100-fold during 
exercise (Pedersen 2007).  IL-6  activity within muscle leads to increased oxidation of 
fatty acids and activation of AMPK leading to increased sensitivity to insulin and 
enhanced glucose uptake (Pedersen and Febbraio 2008).   IL-6 produced by muscle can 
also act in endocrine fashion to stimulate glucose production by the liver and lipolysis in 
adipocytes (Pedersen and Febbraio 2008).  IL-6-deficient mice develop late-onset obesity 
and insulin-resistance (Pedersen and Febbraio 2012).  Finally, rheumatoid arthritis 
patients treated with anti-IL-6 antibodies display an increase in plasma cholesterol and 
glucose levels (Pedersen and Febbraio 2008).   Preliminary results indicate a significant 
reduction in IL-6 transcript within the muscle of Irf5-deficient C57BL/6 compared to 
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Irf5-sufficient C57BL/6 mice and in Irf5-deficient gld.apoE-/- mice compared to Irf5-
sufficient gld.apoE-/- mice.  (Figure 30 A and B).  IRF5 has been shown to directly bind 
to the IL-6 promoter in response to TLR-stimulation in immune cells (Feng et al. 2010a).  
Therefore, it is plausible that one mechanism by which Irf5-deficiency in non-
hematopoietic cells leads to hypertriglyceridemia, hypercholesterolemia, obesity and 
insulin-resistance is through its regulation of IL-6 within muscle.   
 The function of IRF5 in non-hematopoietic cells in maintaining metabolic 
homeostasis in response to high fat diet is likely complex and may be a result of IRF5 
activity in multiple non-immune cell types.  Future work will involve a detailed 
metabolic analysis of mice lacking IRF5 in adipocytes, hepatocytes and myocytes using 
cell-specific Cre-Irf5 flox mice on a gld.apoE-/- background.  (See Figure 38 for summary 
of potential mechanisms by which IRF5 is protective against atherosclerosis through 
regulation of metabolism). 
 
What regulates Irf5 in metabolic tissues? 
 What is the upstream activator of IRF5 in metabolic tissues?  A major clue may 
be in the fact that we only observed the metabolic effect of Irf5-deficiency in mice with 
the gld mutation.  gld mice have a point mutation in the gene encoding Fas ligand which 
results in a loss of Fas-FasL signaling (Bhandoola et al. 1994; Karray et al. 2004).  Fas is 
a member of the death receptor family and is critical for the extrinsic apoptotic pathway 
in lymphocytes (Guicciardi and Gores 2009).  Recently, the role of death receptors in 
metabolism has gained substantial interest.  Levels of FasL are reported to be increased in 
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the serum of obese patients (Wueest et al. 2010).  Fas signaling in adipocytes has been 
shown to promote lipolysis and Fas-deficient mice were shown to be protected from diet-
induced obesity and liver steatosis (Wueest et al. 2010).  Furthermore, Fas signaling in 
adipocytes also leads to insulin resistance.  gld and lpr mice, which express mutated and 
inactive forms of Fas ligand and Fas, respectively, are protected from the development of 
diabetes, and Fas-deficient mice were protected from insulin-resistance in the context of 
a high fat diet (Mohamood et al. 2007; Xiao et al. 2011).   In Figures 34 (A & B) and 35 
(A & B) we compare the metabolic features of apoE-/- and gld.apoE-/- mice with or 
without Irf5.  Both male and female gld.apoE-/- mice displayed a significant decrease in 
the size of perigonadal and subcutaneous fat compared to male and female apoE-/- mice 
consistent with published results (Wueest et al. 2010).  Notably, Irf5-deficiency in both 
male and female gld.apoE-/- mice, but not apoE-/- mice led to an increase in perigonadal 
and subcutaneous fat.  
 Furthermore, when we compared serum lipid levels of apoE-/- and gld.apoE-/- 
mice, both male and female gld.apoE-/- mice displayed a significant decrease in serum 
triglycerides and total cholesterol compared to male and female apoE-/- mice.  (Figure 36 
A & B).   Similar to that observed in adipose tissue size, Irf5-deficiency in both male and 
female gld.apoE-/- mice, but not apoE-/- mice led to an increase in serum lipid levels.  
Therefore, Irf5-deficiency specifically rescues the metabolic perturbations resulting from 
gld  (lack of Fas-FasL signaling).   
 One caveat of this experiment is that is that male apoE-/- mice were on western 
diet for approximately 3 weeks longer than male gld.apoE-/- mice.  Therefore, the 
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difference in metabolic features observed between male apoE-/- and male gld.apoE-/- mice 
may be a result of a differences in the number of weeks on western diet.  However, 
female apoE-/- and gld.apoE-/- mice were all on western diet for 12 weeks.  As the number 
of weeks on western diet is not a variable in this experiment, the difference in fat and 
serum lipids is likely due to gld.   
 The dependence of the IRF5 metabolic effect on Fas-FasL deficiency could be for 
one or both of the following reasons: 1) The presence of the gld mutation lowers the 
metabolic threshold in response to western diet allowing for the IRF5 effect on 
metabolism to be seen.  And/or 2) IRF5 is critical in regulating metabolism through its 
function in a pathway that normally interacts with the Fas-FasL pathway such that 
deficiency in Fas-FasL signaling enhances the IRF5 signaling pathway.   
 1.  Lack of Fas-FasL may be lowering the metabolic threshold in response to 
western diet allowing for the IRF5 effect on metabolism to be seen.  IRF5 may influence 
metabolism in a redundant manner such that in a C57BL/6 or apoE-/- mouse on western 
diet, where metabolic thresholds are higher, Irf5-deficiency is not sufficient to alter 
metabolism.  In this sense, IRF5 may be acting in a pathway that does not directly 
interact with the Fas-FasL signaling pathway.  For example, IRF5 may act downstream 
from the insulin receptor in adipocytes.  Insulin signaling regulates IRF4 in adipocytes 
and its ability to control genes required for lipolysis and lipogenesis (Eguchi et al. 2011).  
In a similar manner, IRF5 may be suppressed by, or respond to insulin receptor activation 
and regulate the expression of genes that alter adipocyte lipid handling.  Fas-deficient  
mice are protected from diet-induced insulin resistance as are Irf5-sufficient gld.apoE-/- 
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mice.  Irf5-deficiency abrogates this protective effect of gld and promotes insulin-
resistance.  Loss of IRF5 downstream from the insulin receptor might be sufficient to 
render adipocytes resistant to insulin signaling despite the insulin-sensitizing effects of 
Fas-deficiency.  Thus, understanding how Fas-deficiency leads to insulin-sensitivity in 
adipocytes is not critical for determining how Irf5-deficiency might lead to a reduction in 
insulin-sensitivity.  One future experiment would entail culturing Irf5+/+ and Irf5-/- 
adipocytes and determining if IRF5 is required for the expression of insulin-dependent 
genes.  In addition, it would be expected that Irf5-deficiency in mice with a lower 
metabolic threshold would lead to similar metabolic effects as we have observed with 
gld.apoE-/- mice.  Therefore, one future experiment would be to compare the metabolic 
effects of Irf5-deficiency in C57BL/6, gld  and apoE-/- mice on normal diet.   
 2.  IRF5 may regulate metabolism in a pathway that directly interacts with the 
Fas-FasL pathway.  (Figure 39) For this hypothesis, we propose two potential 
possibilities: TLRs and TRAIL receptors. 
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Figure 39 Fas and IRF5 crosstalk. 
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 Much work on the role of TLRs in metabolic dysfunction has involved TLR2 and 
TLR4.  IRF5 has been shown to act downstream from TLR4 in macrophages and 
dendritic cells and induce the expression of pro-inflammatory cytokines (Krausgruber et 
al. 2011; Krausgruber et al. 2010; Takaoka et al. 2005).  However, Tlr2 and Tlr4-
deficiency is protective against metabolic dysfunction.  (Ehses et al. 2010; Saberi et al. 
2009; Tsukumo et al. 2007).  Thus, it is unlikely that Irf5-deficiency leads to metabolic 
dysfunction due to its expression downstream from TLR2 or TLR4.  In this study we 
show, that at least in immune cells, IRF5 functions downstream from TLR7 and TLR9 to 
induce the expression of the anti-inflammatory cytokine IL-10.  IL-10 limits 
inflammation and deficiency of IL-10 may promote obesity (Esposito et al. 2003; Orr et 
al. 2012; Ouyang et al. 2011).  However, we show here that IRF5 regulates metabolism in 
non-hematopoietic cells.  Little is known about the role of TLR7 and TLR9 in non-
hematopoietic cells in metabolism.  Of interest, Tlr9-/-.apoE-/- mice develop more severe 
atherosclerosis, in part, through regulation of immune cells (Koulis et al. 2014).  
However, Tlr9-/-.apoE-/- mice also displayed increased serum cholesterol and triglyceride 
levels (Koulis et al. 2014).  As Irf5-deficient gld.apoE-/- mice also displayed increased 
serum cholesterol and triglyceride levels, it is possible that IRF5 is acting downstream 
from TLR9 in non-hematopoietic cells to regulate lipids.  The use of TLR7 and TLR9 
bone marrow chimeras will help to determine whether TLR7 or TLR9 expression in non-
hematopoietic cells regulates metabolism. 
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 If IRF5 is acting downstream from either TLR7 or TLR9 in non-hematopoietic 
cells, it may partially explain why we only observe the metabolic effect of IRF5 in 
gld.apoE-/- mice.  Aprahamian et al showed that gld.apoE-/- mice have elevated apoptotic 
fragments in lymph nodes and in the circulation compared to apoE-/- mice (Aprahamian 
et al. 2004).  Apoptotic fragments contain endogenous RNA and DNA capable of 
stimulating TLR7 and TLR9, respectively.  Thus, gld.apoE-/- mice might have enhanced 
TLR7 and TLR9 signaling relative to apoE-/- mice as a result of elevated levels of 
endogenous nucleic-acid ligands.  In addition, several studies have supported the 
existence of crosstalk between the Fas and TLR9 signaling pathways (Fukui et al. 2003; 
Hancz et al. 2012).  It is possible that Fas-FasL deficiency enhances TLR9-IRF5 
metabolic pathways in gld.apoE-/- mice allowing for a greater difference in metabolic 
phenotype between Irf5-sufficient and Irf5-deficient gld.apoE-/- mice to be observed. 
 IRF5 may also function downstream from TNF-related apoptosis-inducing ligand 
(TRAIL) receptors in gld.apoE-/- mice to regulate metabolism.  TRAIL receptors are also 
members of the death receptor family which promote apoptosis in immune cells 
(Guicciardi and Gores 2009).  IRF5 functions downstream from the TRAIL receptors, 
DR4 and DR5, in tumor cells to induce apoptosis (Hu and Barnes 2009).  Similar to 
FasL, levels of TRAIL are increased in the serum from obese patients (Harith, Morris, 
and Kavurma 2013).  Unlike the protective metabolic effects of Fas-FasL deficiency, 
TRAIL-/- mice actually develop more severe insulin resistance than wild type mice when 
placed on a western diet (Di Bartolo et al. 2011).   Furthermore, when crossed to apoE-/- 
mice and placed on a western diet, TRAIL-/-.apoE-/- mice displayed an increase in serum 
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triglycerides, cholesterol, glucose and increased atherosclerosis compared to apoE-/- 
counterparts (Di Bartolo et al. 2011).  Mechanistically, TRAIL regulates cholesterol and 
triglyceride homeostasis most likely by downregulating genes required for cholesterol 
synthesis and absorption as well as genes required for lipogenesis (Keuper et al. 2013).  
In support of a protective role for TRAIL in diet-induced metabolic dysfunction, 
C57BL/6 mice placed on a high fat diet and treated with recombinant TRAIL displayed a 
decrease in adiposity, improved insulin-sensitivity and glucose tolerance as well as a 
decrease in atherosclerosis compared to mice not treated with TRAIL (Bernardi et al. 
2012; Secchiero et al. 2006). Interestingly, TRAIL levels are reduced in the serum of 
patients with type 2 diabetes and cardiovascular disease, further supporting a potential 
protective role for TRAIL and its receptors (Harith et al. 2013).  In summary, TRAIL 
signaling appears to be altering metabolism in a manner that is surprisingly distinct from 
that of Fas signaling. 
 Whereas the metabolic phenotype of Irf5-sufficient gld.apoE-/- mice recapitulates 
that of Fas-deficient mice, the phenotype of Irf5-deficient gld.apoE-/- mice recapitulates 
that of TRAIL-/- mice.  IRF5 has been shown to function downstream from both Fas and 
TRAIL receptors in apoptosis, but whether IRF5 participates in Fas and/or TRAIL 
receptor signaling in metabolism is not known.  In addition, it is not known whether the 
Fas-FasL and TRAIL-TRAIL receptors interact in metabolic tissues.  However, it is 
possible that as IRF5 functions downstream from both receptors to induce apoptosis in 
immune cells, it may act as a potential link between the two pathways in metabolism. 
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Summary and future directions. 
 IRF5 is a key therapeutic target due to its significance in the pathogenesis of SLE, 
as well as other autoimmune disorders.  Our finding that Irf5-deficiency leads to an 
increase in atherosclerosis in the gld.apoE-/- mouse model suggests that global inhibition 
of IRF5 in autoimmune patients may actually exacerbate atherosclerosis.   We found that 
Irf5-deficiency led to more severe atherosclerosis due to its expression in both 
hematopoietic and non-hematopoietic cells.  As IRF5 is a major transcription factor 
downstream from nucleic acid-sensing TLRs, such as TLR3, 7 and 9, the atheroprotective 
effect of IRF5 in immune cells supports the recent findings that these TLRs are in fact 
protective in atherosclerosis.  TLR7 and TLR9 inhibitors are also potential therapies for 
SLE.  Therefore, it is critical to understand the molecular pathways by which these TLRs, 
as well as IRF5, inhibit the development of atherosclerosis.   
 Our most novel finding is the metabolic effect of Irf5-deficiency in non-
hematopoietic cells.  The data provided here hint at the possibility of detrimental 
metabolic effects if IRF5 is inhibited in a global manner.  Hyperlipidemia, 
hypercholesterolemia, obesity and insulin-resistance are all linked to the development of 
atherosclerosis in humans.  Understanding the IRF5-dependent metabolic pathways in 
non-hematopoietic cells as well as the receptors that activate IRF5 in these cells may 
allow us to inhibit the pathogenic effects of IRF5 in lupus, without disrupting metabolic 
homeostasis.   For example, IRF5 activation downstream from TLR7 and TLR9 signaling 
in immune cells requires the adaptor protein MyD88.  If the pathway that IRF5 functions 
in to regulate metabolism does not require MyD88 then a drug that specifically inhibits 
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the interaction of IRF5 and MyD88 might inhibit the pathogenic effects of IRF5 in lupus 
while maintaining the protective effects of IRF5 in metabolism. 
 The use of cell-specific Irf5 knock out gld.apoE-/- mice will allow us to determine 
in which immune cell Irf5 expression is critical in for protection against atherosclerosis.  
It will also allow us to determine the non-immune cell that Irf5 expression is critical in 
for protection against metabolic dysfunction and atherosclerosis.   
 Finally, although the immune system and metabolic system in mice are 
sufficiently similar to that of humans, it remains to be determined whether IRF5 is 
associated with metabolic abnormalities in humans.  Based on this work, we suggest 
human studies be performed in which associations between atherosclerosis and other 
metabolic abnormalities with polymorphisms in Irf5 are investigated in autoimmune 
patients as well as in the normal population. 
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 CHAPTER THREE 
The role of IRF5 in the MRL.lpr model of lupus. 
Abstract 
 Gain-of-function polymorphisms in the gene encoding human interferon 
regulatory factor-5 (IRF5) are associated with an increase in risk for the development of 
the autoimmune disease Systemic Lupus Erythematosus (SLE).  IRF5 is a transcription 
factor that participates in the activation of the immune system through its role in both 
innate and adaptive immune cells. To determine the role of IRF5 in lupus pathogenesis in 
vivo, we evaluated the effect of Irf5-deficiency in the MRL/lpr lupus mouse model.  We 
found that Irf5-deficient (Irf5-/-) MRL/lpr mice developed much less severe disease than 
their Irf5-sufficient (Irf5+/+) littermates, demonstrating an important role for IRF5 in 
disease pathogenesis in vivo.   
Introduction 
 Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by 
the loss of tolerance to chromatin and ribonucleoproteins and the deposition of immune 
complexes in various organs (Liu and Davidson 2012). The clinical presentation is 
heterogeneous but disease manifestations may be severe.  
 SLE is caused by an incompletely understood interaction between genetic and 
environmental factors (Liu and Davidson 2012).  Polymorphisms in the transcription 
factor interferon regulatory factor 5 (IRF5) have been strongly associated with an 
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increased risk of developing lupus in multiple human genetic studies (Graham et al. 2006; 
Graham et al. 2007; Sigurdsson et al. 2005).  The polymorphisms contributing to the 
high-risk IRF5 haplotype are thought to induce novel IRF5 isoforms and/or increase the 
level of IRF5 expression by increasing the stability of IRF5 protein or mRNA leading to 
IRF5 gain-of –function (Feng et al. 2010b; Graham et al. 2007). 
 IRF5 plays an important role in TLR signaling through the induction of pro-
inflammatory cytokines, type I interferons and chemokines and class switching to IgG2a 
(Savitsky et al. 2010; Takaoka et al. 2005; Yasuda et al. 2007).  The degree to which 
IRF5 plays a role in these TLR-induced responses is ligand-, cell type- and cytokine- 
dependent but IRF5 appears to be consistently involved in many TLR7- and TLR9-driven 
responses (Paun and Pitha 2007; Schoenemeyer et al. 2005; Yasuda et al. 2013).  As 
dysregulated TLR signaling, particularly through TLR7 and TLR9, may contribute to 
lupus pathogenesis it is possible that the effects of IRF5 in lupus are mediated through 
alterations in the strength or nature of TLR signaling events.  IRF5 also participates in 
apoptotic pathways induced by viral infection, DNA damage, Fas ligand and TNF-related 
apoptosis-inducing ligand (TRAIL) (Couzinet et al. 2008; Hu and Barnes 2009).  Given 
the association of abnormal apoptosis regulation to lupus pathogenesis it is possible that 
IRF5 might also impact lupus pathogenesis through this mechanism. 
 Our laboratory was the first to report on the role of IRF5 in a mouse model of 
SLE using Irf5 knockout mice. We found that IRF5 was critical for disease development 
in the FcRIIB-/-Yaa and FcRIIB-/- lupus models as Irf5-deficient FcRIIB-/-Yaa and 
FcRIIB-/- mice developed minimal disease manifestations (Richez et al. 2010).  Even 
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deficiency of a single IRF5 allele conferred substantial protection as IRF5 heterozygous 
mice developed very little disease. Our next goal was to determine if IRF5 was 
pathogenic in a different mouse model of lupus.  On the autoimmune-prone MRL 
background, mice with a mutation in the Fas gene develop lymphoproliferation (lpr) and 
a spontaneous lupus-like phenotype (Bhandoola et al. 1994).  Autoimmunity in MRL/lpr 
mice is due to a number of factors including an increased number of autoreactive B- and 
T-cells, impaired apoptosis, and an increased level of circulating, immunostimulatory 
RNA and DNA containing immune complexes (Kelley and Roths 1985; Perry et al. 
2011).  MRL/lpr mice develop autoantibodies to chromatin, RNA and RNA-associated 
proteins that are detectable with standard assays after 3-months of age. Subsequently, 
animals develop massive adenopathy and splenomegaly, dermatitis and 
glomerulonephritis (Andrews et al. 1978; Kelley and Roths 1985).  We bred Irf5-/- mice 
to the MRL/lpr strain and analyzed the disease phenotype of 16 week old female Irf5+/+, 
Irf5+/- and Irf5-/- mice.  During the course of this study, a report was published describing 
the pathogenic role of IRF5 in the MRL/lpr model (Tada et al. 2011).  Irf5-deficient 
MRL/lpr mice were protected from the development of splenomegaly, lymphadenopathy, 
and kidney disease.  They also displayed a significant decrease in serum ANA (Tada et 
al. 2011).   
 Shortly after the publication by Tada et al describing a pathogenic role for IRF5 in 
the MRL/lpr lupus mouse model, it was reported that the Irf5 knockout mouse line 
contained a mutation in the dedicator of cytokinesis 2 (DOCK2) gene (Purtha et al. 2012; 
Yasuda et al. 2013).  This mutation causes unstable DOCK2 mRNA expression resulting 
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in very low DOCK2 protein expression.  Previous studies in DOCK2 knockout (DOCK2-
/-) mice have shown that DOCK2 has important functions in the immune system. 
Trafficking of T cells, B cells and neutrophils is impaired in DOCK2-/- mice due to 
defective chemokine receptor signaling (Fukui et al. 2001; Nishikimi et al. 2009).  
DOCK2-/- mice develop enhanced T helper cell type 2 (Th2) responses because DOCK2-
deficient CD4+ T cells cannot down-regulate surface IL-4 receptor  expression (Tanaka 
et al. 2007).  Plasmacytoid dendritic cells (pDCs) from DOCK2-/- mice have a reduced 
capacity to produce IFN- and IFN- in response to TLR7 and TLR9 ligands (Gotoh et 
al. 2010).  The DOCK2 mutation present in IRF5-/- C57BL/6 mice has been shown to 
cause a marked reduction in splenic marginal zone and mature B cell numbers, to 
enhance Th2-type IgG production and to affect certain aspects of TLR signaling (Purtha 
et al. 2012; Yasuda et al. 2013). 
 Given the effects of DOCK2 on immune function noted above, it is possible that 
if the DOCK2 mutation was present in the mouse lupus models studied then some of the 
protective effects attributed to Irf5-deficiency may instead have been due to DOCK2 
deficiency. We have screened archived tail DNA using a PCR that we recently developed 
to specifically detect the DOCK2 mutation and found that many of the FcRIIB-/-Yaa and 
FcRIIB-/- mice in our previous study contained the DOCK2 mutation.   It is also possible 
that the Irf5-deficient MRL/lpr mice used in the publication by Tada et al were 
confounded by the presence of the DOCK2 mutation.  Therefore, we have examined the 
role of Irf5 in the MRL/lpr lupus model using mice without the DOCK mutation. We 
have also specifically examined the effect of deficiency of a single allele of Irf5 in 
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MRL/lpr, as we previously observed a marked protective effect of IRF5 in the FcRIIB-/-
Yaa and FcRIIB-/- models.   
Materials & Methods  
Mice. 
IRF5-/- mice backcrossed eight generations to C57BL/6 were obtained from T. Taniguchi 
(University of Tokyo, Tokyo, Japan) and T. Mak (University of Toronto, Toronto, 
Ontario, Canada) (Takaoka et al. 2005).  IRF5-/- mice were backcrossed 7 generations to 
MRL/MpJ-Faslpr mice (Stock number 000485, Jackson, Bar Harbor, ME). Experimental 
mice were generated by breeding IRF5 heterozygous (IRF5+/-) MRL/lpr mice to obtain 
IRF5+/+, IRF5+/- and IRF5-/- littermates.  Only female mice were used for this study.  
Animal experiments were approved by the Institutional Animal Care and Use Committee 
at Boston University.   
PCR 
The PCR used to detect wild type DOCK2 and the DOCK2 mutation was described 
previously (Yasuda et al. 2013).  PCR primers to detect DOCK2 mutation are; 5’-GAC 
CTT ATG AGG TGG AAC CAC AAC C-3’ and 5’-GAT CCA AAG ATT CCC TAC 
AGC TCC AC-3’.  The PCR detects the DOCK2 mutation as a 305-bp product.  PCR 
primer sequences that recognize the CD19 gene were obtained from the Web site of The 
Jackson Laboratory (http://jaxmice.jax.org/strain/004126.html), and the primers used 
as an internal control to ensure that DNA preparation was adequate in all tail samples.   
All experimental MRL/mice were confirmed to have only wild type DOCK2 (Fig. 1).  
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Flow cytometry 
 
Splenocytes were labeled with monoclonal antibodies (BD Biosciences, San Jose, CA) 
specific for CD4, CD8 and CD3 to identify T cell populations, and CD19 and B220 to 
identify B cells.  Immunoflourescence was measured with a FACScan flow cytometer or 
LSRII (BD Bioscience).  The data was analyzed using FlowJo software (Tree Star, 
Ashland, OR). 
Serological assays 
 
IgG isotypes and IgM were measured by ELISA established using antibodies from BD 
Biosciences (San Jose, CA) and SouthernBiotech (Birmingham, AL).  Anti-nuclear 
autoantibody (ANA) titer was measured by immunofluorescence using HEp-2-coated-
slides (Antibodies Incorporated, Davis, CA).  Anti-dsDNA autoantibodies were measured 
by immunoflorescence analysis of Crithidia lucillae kinetoplast staining (Antibodies 
Incorporated, Davis, CA).  Blood urea nitrogen (BUN) levels were measured using a 
QuantiChrom Urea Assay kit (BioAssay Systems, Hayward, CA).  Serum BLyS levels 
were measured by ELISA developed using antibodies from R&D Systems (Minneapolis, 
MN). 
Histology 
 
Hematoxylin and eosin-stained kidney sections were evaluated in a blinded manner. 
Randomly selected areas of cortex were digitally photographed by a blinded investigator 
using an RT color spot camera (Diagnostic Instruments, Sterling Heights, MI), and Spot 
Advanced software version 4.0.9 (Diagnostic Instruments). Fifty glomeruli from each 
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animal were examined to determine the percentage of glomeruli with severe lesions (i.e. 
glomerular crescents or areas of necrosis), mild lesions (i.e. mesangial expansion) or no 
lesions. In severe glomerular lesions crescents were identified by the presence of >3 
palisading layers of cells in the extra-capillary space and fibranoid necrosis was identified 
by its classic eosinophillic and acellular appearance. Mild glomerular lesions were 
defined as prominence of the mesangial matrix as compared to normal glomeruli that 
occurred in the absence of severe lesions.  
Statistical analysis 
 
In all cases groups were compared using a Kruskal-Wallis analysis of variance on ranks 
because some of our data (e.g. the ANA titres) are not normally distributed.  In 
experiments where there were significant differences between groups (P < 0.05), the 
Holm-Sidak method was employed for post-hoc analysis and to correct for multiple 
comparisons. The Kaplan-Meier method with log-rank statistic was used to analyze the 
survival studies.  All statistics were performed using SigmaPlot 12.5 (Systat, San Jose, 
USA) with P < 0.05 considered as statistically significant.  
Results 
Experimental mice used in this study did not have the DOCK2 mutation 
   
 In this study we wanted to avoid as far as possible the presence of factors other 
than Irf5 expression itself that might alter disease development, including differences in 
the microbiome, genetic differences between independently maintained mouse lines, 
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gender differences and, in particular, the presence of the DOCK2 mutation. We therefore 
generated the experimental groups by breeding Irf5 heterozygous (Irf5+/-) MRL/lpr mice 
to generate Irf5-sufficient (Irf5+/+), Irf5-heterozygous (Irf5+/-) and Irf5-deficient (Irf5-/-) 
littermates. Only female littermates were used and were kept together in the same cage 
until the termination of the experiment at 16 weeks of age.  We previously developed a 
genomic PCR to detect the DOCK2 mutation and we used this PCR to determine whether 
the experimental mice had the DOCK2 mutation.  As shown in Figure 40, none of these 
mice had the DOCK2 mutation. 
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Figure 40 MRL/lpr mice used in this study were wild type for DOCK2. 
PCR from tail DNA was used to detect the wild type and DOCK2 mutant alleles.  
Experimental mice are indicated by number.  Control mutant DOCK2 DNA give a PCR 
product of 305 bp.  CD19 PCR was used as an internal control to verify the adequacy of 
DNA preparation in each sample.  DNA from DOCK2 wild type mice (WT) and from a 
mouse with the DOCK2 mutation (Mu) were included as controls. 
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Lymphoid tissue size and splenic T cell number are reduced in Irf5-
deficient MRL/lpr mice, whereas the percentage of splenic B cells is 
increased 
 
 Lymphadenopathy and splenomegaly are prominent features of mouse lupus 
models and, as expected, this was observed in the Irf5+/+ MRL/lpr mice. The degree of 
lymphadenopathy and splenomegaly was substantially reduced in the Irf5-/- MRL/lpr 
mice with a concomitant reduction in total spleen cell number (Figure 41A & B and 
Figure 42). The reduction in spleen cell number  was due largely to reductions in the 
number of CD4+ T cells and CD4-CD8- (double negative) T cells although there was also 
a trend towards a reduction in CD8+ T cells (Figures 43-45). In contrast, the percentage 
of splenic B cells was approximately twice as high in the Irf5-/- MRL/lpr mice as 
compared to the Irf5+/+ MRL/lpr mice with a trend towards an increased B cell number 
(Figure 46). Thus, IRF5 plays an important role in regulating splenic T cell numbers, but 
not B cell numbers, in MRL/lpr mice. 
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Figure 41 Splenomegaly and lymphadenopathy are reduced in Irf5+/+ and Irf5-/- MRL/lpr mice. 
 A)  Lymph node and B)  spleen weights from female Irf5+/+ (n=14), Irf5+/- (n=11), and 
Irf5-/- (n=11) littermate mice were measured at 16 weeks of age Statistics: Unpaired T 
test. *p<0.05, **p<0.01. 
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Figure 42 Splenocyte number is reduced in Irf5+/- and Irf5-/- MRL/lpr mice. 
 Total splenocyte number from female Irf5+/+ (n=14), Irf5+/- (n=11), and Irf5-/- (n=11) 
littermate mice were measured at 16 weeks of age. Statistics: Unpaired T test. *p<0.05. 
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Figure 43 Percentage and number of splenic CD4+ T cells are decreased in Irf5+/- and Irf5-/- MRL/lpr mice. 
The percentage (A) and total number (B) of splenic CD4+ T cells were measured from 
female Irf5+/+ (n=14), Irf5+/- (n=11), and Irf5-/- (n=11) littermate mice were measured at 
16 weeks of age. Statistics: Unpaired T test. *p<0.05. 
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Figure 44 The number of splenic double negative T cells are decreased in Irf5-/- MRL/lpr mice. 
The percentage (A) and total number (B) of splenic double negative T cells were 
measured from female Irf5+/+ (n=14), Irf5+/- (n=11), and Irf5-/- (n=11) littermate mice at 
16 weeks of age. Statistics: Unpaired T test. *p<0.05. 
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Figure 45 The number of splenic CD8+ T cells are decreased in Irf5-/- MRL/lpr mice. 
The percentage (A) and total number (B) of splenic CD8+ T cells were measured from 
female Irf5+/+ (n=14), Irf5+/- (n=11), and Irf5-/- (n=11) littermate mice were measured at 
16 weeks of age. Statistics: Unpaired T test. *p<0.05. 
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Figure 46 Percentage of splenic B cells are increased in Irf5+/- and Irf5-/- MRL/lpr mice. 
The percentage (A) and total number (B) of splenic B220+CD19+ cells were measured 
from female Irf5+/+ (n=14), Irf5+/- (n=11), and Irf5-/- (n=11) littermate mice were 
measured at 16 weeks of age. Statistics: Unpaired T test. *p<0.05. 
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Serum autoantibody levels and Th1-driven IgG isotypes are reduced in 
Irf5-deficient MRL/lpr mice 
 
 Autoantibodies against nuclear antigens are a characteristic feature of SLE and 
likely contribute to disease pathogenesis (Liu and Davidson 2012).  Most Irf5+/+ MRL/lpr 
mice had high serum levels of anti-nuclear antibodies (ANA) as measured by 
immunofluorescence on HEp2 cells, whereas ANA levels were markedly reduced in the 
Irf5-/- MRL/lpr mice (Figure 47A). Similarly, anti-double-stranded (ds) DNA 
autoantibody levels, as measured by Crithidia immunofluorescence, were much lower in 
Irf5-/- MRL/lpr mice (Figure 47B).       
 In terms of serum IgG isotypes, IgG2a levels were lower in Irf5-/- MRL/lpr mice 
as compared with Irf5+/+ MRL/lpr mice (Figure 48).  This was expected as IRF5 has been 
shown to induce IgG2a production by directly binding to the IgG2a locus (Savitsky et al. 
2010).  However levels of IgG2b and IgG3, but not of IgG1 or IgM, were also lower in 
Irf5-/- MRL/lpr mice suggesting that IRF5 may regulate IgG isotype production in 
MRL/lpr mice not only through direct binding to the IgG2a locus but also through the 
generation of a Th1-like immune response.    
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Figure 47 Decreased autoantibody production Irf5-deficient MRL/lpr mice. 
Sera from Irf5+/+, Irf5+/-, and Irf5-/- MRL/lpr littermates were analyzed at 16 weeks of 
age.  A) Anti-nuclear antibody (ANA) titers were measured by HEp2 cell 
immunofluorescence.  B) Anti-double stranded DNA (dsDNA) antibodies were measured 
by Crithidia lucillae luminescence. Statistics: Unpaired T test. *p<0.05, **p<0.01. 
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Figure 48 Decreased serum IgG2a, IgG2b and IgG3 levels Irf5-deficient MRL/lpr mice. 
Sera from Irf5+/+(n=12), Irf5+/- (n=11), and Irf5-/- (n=8) MRL/lpr littermates were 
analyzed at 16 weeks of age.  IgG and IgM levels were measured by ELISA.  Statistics: 
**p<0.01. 
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Renal disease is less severe in IRF5-deficient MRL/lpr mice 
 
 Mesangial matrix expansion or mesangial hypercellularity are features of mild 
human lupus nephritis (class II) whereas glomerular crescents and necrosis are features of 
more severe lupus nephritis (class III or IV) (Borchers et al. 2012).  All Irf5+/+ MRL/lpr 
mice exhibited a moderate to high degree of mesangial expansion with much less 
mesangial expansion being seen in Irf5-/- MRL/lpr mice (Figure 49). Approximately half 
the Irf5+/+ MRL/lpr mice had developed severe renal disease by the end-point of the study 
at 16 weeks of age as evidenced by the presence of glomerular crescents or necrosis.  In 
contrast, severe renal disease was not observed on histological examination in Irf5-/- 
MRL/lpr mice (Figure 49).  Functional renal failure is characterized by an elevation in 
serum blood urea nitrogen (BUN) levels with BUN levels starting to rise when more than 
50% of renal function has been lost (Bellomo, Kellum, and Ronco 2012).  The serum 
BUN level in non-autoimmune 16 week old female C57BL/6 mice is approximately 22 
mg/dl (http://jaxmice.jax.org/support/phenotyping/B6data000664.pdf). The serum 
BUN levels were 28.8 mg/dl in the Irf5+/+ MRL/lpr mice, indicating marked renal failure 
(Figure 49).  However, approximately half the Irf5+/+ MRL/lpr mice had less severe renal 
disease with serum BUN levels either normal or modestly elevated.  Irf5-/- MRL/lpr mice 
had serum BUN levels of 22.1 mg/dl, consistent with the absence of severe disease on 
renal histology.
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Figure 49 Less severe renal disease in Irf5-deficient MRL/lpr mice. 
A and B, Kidneys from Irf5+/+ (n = 13), Irf5+/- (n = 10) and Irf5-/- (n = 10) female 
MRL/lpr littermates were analyzed at 16 weeks of age. Renal disease was quantified by 
measuring A, the percentage of glomeruli in each mouse showing evidence of mesangial 
expansion and B, the percentage of glomeruli in each mouse with crescents or necrosis. 
C, Serum BUN levels in Irf5+/+ (n = 12), Irf5+/- (n = 12) and Irf5-/- (n = 12) female 
MRL/lpr littermates at 16 weeks of age. Statistics:*p<0.05, **p<0.01. 
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Irf5-deficient MRL/lpr mice survive longer than Irf5-sufficient MRL/lpr 
mice 
 
 To determine whether the decrease in disease severity would translate into 
differences in survival, we bred new cohorts of female Irf5+/+, Irf5+/-and Irf5-/- MRL/lpr 
littermates and monitored them until the time of death or until they met predetermined 
criteria for euthanasia. Irf5+/+ MRL/lpr mice had a median survival of 155 days, 
consistent with previous reports (Figure 50) (Andrews et al. 1978; Cash et al. 2010).  The 
Irf5-/- MRL/lpr littermates survived significantly longer with a median survival of 272 
days. (p<0.01)  
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Figure 50 Increased survival in Irf5-deficient MRL/lpr mice. 
Irf5+/+ (n = 12), Irf5+/- (n = 14) and Irf5-/- (n = 14) female MRL/lpr littermates were 
observed until they met predetermined criteria for euthanasia (lymph node size greater 
than 2 cm). **p<0.01. 
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Irf5-heterozygote MRL/lpr mice are only modestly protected from disease 
 
 We had previously found in the FcRIIB-/-Yaa and FcRIIB-/- lupus models that 
Irf5 heterozygote mice developed minimal clinical manifestations even though they still 
expressed approximately 40% as much IRF5 protein as IRF5-sufficient mice (Richez et 
al. 2010). To determine whether loss of a single allele of IRF5 would have similar effects 
in the MRL/lpr model, we included Irf5 heterozygote littermates in all experiments. We 
found that Irf5+/- MRL/lpr mice had smaller spleens and an increased percentage of 
splenic B cells as compared with Irf5+/+ littermates, but there were no statistically 
significant differences in T cell percentages, autoantibody production or serum IgG 
isotypes (Figure 43-48).  Irf5+/- mice exhibited less severe end-organ disease in that 
Irf5+/- mice had lower serum BUN levels and a trend toward longer survival (median = 
188 days in Irf5+/- MRL/lpr mice vs 155 days in Irf5+/+ MRL/lpr mice, p = 0.07), 
however the increase is survival was modest as compared with Irf5-/-  littermates which 
lived to a median of 272 days (Figures 49 and 50).  
Discussion 
 The Irf5 knockout mouse line has been used by many investigators to determine 
the function of IRF5.  It was recently reported that this line contains a loss-of-function 
mutation in the DOCK2 gene (Purtha et al. 2012).   As DOCK2 plays an important role in 
immune function including in TLR signaling, lymphocyte trafficking and the 
development of Th2-type immune responses it is conceivable that certain effects 
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previously attributed to Irf5-deficiency might instead have been due to the DOCK2 
mutation. The effect of Irf5-deficiency in the MRL/lpr lupus model was reported before 
the DOCK2 mutation was discovered (Tada et al. 2011) and no information is available 
as to whether the DOCK2 mutation was present in the experimental mice in that study. 
One goal of our current study was to determine the effect of IRF5 in MRL/lpr mice in 
which the DOCK2 mutation was known to be absent.   
 We found that Irf5-/- MRL/lpr mice developed substantially less severe disease 
than their Irf5+/+ MRL/lpr littermates. Irf5-/- MRL/lpr mice had smaller spleens and 
lymph nodes, reduced titers of anti-nuclear and anti-dsDNA autoantibodies, lower levels 
of the complement-fixing IgG isotypes IgG2a, IgG2b and IgG3, less severe kidney 
disease and greatly improved survival. This protective effect of Irf5-deficiency is similar 
to that previously reported (Tada et al. 2011) although there are some differences.  The 
Irf5+/+ MRL/lpr mice in our study had a more severe phenotype as judged by the length 
of survival with a median survival of 155 days as compared to about 220 days in the 
study by Tada et al.  This may explain why the median survival of the Irf5-/- MRL/lpr 
mice in our study was shorter (272 days versus greater than 350 days).  Thus, IRF5 
inhibition may be less effective when disease is more severe.  We also observed a marked 
reduction in total serum IgG2a levels which was not seen in the study by Tada et al. 
 Another goal of this current study was to determine the effect of the loss of a 
single allele of IRF5 on disease pathogenesis in the MRL/lpr model. We had previously 
found that in the FcRIIB-/-Yaa and FcRIIB-/- lupus models, the Irf5 heterozygotes were 
markedly protected from disease and exhibited a phenotype similar to the Irf5-deficient 
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mice, even though IRF5 protein expression was still approximately 40% of the wildtype 
level (Richez et al. 2010). In this current study we found that the Irf5+/- MRL/lpr mice 
developed less severe disease than Irf5+/+ MRL/lpr littermates but the degree of 
protection was not as marked as was seen in the FcRIIB-/-Yaa and FcRIIB-/- models. 
One possible explanation for this difference is that the pathogenesis of disease may differ 
somewhat in the different models with certain cell types playing a more important role in 
one model than the other. As the relative contribution of IRF5 to TLR signaling events is 
known to be cell-type and ligand-dependent, the level of Irf5 expression may have a more 
dramatic effect in some cell types than in others. Future studies with cell-specific IRF5 
deletion may help to address this issue.  Another possible explanation is that the 
combination of Irf5 heterozygosity and the DOCK2 mutation may have exerted a more 
protective effect than Irf5 heterozygosity alone. We are currently generating new cohorts 
of Irf5+/+, Irf5+/- and Irf5-/- FcRIIB-/-Yaa and FcRIIB-/- mice without the DOCK2 
mutation to definitively answer this question. 
 Although the total number of spleen cells was reduced in Irf5-/- MRL/lpr mice as 
compared with Irf5+/+ MRL/lpr mice, the total number of splenic B cells was the same or 
even greater in the Irf5-/- MRL/lpr mice.  Despite this lack of effect of IRF5 on B cell 
number, serum levels of anti-nuclear autoantibodies and the IgG isotypes IgG2a, IgG2b 
and IgG3 were greatly reduced in Irf5-/- MRL/lpr mice.  As IgG2a, IgG2b and IgG3 are 
all pathogenic isotypes in murine lupus (Baudino et al. 2006; Ehlers et al. 2006) 
(Greenspan et al. 2012; Takahashi et al. 1991), Irf5-deficiency may ameliorate lupus at 
least in part through reduction of B cell antibody production. It is likely that this is due to 
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a critical role for IRF5 in regulating MyD88-dependent antibody production downstream 
of TLR7 and TLR9, as the autoantibody and IgG isotype profiles are similar to those 
observed in MyD88-deficient MRL/lpr mice and TLR7/TLR9 double-deficient MRL/lpr 
mice (Nickerson et al. 2010). 
 The mechanisms through which IRF5 might regulate IgG class switching are 
incompletely understood.  IRF5 regulates IgG2a class switching downstream of TLR9 in 
a B cell-intrinsic manner by directly binding to the IgG2a promoter (Savitsky et al. 2010).  
However, the effects of IRF5 on IgG2b and IgG3 production suggest that additional 
mechanisms are operative. It is likely that these additional mechanisms apply only under 
certain activation conditions as, in healthy non-autoimmune C57BL/6 mice, Irf5-
deficiency leads to reduced serum IgG2a levels but does not affect IgG2b or IgG3 levels 
(Krausgruber et al. 2011; Yasuda et al. 2013). Additional studies will be required to 
determine whether the dominant IRF5-dependent pathways regulating autoantibody 
production and IgG class-switching in vivo are B cell-intrinsic or B cell-extrinsic. 
 Our finding that splenic CD4+ T cell numbers were substantially reduced in the 
Irf5-/- MRL/lpr mice would be consistent with an important role for IRF5 in regulating T 
cell activation and/or survival.  IRF5 in macrophages has been shown to promote Th1 
and Th17 skewing following LPS activation (Krausgruber et al. 2011).  It has also 
reported that T cells express IRF5 in the presence of IFN-(Mancl et al. 2005), a 
cytokine thought to play a role in lupus pathogenesis (Bronson et al. 2012).   Thus, IRF5 
could potentially regulate T cell numbers either indirectly through effects on antigen-
presenting cells or directly through a T cell intrinsic effects.  
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 In summary, we have shown that IRF5 plays an important role in the development 
of disease in the MRL/lpr mouse model of lupus in the absence of the DOCK2 mutation. 
Taken together with the human genetic data showing that polymorphisms in Irf5 are 
associated with an increased risk of developing lupus, this suggests that IRF5 may be a 
useful therapeutic target in lupus.   
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APPENDIX 
Discovery of the DOCK2 mutation in gld.apoE-/-.Irf5+/+, Irf5+/- and Irf5-/- mice and 
analysis of DOCK2 versus IRF5 in disease phenotype. 
Introduction 
 Our goal was to determine the role of IRF5 in lupus and atherosclerosis using the 
gld.apoE-/- mouse model.  Therefore, in 2007, we generated Irf5+/+ gld.apoE-/- and Irf5-/- 
gld.apoE-/-  mouse lines and placed them on western diet for 12 weeks starting at 7 weeks 
of age.  In addition, we intercrossed Irf5+/-gld.apoE-/- mice to generate Irf5+/+gld.apoE-/-, 
Irf5+/-gld.apoE-/-  and Irf5-/-gld.apoE-/- littermates and also placed them on western diet 
for 12 weeks. Analysis of SLE-associated disease characteristics was performed 
including measurements of splenomegaly, lymphadenopathy, ANA titers and serum IgG 
isotype titers.  In addition, the total amount of atherosclerosis present within aortas was 
quantified using Oil Red O.  However, after the analysis was performed, it was 
discovered that a confounding mutation in a gene other than Irf5 was present in many of 
the experimental mice.   
 As described in Chapter 3, a confounding gene mutation in the Irf5-/- mouse line 
was identified as a duplication of exons 28 and 29 in the gene encoding Dedicator Of 
Cytokinesis 2 (DOCK2) (Purtha et al. 2012; Yasuda et al. 2013).  This exon insertion 
mutation leads to unstable mRNA and results in low DOCK2 expression.  Although not 
selected for, data from our laboratory showed that the DOCK2 mutation was not 
normally bred out of our experimental Irf5-/- mouse lines until the mice has been 
backcrossed at least 14 generations to C57BL/6 mice.  As described below, 
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Irf5+/+gld.apoE-/- and Irf5-/- gld.apoE-/- mice analyzed were at most 9 generations 
backcrossed to C57BL/6.  Therefore, it seemed very likely that many, if not all, of the 
Irf5+/+ and Irf5-/- gld.apoE-/- mice analyzed were confounded by the existence of the 
DOCK2 mutation.  In 2010,  Dr. Kei Yasuda designed a PCR protocol able to recognize 
the 3’ insertion point of the exon 28-29 duplication in the mouse DOCK2 gene (Yasuda 
et al. 2013).    Using these primers, tail DNA from gld.apoE-/- experimental mice were 
screened and phenotype data was sorted based on the presence of Irf5 and the DOCK2 
mutant alleles.  The data shown in the results section of this Appendix is from the 
original gld.apoE-/- non-littermate study after sorting based on expression of wild type 
DOCK2 and re-analysis. 
Materials and Methods 
Mice 
 
Irf5-/- mice backcrossed to C57BL/6 8 generations were crossed with a gld.apoE-/- mouse 
on a C57BL/6 background.  The resulting heterozygote offspring were then intercrossed 
to fix the gld and apoE mutations homozygously.  gld.apoE-/-.Irf5+/- mice were then 
intercrossed and Irf5+/+ and Irf5-/- experimental non-littermate lines were established.  In 
addition, gld.apoE-/-.IRF5+/- mice were intercrossed to generate a second experimental 
cohort consisting of Irf5+/+, Irf5+/- and Irf5-/- littermates.  At 7 weeks of age mice were 
placed on western diet for 12 weeks, then euthanized at 19 weeks of age. 
DOCK2 Primers 
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Primers  able to recognize the 3’ insertion point of the exon 28-29 duplication in the 
mouse DOCK2 gene (Yasuda et al. 2013). 
ANA Assay 
 
As described in Chapter 2 Materials and Methods. 
Serological Assays 
 
ANA was perfomed as described in Chapter 2 Materials and Methods.  Serum IgG 
isotypes were performed as described in Chapter 3 Materials and Methods.  Natural IgM 
(T15 Id+) was measured by Dr. Christoph Binder in association with Dr. Joseph 
Witztum’s laboratory. 
C3 Deposition in Kidney 
 
Kidneys were snap-frozen in OCT and stored at -80 C.  8 um cryosections were cut and 
blocked with 1% donkey serum and then stained with FITC-conjugated goat anti-mouse 
C3.  Stained sections were coded and then digitally photographed and analyzed in a 
blinded manner using a fluorescent microscope.  Fluorescence intensity, representing C3 
deposition, was measured as the mean luminosity in 7-10 glomeruli per mouse using 
Adobe Photoshop CS3.   
Analysis of Atherosclerosis 
 
The aorta from each mouse was fixed in 4% paraformaldehyde, cut longitudinally, pinned 
and stained with Oil Red O to detect lipid deposition.  In a blinded manner, the area of 
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the total aortic arch and area stained positive for Oil Red O was quantified using Adobe 
Photoshop CS3 color range tool.  The data is reported as average percentage of total aorta 
stained positive for Oil Red O in each experimental group or as individual data points. 
Statistical analysis 
 
Groups were compared using the Unpaired T test, two-tailed.  The Mann-Whitney U was 
used  for ANA titers as the data was not normally distributed.  All statistics were 
performed using GraphPad Instat or SigmaPlot 12.5 (Systat, San Jose, USA) with P < 
0.05 considered as statistically significant.  
 
Results   
 With the discovery of primers able to detect the confounding DOCK2 mutation, 
DNA purified from tails from Irf5+/+ and Irf5-/- experimental gld.apoE-/- mice was used to 
screen for the DOCK2 mutation.  As shown in Figure 51, 80% of the Irf5+/+gld.apoE-/- 
and 40% of the IRF5+/-gld.apoE-/-  non-littermate experimental cohort were positive for at 
least one mutant DOCK2 allele.  Unfortunately, only one of the IRF5-/-gld.apoE-/- mice 
screened was wild type for the DOCK2 allele.  Because such a high percentage of Irf5-/- 
gld.apoE-/-  mice were mutant for DOCK2, it seemed possible that the presence of the 
DOCK2 mutation instilled some type of survival advantage for Irf5-/-gld.apoE-/-  disease 
mice.  However, when the Irf5+/+gld.apoE-/-, Irf5+/-gld.apoE-/-  and Irf5-/- gld.apoE-/-  
littermates were screened, we found that on average ~80% of mice in each group were 
positive for at least one mutant DOCK2 allele.  Therefore, the DOCK2 mutation was 
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distributed equally between the mice supporting a more Mendelian mode if inheritance 
for the mutation (Figure 51).   
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Figure 51 Percentage of gld.apoE-/- experimental mice that were wild type or mutant for DOCK2.   
Tail DNA was purified and PCR was performed using primers specific for the insertion 
point of the DOCK2 28-29 exon duplication.  Bars represent the percentage of mice that 
expressed wild type or mutant DOCK2.   Irf5+/+gld.apoE-/-, Irf5+/-gld.apoE-/- and Irf5-/- 
gld.apoE-/- non-littermate mice (A) and littermates (B).  
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 Fortunately, 20% of the Irf5+/ gld.apoE-/-  and 60% of the Irf5+/- gld.apoE-/- non-
littermate groups (Figure 1) were wild type for the DOCK2 allele.  As a result, we were 
able to separate out the disease phenotype data from gld.apoE-/- mice with and without 
the DOCK2 mutation.  As shown in Figures 52-54, there is a true pathogenic role for 
IRF5 in the gld.apoE-/- model.  By comparing Irf5+/+gld.apoE-/- and Irf5+/-gld.apoE-/-  
data, it can be clearly seen that lymphadenopathy, splenomegaly, ANA production and 
serum IgG2a isotype levels are dependent on IRF5.  Figure 55 shows that Irf5-deficient 
gld.apoE-/- mice display a significant reduction in complement deposition within kidneys.  
When DOCK2 wild type mice were separated out for re-analysis, we did not observe a 
significant difference between Irf5+/+gld.apoE-/-  and Irf5+/- gld.apoE-/- mice.  However, 
because of the low sample size, a conclusive role for IRF5 in the pathogenesis of lupus 
nephritis could not be made. 
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Figure 52 Splenomegaly and lymphadenopathy in gld.apoE-/- mice that were wild type for DOCK2. 
Spleen (A) and lymph node (B) weights from Irf5+/+ (n=4), Irf5+/- (n=8) and Irf5-/- (n=1).  
Statistics: Unpaired T test. *p<0.05, **p<0.01. 
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Figure 53 ANA titers in gld.apoE-/- mice that were wild type for DOCK2. 
Serum anti-nuclear autoantibody titers (ANA) from Irf5+/+gld.apoE-/-  (n=3), Irf5+/- 
gld.apoE-/-  (n=8) and Irf5-/- gld.apoE-/-  (n=1) mice were measured using 
immunoflourescence and HEp2-coated slides.  Statistics: Mann-Whitney U test. *p<0.05. 
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Figure 54 IgG isotypes from  gld.apoE-/- mice that were wild type for DOCK2. 
Serum IgG isotype levels from Irf5+/+gld.apoE-/-  (n=6), Irf5+/-gld.apoE-/-  (n=5-10) and 
Irf5-/-gld.apoE-/-  (n=3) mice were measured by ELISA.  Statistics: Unpaired T test. 
*p<0.05. 
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Figure 55 Complement deposition within the kidneys of gld.apoE-/- mice.   
Kidney sections from Irf5+/+gld.apoE-/-  (n=9), Irf5+/-gld.apoE-/- (n=10) and Irf5-/- 
gld.apoE-/- (n=7) mice that were wild type or mutant for DOCK2 (A) and from Irf5+/+ 
(n=3) and Irf5+/- (n=3)  mice that were wild type for DOCK2 were stained using an anti-
C3 antibody conjugated to FITC to detect complement deposition within the glomeruli.  
Data show the mean intensity of fluorescence in 8-10 glomeruli per mouse.  Statistics: 
Unpaired T test. *p<0.05.
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 We also analyzed the severity of atherosclerosis by quantifying the amount of Oil 
Red O+ lesion area on en face aortas from Irf5+/+gld.apoE-/-, Irf5+/-gld.apoE-/- and Irf5-/- 
gld.apoE-/- mice.  Figure 56a shows that Irf5-deficiency was protective against the 
development of atherosclerosis in gld.apoE-/- mice.  We then removed the data points 
confounded by the presence of the DOCK2 mutation.  Figure 56b shows atherosclerotic 
lesion size from gld.apoE-/- mice that were wild type for DOCK2.  Irf5+/-gld.apoE-/- 
seemed to develop slightly smaller atherosclerotic lesions then Irf5+/+ gld.apoE-/-  mice.  
Although we only had atherosclerotic lesion data from one Irf5-/- gld.apoE-/- mouse that 
was wild type for DOCK2, this mouse had the largest atherosclerotic lesion when 
compared to Irf5+/+gld.apoE-/- and Irf5+/-gld.apoE-/- mice.  However, because of the low 
sample size, a conclusive atheroprotective role for IRF5 could not be made.     
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Figure 56 Atherosclerosis in aorta of  gld.apoE-/- mice. 
Aorta from Irf5+/+gld.apoE-/-  (n=17), Irf5+/-gld.apoE-/-  (n=13) and Irf5-/-gld.apoE-/- 
(n=22) mice that were wild type or mutant for DOCK2 (A) and from Irf5+/+gld.apoE-/-  
(n=4), Irf5+/- gld.apoE-/-  (n=2) and Irf5-/- gld.apoE-/- (n=1) mice that were wild type for 
DOCK2 were formalin-fixed, pinned and stained with Oil Red O to detect lipid 
deposition within lesions.  In a blinded manner, the area of the total aorta and area stained 
positive for Oil Red O was quantified using Adobe Photoshop color range tool.  Y-axis 
represents average % of aortic arch stained positive for Oil Red O within each group.  
Statistics: Unpaired T test. *p<0.05. 
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We hypothesized that IRF5 may be required for the production of atheroprotective 
natural IgM.  IgM specific for phosphorylcholine present in oxLDL and apoptotic cells 
promotes their clearance from the atherosclerotic lesion (Binder et al. 2008).  We found 
that Irf5+/- gld.apoE-/- mice displayed a significant decrease in T15 idiotype IgM levels, 
the prototypical natural IgM shown to be atheroprotective compared to Irf5+/+ gld.apoE-/- 
mice (Figure 57).  
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Figure 57 Serum Natural IgM titers in gld.apoE-/- mice that were wild type for DOCK2. 
Serum Natural IgM (T15+ Id) from Irf5+/+gld.apoE-/-  (n=3), Irf5+/-gld.apoE-/-  (n=6) and 
Irf5-/-gld.apoE-/- (n=1) mice were measured by C. Binder of the Witztum lab.  Statistics: 
Mann-Whitney U test. ***p<0.001. 
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 Despite the fact that the DOCK2 mutation was distributed evenly, DOCK2 is 
important in normal immune cell development and function and it seemed likely that the 
existence of the DOCK2 mutation in the gld.apoE-/- experimental mice might have 
affected the phenotype observed.  Table I compares the average levels of ANA, spleen 
and lymph node values in DOCK2 wild type versus DOCK2 mutant experimental 
gld.apoE-/- mice.  As can be seen, there was little difference between the DOCK2 wild 
type and DOCK2 mutant experimental gld.apoE-/- mice that are Irf5+/- or Irf5-/-.  
However, a DOCK2 affect can be seen when comparing Irf5+/+.DOCK2 wild type to 
Irf5+/+.DOCK2 mutant ANA, spleen size and lymph node size.  Based on this data, we 
surmised that the presence of the DOCK2 mutation in the experimental cohorts might 
have actually diluted the IRF5-dependent affects previously documented.  As a result, we 
concluded that the role of IRF5 in the gld.apoE-/- model is completely independent of the 
DOCK2 mutation.   However, to confirm this, it was necessary to regenerate new 
experimental Irf5+/+gld.apoE-/-, Irf5+/-gld.apoE-/-  and Irf5-/- gld.apoE-/- mice without the 
DOCK2 mutation and repeat the phenotype analysis.  Fortunately, when I screened the 
Irf5-/-.gld.apoE-/- descendents of the experimental mice described above, we found that 
100% of the mice were wild type for DOCK2.  These Irf5-/-.gld.apoE-/- mice that were 
wild type for DOCK2 were used for the generation of experimental cohorts analyzed in 
Chapter 2 of this dissertation. 
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Table 4 Effect of the DOCK2 mutation on the Irf5-dependent phenotype. 
Phenotype data from non-littermate experimental gld.apoE-/- mice were separated based 
on the Irf5 genoype and the DOCK2 geneotype.  The median ANA is shown as well as 
the mean spleen and lymph node sizes.
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